#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome
#Text=Psychosis has been proposed to develop from dysfunction in a hippocampal-striatal-midbrain circuit, leading to aberrant salience processing.
1-1	0-6	Neural	_	
1-2	7-16	Circuitry	_	
1-3	17-19	of	_	
1-4	20-27	Novelty	_	
1-5	28-36	Salience	_	
1-6	37-47	Processing	_	
1-7	48-50	in	_	
1-8	51-60	Psychosis	_	
1-9	61-65	Risk	_	
1-10	65-66	:	_	
1-11	67-78	Association	_	
1-12	79-83	With	_	
1-13	84-92	Clinical	_	
1-14	93-100	Outcome	_	
1-15	101-110	Psychosis	_	
1-16	111-114	has	_	
1-17	115-119	been	_	
1-18	120-128	proposed	_	
1-19	129-131	to	_	
1-20	132-139	develop	_	
1-21	140-144	from	_	
1-22	145-156	dysfunction	_	
1-23	157-159	in	_	
1-24	160-161	a	_	
1-25	162-191	hippocampal-striatal-midbrain	_	
1-26	192-199	circuit	_	
1-27	199-200	,	_	
1-28	201-208	leading	_	
1-29	209-211	to	_	
1-30	212-220	aberrant	_	
1-31	221-229	salience	_	
1-32	230-240	processing	_	
1-33	240-241	.	_	

#Text=Here, we used functional magnetic resonance imaging (fMRI) during novelty salience processing to investigate this model in people at clinical high risk (CHR) for psychosis according to their subsequent clinical outcomes.
2-1	242-246	Here	_	
2-2	246-247	,	_	
2-3	248-250	we	_	
2-4	251-255	used	_	
2-5	256-266	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-6	267-275	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-7	276-285	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-8	286-293	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-9	294-295	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-10	295-299	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-11	299-300	)	_	
2-12	301-307	during	_	
2-13	308-315	novelty	_	
2-14	316-324	salience	_	
2-15	325-335	processing	_	
2-16	336-338	to	_	
2-17	339-350	investigate	_	
2-18	351-355	this	_	
2-19	356-361	model	_	
2-20	362-364	in	_	
2-21	365-371	people	_	
2-22	372-374	at	_	
2-23	375-383	clinical	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
2-24	384-388	high	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
2-25	389-393	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
2-26	394-395	(	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
2-27	395-398	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
2-28	398-399	)	_	
2-29	400-403	for	_	
2-30	404-413	psychosis	_	
2-31	414-423	according	_	
2-32	424-426	to	_	
2-33	427-432	their	_	
2-34	433-443	subsequent	_	
2-35	444-452	clinical	_	
2-36	453-461	outcomes	_	
2-37	461-462	.	_	

#Text=Seventy-six CHR participants as defined using the Comprehensive Assessment of At-Risk Mental States (CAARMS) and 31 healthy controls (HC) were studied while performing a novelty salience fMRI task that engaged an a priori hippocampal-striatal-midbrain circuit of interest.
3-1	463-474	Seventy-six	_	
3-2	475-478	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk	
3-3	479-491	participants	_	
3-4	492-494	as	_	
3-5	495-502	defined	_	
3-6	503-508	using	_	
3-7	509-512	the	_	
3-8	513-526	Comprehensive	_	
3-9	527-537	Assessment	_	
3-10	538-540	of	_	
3-11	541-548	At-Risk	_	
3-12	549-555	Mental	_	
3-13	556-562	States	_	
3-14	563-564	(	_	
3-15	564-570	CAARMS	_	
3-16	570-571	)	_	
3-17	572-575	and	_	
3-18	576-578	31	_	
3-19	579-586	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
3-20	587-595	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
3-21	596-597	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
3-22	597-599	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
3-23	599-600	)	_	
3-24	601-605	were	_	
3-25	606-613	studied	_	
3-26	614-619	while	_	
3-27	620-630	performing	_	
3-28	631-632	a	_	
3-29	633-640	novelty	_	
3-30	641-649	salience	_	
3-31	650-654	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
3-32	655-659	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
3-33	660-664	that	_	
3-34	665-672	engaged	_	
3-35	673-675	an	_	
3-36	676-677	a	_	
3-37	678-684	priori	_	
3-38	685-714	hippocampal-striatal-midbrain	_	
3-39	715-722	circuit	_	
3-40	723-725	of	_	
3-41	726-734	interest	_	
3-42	734-735	.	_	

#Text=The CHR sample was then followed clinically for a mean of 59.7 months (~5 y), when clinical outcomes were assessed in terms of transition (CHR-T) or non-transition (CHR-NT) to psychosis (CAARMS criteria): during this period, 13 individuals (17%) developed a psychotic disorder (CHR-T) and 63 did not.
4-1	736-739	The	_	
4-2	740-743	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk	
4-3	744-750	sample	_	
4-4	751-754	was	_	
4-5	755-759	then	_	
4-6	760-768	followed	_	
4-7	769-779	clinically	_	
4-8	780-783	for	_	
4-9	784-785	a	_	
4-10	786-790	mean	_	
4-11	791-793	of	_	
4-12	794-798	59.7	_	
4-13	799-805	months	_	
4-14	806-807	(	_	
4-15	807-808	~	_	
4-16	808-809	5	_	
4-17	810-811	y	_	
4-18	811-812	)	_	
4-19	812-813	,	_	
4-20	814-818	when	_	
4-21	819-827	clinical	_	
4-22	828-836	outcomes	_	
4-23	837-841	were	_	
4-24	842-850	assessed	_	
4-25	851-853	in	_	
4-26	854-859	terms	_	
4-27	860-862	of	_	
4-28	863-873	transition	_	
4-29	874-875	(	_	
4-30	875-880	CHR-T	_	
4-31	880-881	)	_	
4-32	882-884	or	_	
4-33	885-899	non-transition	_	
4-34	900-901	(	_	
4-35	901-907	CHR-NT	_	
4-36	907-908	)	_	
4-37	909-911	to	_	
4-38	912-921	psychosis	_	
4-39	922-923	(	_	
4-40	923-929	CAARMS	_	
4-41	930-938	criteria	_	
4-42	938-939	)	_	
4-43	939-940	:	_	
4-44	941-947	during	_	
4-45	948-952	this	_	
4-46	953-959	period	_	
4-47	959-960	,	_	
4-48	961-963	13	_	
4-49	964-975	individuals	_	
4-50	976-977	(	_	
4-51	977-980	17%	_	
4-52	980-981	)	_	
4-53	982-991	developed	_	
4-54	992-993	a	_	
4-55	994-1003	psychotic	_	
4-56	1004-1012	disorder	_	
4-57	1013-1014	(	_	
4-58	1014-1019	CHR-T	_	
4-59	1019-1020	)	_	
4-60	1021-1024	and	_	
4-61	1025-1027	63	_	
4-62	1028-1031	did	_	
4-63	1032-1035	not	_	
4-64	1035-1036	.	_	

#Text=Functional activation and effective connectivity within a hippocampal-striatal-midbrain circuit were compared between groups.
5-1	1037-1047	Functional	_	
5-2	1048-1058	activation	_	
5-3	1059-1062	and	_	
5-4	1063-1072	effective	_	
5-5	1073-1085	connectivity	_	
5-6	1086-1092	within	_	
5-7	1093-1094	a	_	
5-8	1095-1124	hippocampal-striatal-midbrain	_	
5-9	1125-1132	circuit	_	
5-10	1133-1137	were	_	
5-11	1138-1146	compared	_	
5-12	1147-1154	between	_	
5-13	1155-1161	groups	_	
5-14	1161-1162	.	_	

#Text=In CHR individuals compared to HC, hippocampal response to novel stimuli was significantly attenuated (P = .041 family-wise error corrected).
6-1	1163-1165	In	_	
6-2	1166-1169	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk	
6-3	1170-1181	individuals	_	
6-4	1182-1190	compared	_	
6-5	1191-1193	to	_	
6-6	1194-1196	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-7	1196-1197	,	_	
6-8	1198-1209	hippocampal	_	
6-9	1210-1218	response	_	
6-10	1219-1221	to	_	
6-11	1222-1227	novel	_	
6-12	1228-1235	stimuli	_	
6-13	1236-1239	was	_	
6-14	1240-1253	significantly	_	
6-15	1254-1264	attenuated	_	
6-16	1265-1266	(	_	
6-17	1266-1267	P	_	
6-18	1268-1269	=	_	
6-19	1270-1274	.041	_	
6-20	1275-1286	family-wise	_	
6-21	1287-1292	error	_	
6-22	1293-1302	corrected	_	
6-23	1302-1303	)	_	
6-24	1303-1304	.	_	

#Text=Dynamic Causal Modelling revealed that stimulus novelty modulated effective connectivity from the hippocampus to the striatum, and from the midbrain to the hippocampus, significantly more in CHR participants than in HC.
7-1	1305-1312	Dynamic	_	
7-2	1313-1319	Causal	_	
7-3	1320-1329	Modelling	_	
7-4	1330-1338	revealed	_	
7-5	1339-1343	that	_	
7-6	1344-1352	stimulus	_	
7-7	1353-1360	novelty	_	
7-8	1361-1370	modulated	_	
7-9	1371-1380	effective	_	
7-10	1381-1393	connectivity	_	
7-11	1394-1398	from	_	
7-12	1399-1402	the	_	
7-13	1403-1414	hippocampus	_	
7-14	1415-1417	to	_	
7-15	1418-1421	the	_	
7-16	1422-1430	striatum	_	
7-17	1430-1431	,	_	
7-18	1432-1435	and	_	
7-19	1436-1440	from	_	
7-20	1441-1444	the	_	
7-21	1445-1453	midbrain	_	
7-22	1454-1456	to	_	
7-23	1457-1460	the	_	
7-24	1461-1472	hippocampus	_	
7-25	1472-1473	,	_	
7-26	1474-1487	significantly	_	
7-27	1488-1492	more	_	
7-28	1493-1495	in	_	
7-29	1496-1499	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk	
7-30	1500-1512	participants	_	
7-31	1513-1517	than	_	
7-32	1518-1520	in	_	
7-33	1521-1523	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
7-34	1523-1524	.	_	

#Text=Conversely, stimulus novelty modulated connectivity from the midbrain to the striatum significantly less in CHR participants than in HC, and less in CHR participants who subsequently developed psychosis than in CHR individuals who did not become psychotic.
8-1	1525-1535	Conversely	_	
8-2	1535-1536	,	_	
8-3	1537-1545	stimulus	_	
8-4	1546-1553	novelty	_	
8-5	1554-1563	modulated	_	
8-6	1564-1576	connectivity	_	
8-7	1577-1581	from	_	
8-8	1582-1585	the	_	
8-9	1586-1594	midbrain	_	
8-10	1595-1597	to	_	
8-11	1598-1601	the	_	
8-12	1602-1610	striatum	_	
8-13	1611-1624	significantly	_	
8-14	1625-1629	less	_	
8-15	1630-1632	in	_	
8-16	1633-1636	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk	
8-17	1637-1649	participants	_	
8-18	1650-1654	than	_	
8-19	1655-1657	in	_	
8-20	1658-1660	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
8-21	1660-1661	,	_	
8-22	1662-1665	and	_	
8-23	1666-1670	less	_	
8-24	1671-1673	in	_	
8-25	1674-1677	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk	
8-26	1678-1690	participants	_	
8-27	1691-1694	who	_	
8-28	1695-1707	subsequently	_	
8-29	1708-1717	developed	_	
8-30	1718-1727	psychosis	_	
8-31	1728-1732	than	_	
8-32	1733-1735	in	_	
8-33	1736-1739	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk	
8-34	1740-1751	individuals	_	
8-35	1752-1755	who	_	
8-36	1756-1759	did	_	
8-37	1760-1763	not	_	
8-38	1764-1770	become	_	
8-39	1771-1780	psychotic	_	
8-40	1780-1781	.	_	

#Text=Our findings are consistent with preclinical evidence implicating hippocampal-striatal-midbrain circuit dysfunction in altered salience processing and the onset of psychosis.
9-1	1782-1785	Our	_	
9-2	1786-1794	findings	_	
9-3	1795-1798	are	_	
9-4	1799-1809	consistent	_	
9-5	1810-1814	with	_	
9-6	1815-1826	preclinical	_	
9-7	1827-1835	evidence	_	
9-8	1836-1847	implicating	_	
9-9	1848-1877	hippocampal-striatal-midbrain	_	
9-10	1878-1885	circuit	_	
9-11	1886-1897	dysfunction	_	
9-12	1898-1900	in	_	
9-13	1901-1908	altered	_	
9-14	1909-1917	salience	_	
9-15	1918-1928	processing	_	
9-16	1929-1932	and	_	
9-17	1933-1936	the	_	
9-18	1937-1942	onset	_	
9-19	1943-1945	of	_	
9-20	1946-1955	psychosis	_	
9-21	1955-1956	.	_	

#Text=Introduction
#Text=The inappropriate attribution of salience to what would normally be irrelevant or neutral stimuli is a robust feature of psychotic disorders and is linked to altered subcortical dopaminergic signaling.
10-1	1957-1969	Introduction	_	
10-2	1970-1973	The	_	
10-3	1974-1987	inappropriate	_	
10-4	1988-1999	attribution	_	
10-5	2000-2002	of	_	
10-6	2003-2011	salience	_	
10-7	2012-2014	to	_	
10-8	2015-2019	what	_	
10-9	2020-2025	would	_	
10-10	2026-2034	normally	_	
10-11	2035-2037	be	_	
10-12	2038-2048	irrelevant	_	
10-13	2049-2051	or	_	
10-14	2052-2059	neutral	_	
10-15	2060-2067	stimuli	_	
10-16	2068-2070	is	_	
10-17	2071-2072	a	_	
10-18	2073-2079	robust	_	
10-19	2080-2087	feature	_	
10-20	2088-2090	of	_	
10-21	2091-2100	psychotic	_	
10-22	2101-2110	disorders	_	
10-23	2111-2114	and	_	
10-24	2115-2117	is	_	
10-25	2118-2124	linked	_	
10-26	2125-2127	to	_	
10-27	2128-2135	altered	_	
10-28	2136-2147	subcortical	_	
10-29	2148-2160	dopaminergic	_	
10-30	2161-2170	signaling	_	
10-31	2170-2171	.	_	

#Text=While there are a number of animal models that attempt to describe the pathology and development of psychosis (eg, chronic phencyclidine models, prenatal immune activation models (for review, see ref.), a particularly influential model proposes that psychosis develops when hippocampal dysfunction drives increased subcortical dopamine activity through descending projections to the striatum.
11-1	2172-2177	While	_	
11-2	2178-2183	there	_	
11-3	2184-2187	are	_	
11-4	2188-2189	a	_	
11-5	2190-2196	number	_	
11-6	2197-2199	of	_	
11-7	2200-2206	animal	_	
11-8	2207-2213	models	_	
11-9	2214-2218	that	_	
11-10	2219-2226	attempt	_	
11-11	2227-2229	to	_	
11-12	2230-2238	describe	_	
11-13	2239-2242	the	_	
11-14	2243-2252	pathology	_	
11-15	2253-2256	and	_	
11-16	2257-2268	development	_	
11-17	2269-2271	of	_	
11-18	2272-2281	psychosis	_	
11-19	2282-2283	(	_	
11-20	2283-2285	eg	_	
11-21	2285-2286	,	_	
11-22	2287-2294	chronic	_	
11-23	2295-2308	phencyclidine	_	
11-24	2309-2315	models	_	
11-25	2315-2316	,	_	
11-26	2317-2325	prenatal	_	
11-27	2326-2332	immune	_	
11-28	2333-2343	activation	_	
11-29	2344-2350	models	_	
11-30	2351-2352	(	_	
11-31	2352-2355	for	_	
11-32	2356-2362	review	_	
11-33	2362-2363	,	_	
11-34	2364-2367	see	_	
11-35	2368-2371	ref	_	
11-36	2371-2372	.	_	
11-37	2372-2373	)	_	
11-38	2373-2374	,	_	
11-39	2375-2376	a	_	
11-40	2377-2389	particularly	_	
11-41	2390-2401	influential	_	
11-42	2402-2407	model	_	
11-43	2408-2416	proposes	_	
11-44	2417-2421	that	_	
11-45	2422-2431	psychosis	_	
11-46	2432-2440	develops	_	
11-47	2441-2445	when	_	
11-48	2446-2457	hippocampal	_	
11-49	2458-2469	dysfunction	_	
11-50	2470-2476	drives	_	
11-51	2477-2486	increased	_	
11-52	2487-2498	subcortical	_	
11-53	2499-2507	dopamine	_	
11-54	2508-2516	activity	_	
11-55	2517-2524	through	_	
11-56	2525-2535	descending	_	
11-57	2536-2547	projections	_	
11-58	2548-2550	to	_	
11-59	2551-2554	the	_	
11-60	2555-2563	striatum	_	
11-61	2563-2564	.	_	

#Text=Neuroimaging studies of reward salience suggest that salience processing and associated neural hippocampal-striatal-midbrain responses are perturbed in both patients with psychosis and individuals at clinical high risk (CHR) for psychosis, and that this is associated with positive symptoms.
12-1	2565-2577	Neuroimaging	_	
12-2	2578-2585	studies	_	
12-3	2586-2588	of	_	
12-4	2589-2595	reward	_	
12-5	2596-2604	salience	_	
12-6	2605-2612	suggest	_	
12-7	2613-2617	that	_	
12-8	2618-2626	salience	_	
12-9	2627-2637	processing	_	
12-10	2638-2641	and	_	
12-11	2642-2652	associated	_	
12-12	2653-2659	neural	_	
12-13	2660-2689	hippocampal-striatal-midbrain	_	
12-14	2690-2699	responses	_	
12-15	2700-2703	are	_	
12-16	2704-2713	perturbed	_	
12-17	2714-2716	in	_	
12-18	2717-2721	both	_	
12-19	2722-2730	patients	_	
12-20	2731-2735	with	_	
12-21	2736-2745	psychosis	_	
12-22	2746-2749	and	_	
12-23	2750-2761	individuals	_	
12-24	2762-2764	at	_	
12-25	2765-2773	clinical	_	
12-26	2774-2778	high	_	
12-27	2779-2783	risk	_	
12-28	2784-2785	(	_	
12-29	2785-2788	CHR	_	
12-30	2788-2789	)	_	
12-31	2790-2793	for	_	
12-32	2794-2803	psychosis	_	
12-33	2803-2804	,	_	
12-34	2805-2808	and	_	
12-35	2809-2813	that	_	
12-36	2814-2818	this	_	
12-37	2819-2821	is	_	
12-38	2822-2832	associated	_	
12-39	2833-2837	with	_	
12-40	2838-2846	positive	_	
12-41	2847-2855	symptoms	_	
12-42	2855-2856	.	_	

#Text=In this context, although novelty has been less investigated as a dimension of salience than reward in psychosis, preclinical evidence indicates that dopaminergic neurons in the midbrain code the salience of unexpected stimuli and respond to novel stimuli.
13-1	2857-2859	In	_	
13-2	2860-2864	this	_	
13-3	2865-2872	context	_	
13-4	2872-2873	,	_	
13-5	2874-2882	although	_	
13-6	2883-2890	novelty	_	
13-7	2891-2894	has	_	
13-8	2895-2899	been	_	
13-9	2900-2904	less	_	
13-10	2905-2917	investigated	_	
13-11	2918-2920	as	_	
13-12	2921-2922	a	_	
13-13	2923-2932	dimension	_	
13-14	2933-2935	of	_	
13-15	2936-2944	salience	_	
13-16	2945-2949	than	_	
13-17	2950-2956	reward	_	
13-18	2957-2959	in	_	
13-19	2960-2969	psychosis	_	
13-20	2969-2970	,	_	
13-21	2971-2982	preclinical	_	
13-22	2983-2991	evidence	_	
13-23	2992-3001	indicates	_	
13-24	3002-3006	that	_	
13-25	3007-3019	dopaminergic	_	
13-26	3020-3027	neurons	_	
13-27	3028-3030	in	_	
13-28	3031-3034	the	_	
13-29	3035-3043	midbrain	_	
13-30	3044-3048	code	_	
13-31	3049-3052	the	_	
13-32	3053-3061	salience	_	
13-33	3062-3064	of	_	
13-34	3065-3075	unexpected	_	
13-35	3076-3083	stimuli	_	
13-36	3084-3087	and	_	
13-37	3088-3095	respond	_	
13-38	3096-3098	to	_	
13-39	3099-3104	novel	_	
13-40	3105-3112	stimuli	_	
13-41	3112-3113	.	_	

#Text=The first aim of the present study was to examine hippocampal-striatum-midbrain circuit activation and effective connectivity in CHR individuals.
14-1	3114-3117	The	_	
14-2	3118-3123	first	_	
14-3	3124-3127	aim	_	
14-4	3128-3130	of	_	
14-5	3131-3134	the	_	
14-6	3135-3142	present	_	
14-7	3143-3148	study	_	
14-8	3149-3152	was	_	
14-9	3153-3155	to	_	
14-10	3156-3163	examine	_	
14-11	3164-3193	hippocampal-striatum-midbrain	_	
14-12	3194-3201	circuit	_	
14-13	3202-3212	activation	_	
14-14	3213-3216	and	_	
14-15	3217-3226	effective	_	
14-16	3227-3239	connectivity	_	
14-17	3240-3242	in	_	
14-18	3243-3246	CHR	_	
14-19	3247-3258	individuals	_	
14-20	3258-3259	.	_	

#Text=We assessed activation using functional magnetic resonance imaging (fMRI) in conjunction with a novelty salience paradigm based on a task that had previously elicited robust hippocampal-striatal-midbrain responses, and employed Dynamic Casual Modeling (DCM) to assess effective connectivity within this circuit.
15-1	3260-3262	We	_	
15-2	3263-3271	assessed	_	
15-3	3272-3282	activation	_	
15-4	3283-3288	using	_	
15-5	3289-3299	functional	_	
15-6	3300-3308	magnetic	_	
15-7	3309-3318	resonance	_	
15-8	3319-3326	imaging	_	
15-9	3327-3328	(	_	
15-10	3328-3332	fMRI	_	
15-11	3332-3333	)	_	
15-12	3334-3336	in	_	
15-13	3337-3348	conjunction	_	
15-14	3349-3353	with	_	
15-15	3354-3355	a	_	
15-16	3356-3363	novelty	_	
15-17	3364-3372	salience	_	
15-18	3373-3381	paradigm	_	
15-19	3382-3387	based	_	
15-20	3388-3390	on	_	
15-21	3391-3392	a	_	
15-22	3393-3397	task	_	
15-23	3398-3402	that	_	
15-24	3403-3406	had	_	
15-25	3407-3417	previously	_	
15-26	3418-3426	elicited	_	
15-27	3427-3433	robust	_	
15-28	3434-3463	hippocampal-striatal-midbrain	_	
15-29	3464-3473	responses	_	
15-30	3473-3474	,	_	
15-31	3475-3478	and	_	
15-32	3479-3487	employed	_	
15-33	3488-3495	Dynamic	_	
15-34	3496-3502	Casual	_	
15-35	3503-3511	Modeling	_	
15-36	3512-3513	(	_	
15-37	3513-3516	DCM	_	
15-38	3516-3517	)	_	
15-39	3518-3520	to	_	
15-40	3521-3527	assess	_	
15-41	3528-3537	effective	_	
15-42	3538-3550	connectivity	_	
15-43	3551-3557	within	_	
15-44	3558-3562	this	_	
15-45	3563-3570	circuit	_	
15-46	3570-3571	.	_	

#Text=While previous neuroimaging studies had reported altered activation and connectivity in a hippocampal-striatal-midbrain circuit during reward salience processing in CHR individuals, the extent to which these findings are specific to the CHR subset who later develop psychosis has yet to be investigated.
16-1	3572-3577	While	_	
16-2	3578-3586	previous	_	
16-3	3587-3599	neuroimaging	_	
16-4	3600-3607	studies	_	
16-5	3608-3611	had	_	
16-6	3612-3620	reported	_	
16-7	3621-3628	altered	_	
16-8	3629-3639	activation	_	
16-9	3640-3643	and	_	
16-10	3644-3656	connectivity	_	
16-11	3657-3659	in	_	
16-12	3660-3661	a	_	
16-13	3662-3691	hippocampal-striatal-midbrain	_	
16-14	3692-3699	circuit	_	
16-15	3700-3706	during	_	
16-16	3707-3713	reward	_	
16-17	3714-3722	salience	_	
16-18	3723-3733	processing	_	
16-19	3734-3736	in	_	
16-20	3737-3740	CHR	_	
16-21	3741-3752	individuals	_	
16-22	3752-3753	,	_	
16-23	3754-3757	the	_	
16-24	3758-3764	extent	_	
16-25	3765-3767	to	_	
16-26	3768-3773	which	_	
16-27	3774-3779	these	_	
16-28	3780-3788	findings	_	
16-29	3789-3792	are	_	
16-30	3793-3801	specific	_	
16-31	3802-3804	to	_	
16-32	3805-3808	the	_	
16-33	3809-3812	CHR	_	
16-34	3813-3819	subset	_	
16-35	3820-3823	who	_	
16-36	3824-3829	later	_	
16-37	3830-3837	develop	_	
16-38	3838-3847	psychosis	_	
16-39	3848-3851	has	_	
16-40	3852-3855	yet	_	
16-41	3856-3858	to	_	
16-42	3859-3861	be	_	
16-43	3862-3874	investigated	_	
16-44	3874-3875	.	_	

#Text=Our second aim was to address this issue by examining the relationship between activation and connectivity within this circuit and the subsequent onset of a psychotic disorder.
17-1	3876-3879	Our	_	
17-2	3880-3886	second	_	
17-3	3887-3890	aim	_	
17-4	3891-3894	was	_	
17-5	3895-3897	to	_	
17-6	3898-3905	address	_	
17-7	3906-3910	this	_	
17-8	3911-3916	issue	_	
17-9	3917-3919	by	_	
17-10	3920-3929	examining	_	
17-11	3930-3933	the	_	
17-12	3934-3946	relationship	_	
17-13	3947-3954	between	_	
17-14	3955-3965	activation	_	
17-15	3966-3969	and	_	
17-16	3970-3982	connectivity	_	
17-17	3983-3989	within	_	
17-18	3990-3994	this	_	
17-19	3995-4002	circuit	_	
17-20	4003-4006	and	_	
17-21	4007-4010	the	_	
17-22	4011-4021	subsequent	_	
17-23	4022-4027	onset	_	
17-24	4028-4030	of	_	
17-25	4031-4032	a	_	
17-26	4033-4042	psychotic	_	
17-27	4043-4051	disorder	_	
17-28	4051-4052	.	_	

#Text=We, therefore, followed up our CHR participants to determine their clinical outcome.
18-1	4053-4055	We	_	
18-2	4055-4056	,	_	
18-3	4057-4066	therefore	_	
18-4	4066-4067	,	_	
18-5	4068-4076	followed	_	
18-6	4077-4079	up	_	
18-7	4080-4083	our	_	
18-8	4084-4087	CHR	_	
18-9	4088-4100	participants	_	
18-10	4101-4103	to	_	
18-11	4104-4113	determine	_	
18-12	4114-4119	their	_	
18-13	4120-4128	clinical	_	
18-14	4129-4136	outcome	_	
18-15	4136-4137	.	_	

#Text=Our primary hypothesis was that during novelty salience processing, hippocampal-striatal-midbrain circuit activation would be attenuated in CHR individuals compared to healthy controls (HC).
19-1	4138-4141	Our	_	
19-2	4142-4149	primary	_	
19-3	4150-4160	hypothesis	_	
19-4	4161-4164	was	_	
19-5	4165-4169	that	_	
19-6	4170-4176	during	_	
19-7	4177-4184	novelty	_	
19-8	4185-4193	salience	_	
19-9	4194-4204	processing	_	
19-10	4204-4205	,	_	
19-11	4206-4235	hippocampal-striatal-midbrain	_	
19-12	4236-4243	circuit	_	
19-13	4244-4254	activation	_	
19-14	4255-4260	would	_	
19-15	4261-4263	be	_	
19-16	4264-4274	attenuated	_	
19-17	4275-4277	in	_	
19-18	4278-4281	CHR	_	
19-19	4282-4293	individuals	_	
19-20	4294-4302	compared	_	
19-21	4303-4305	to	_	
19-22	4306-4313	healthy	_	
19-23	4314-4322	controls	_	
19-24	4323-4324	(	_	
19-25	4324-4326	HC	_	
19-26	4326-4327	)	_	
19-27	4327-4328	.	_	

#Text=We also examined how pure novelty salience processing altered effective connectivity in this circuit.
20-1	4329-4331	We	_	
20-2	4332-4336	also	_	
20-3	4337-4345	examined	_	
20-4	4346-4349	how	_	
20-5	4350-4354	pure	_	
20-6	4355-4362	novelty	_	
20-7	4363-4371	salience	_	
20-8	4372-4382	processing	_	
20-9	4383-4390	altered	_	
20-10	4391-4400	effective	_	
20-11	4401-4413	connectivity	_	
20-12	4414-4416	in	_	
20-13	4417-4421	this	_	
20-14	4422-4429	circuit	_	
20-15	4429-4430	.	_	

#Text=Our second prediction was that these alterations would be particularly evident in the CHR subgroup who subsequently developed psychosis.
21-1	4431-4434	Our	_	
21-2	4435-4441	second	_	
21-3	4442-4452	prediction	_	
21-4	4453-4456	was	_	
21-5	4457-4461	that	_	
21-6	4462-4467	these	_	
21-7	4468-4479	alterations	_	
21-8	4480-4485	would	_	
21-9	4486-4488	be	_	
21-10	4489-4501	particularly	_	
21-11	4502-4509	evident	_	
21-12	4510-4512	in	_	
21-13	4513-4516	the	_	
21-14	4517-4520	CHR	_	
21-15	4521-4529	subgroup	_	
21-16	4530-4533	who	_	
21-17	4534-4546	subsequently	_	
21-18	4547-4556	developed	_	
21-19	4557-4566	psychosis	_	
21-20	4566-4567	.	_	

#Text=Methods
#Text=Participants
#Text=A total of 116 participants were recruited into the study.
22-1	4568-4575	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
22-2	4576-4588	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-3	4589-4590	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-4	4591-4596	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-5	4597-4599	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-6	4600-4603	116	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-7	4604-4616	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-8	4617-4621	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-9	4622-4631	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-10	4632-4636	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-11	4637-4640	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-12	4641-4646	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
22-13	4646-4647	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Ethical approval was obtained from the National Health Service UK Research Ethics Committee, and all participants provided written informed consent.
23-1	4648-4655	Ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-2	4656-4664	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-3	4665-4668	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-4	4669-4677	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-5	4678-4682	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-6	4683-4686	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-7	4687-4695	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-8	4696-4702	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-9	4703-4710	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-10	4711-4713	UK	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-11	4714-4722	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-12	4723-4729	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-13	4730-4739	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-14	4739-4740	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-15	4741-4744	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-16	4745-4748	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-17	4749-4761	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-18	4762-4770	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-19	4771-4778	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-20	4779-4787	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-21	4788-4795	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
23-22	4795-4796	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=CHR participants (n = 85) were recruited from 4 different clinical sites in England: OASIS (Outreach and Support in South London), part of the South London and Maudsley NHS Trust; CAMEO, part of the Cambridge and Peterborough NHS Trust; the West London Early Intervention Service; and the Coventry and Warwick Warwickshire Partnership NHS Trust.
24-1	4797-4800	CHR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[6]	
24-2	4801-4813	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-3	4814-4815	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-4	4815-4816	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-5	4817-4818	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-6	4819-4821	85	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-7	4821-4822	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-8	4823-4827	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-9	4828-4837	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-10	4838-4842	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-11	4843-4844	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-12	4845-4854	different	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-13	4855-4863	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-14	4864-4869	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-15	4870-4872	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-16	4873-4880	England	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-17	4880-4881	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-18	4882-4887	OASIS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-19	4888-4889	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-20	4889-4897	Outreach	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-21	4898-4901	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-22	4902-4909	Support	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-23	4910-4912	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-24	4913-4918	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-25	4919-4925	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-26	4925-4926	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-27	4926-4927	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-28	4928-4932	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-29	4933-4935	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-30	4936-4939	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-31	4940-4945	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-32	4946-4952	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-33	4953-4956	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-34	4957-4965	Maudsley	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-35	4966-4969	NHS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-36	4970-4975	Trust	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-37	4975-4976	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-38	4977-4982	CAMEO	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-39	4982-4983	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-40	4984-4988	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-41	4989-4991	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-42	4992-4995	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-43	4996-5005	Cambridge	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-44	5006-5009	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-45	5010-5022	Peterborough	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-46	5023-5026	NHS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-47	5027-5032	Trust	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-48	5032-5033	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-49	5034-5037	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-50	5038-5042	West	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-51	5043-5049	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-52	5050-5055	Early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-53	5056-5068	Intervention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-54	5069-5076	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-55	5076-5077	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-56	5078-5081	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-57	5082-5085	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-58	5086-5094	Coventry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-59	5095-5098	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-60	5099-5106	Warwick	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-61	5107-5119	Warwickshire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-62	5120-5131	Partnership	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-63	5132-5135	NHS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-64	5136-5141	Trust	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-65	5141-5142	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=All participants underwent clinical assessments and MRI scanning at King’s College London (KCL) by 2 trained researchers (CS and BQ).
25-1	5143-5146	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-2	5147-5159	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-3	5160-5169	underwent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-4	5170-5178	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-5	5179-5190	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-6	5191-5194	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-7	5195-5198	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[7]	
25-8	5199-5207	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-9	5208-5210	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-10	5211-5215	King	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-11	5215-5216	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-12	5216-5217	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-13	5218-5225	College	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-14	5226-5232	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-15	5233-5234	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-16	5234-5237	KCL	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-17	5237-5238	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-18	5239-5241	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-19	5242-5243	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-20	5244-5251	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-21	5252-5263	researchers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-22	5264-5265	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-23	5265-5267	CS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-24	5268-5271	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-25	5272-5274	BQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-26	5274-5275	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-27	5275-5276	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=CHR signs and symptoms for inclusion were assessed with the Comprehensive Assessment of At-Risk Mental States (CAARMS).
26-1	5277-5280	CHR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[8]	
26-2	5281-5286	signs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-3	5287-5290	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-4	5291-5299	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-5	5300-5303	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-6	5304-5313	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-7	5314-5318	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-8	5319-5327	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-9	5328-5332	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-10	5333-5336	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-11	5337-5350	Comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-12	5351-5361	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-13	5362-5364	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-14	5365-5372	At-Risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-15	5373-5379	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-16	5380-5386	States	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-17	5387-5388	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-18	5388-5394	CAARMS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-19	5394-5395	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-20	5395-5396	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Exclusion criteria were past/present diagnosis of psychotic disorders, past/present/familiar history of neurological illness, substance abuse/dependence according to DSM-5 criteria or contraindication to scanning.
27-1	5397-5406	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-2	5407-5415	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-3	5416-5420	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-4	5421-5425	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-5	5425-5426	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-6	5426-5433	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-7	5434-5443	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-8	5444-5446	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-9	5447-5456	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-10	5457-5466	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-11	5466-5467	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-12	5468-5472	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-13	5472-5473	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-14	5473-5480	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-15	5480-5481	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-16	5481-5489	familiar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-17	5490-5497	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-18	5498-5500	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-19	5501-5513	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-20	5514-5521	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-21	5521-5522	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-22	5523-5532	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-23	5533-5538	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-24	5538-5539	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-25	5539-5549	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-26	5550-5559	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-27	5560-5562	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-28	5563-5566	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-29	5566-5567	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-30	5567-5568	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-31	5569-5577	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-32	5578-5580	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-33	5581-5597	contraindication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-34	5598-5600	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-35	5601-5609	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-36	5609-5610	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=HC (n = 31) were recruited from the same geographical areas as CHR participants.
28-1	5611-5613	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
28-2	5614-5615	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-3	5615-5616	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-4	5617-5618	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-5	5619-5621	31	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-6	5621-5622	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-7	5623-5627	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-8	5628-5637	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-9	5638-5642	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-10	5643-5646	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-11	5647-5651	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-12	5652-5664	geographical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-13	5665-5670	areas	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-14	5671-5673	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-15	5674-5677	CHR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[10]	
28-16	5678-5690	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-17	5690-5691	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=None had a personal/familial history of psychiatric/neurological disorder or were using prescription medication as assessed via self-report.
29-1	5692-5696	None	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-2	5697-5700	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-3	5701-5702	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-4	5703-5711	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-5	5711-5712	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-6	5712-5720	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-7	5721-5728	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-8	5729-5731	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-9	5732-5743	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-10	5743-5744	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-11	5744-5756	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-12	5757-5765	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-13	5766-5768	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-14	5769-5773	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-15	5774-5779	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-16	5780-5792	prescription	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-17	5793-5803	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-18	5804-5806	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-19	5807-5815	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-20	5816-5819	via	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-21	5820-5831	self-report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-22	5831-5832	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Additional exclusion criteria for all participants involved self-reporting illicit substance use in the week prior to scanning or alcohol use in the 24 hours prior to scanning.
30-1	5833-5843	Additional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-2	5844-5853	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-3	5854-5862	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-4	5863-5866	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-5	5867-5870	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-6	5871-5883	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-7	5884-5892	involved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-8	5893-5907	self-reporting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-9	5908-5915	illicit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-10	5916-5925	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-11	5926-5929	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-12	5930-5932	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-13	5933-5936	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-14	5937-5941	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-15	5942-5947	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-16	5948-5950	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-17	5951-5959	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-18	5960-5962	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-19	5963-5970	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-20	5971-5974	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-21	5975-5977	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-22	5978-5981	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-23	5982-5984	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-24	5985-5990	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-25	5991-5996	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-26	5997-5999	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-27	6000-6008	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-28	6008-6009	.	_	

#Text=Clinical Measures
#Text=On the day of the MRI scan, the following measures were collected at KCL by trained raters: psychopathology using the CAARMS, anxiety and depression symptoms using the Hamilton Anxiety and Depression Scales (HAM-A/HAM-D), Premorbid IQ was estimated with the National Adult Reading Test (NART).
31-1	6010-6018	Clinical	_	
31-2	6019-6027	Measures	_	
31-3	6028-6030	On	_	
31-4	6031-6034	the	_	
31-5	6035-6038	day	_	
31-6	6039-6041	of	_	
31-7	6042-6045	the	_	
31-8	6046-6049	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
31-9	6050-6054	scan	_	
31-10	6054-6055	,	_	
31-11	6056-6059	the	_	
31-12	6060-6069	following	_	
31-13	6070-6078	measures	_	
31-14	6079-6083	were	_	
31-15	6084-6093	collected	_	
31-16	6094-6096	at	_	
31-17	6097-6100	KCL	_	
31-18	6101-6103	by	_	
31-19	6104-6111	trained	_	
31-20	6112-6118	raters	_	
31-21	6118-6119	:	_	
31-22	6120-6135	psychopathology	_	
31-23	6136-6141	using	_	
31-24	6142-6145	the	_	
31-25	6146-6152	CAARMS	_	
31-26	6152-6153	,	_	
31-27	6154-6161	anxiety	_	
31-28	6162-6165	and	_	
31-29	6166-6176	depression	_	
31-30	6177-6185	symptoms	_	
31-31	6186-6191	using	_	
31-32	6192-6195	the	_	
31-33	6196-6204	Hamilton	_	
31-34	6205-6212	Anxiety	_	
31-35	6213-6216	and	_	
31-36	6217-6227	Depression	_	
31-37	6228-6234	Scales	_	
31-38	6235-6236	(	_	
31-39	6236-6241	HAM-A	_	
31-40	6241-6242	/	_	
31-41	6242-6247	HAM-D	_	
31-42	6247-6248	)	_	
31-43	6248-6249	,	_	
31-44	6250-6259	Premorbid	_	
31-45	6260-6262	IQ	_	
31-46	6263-6266	was	_	
31-47	6267-6276	estimated	_	
31-48	6277-6281	with	_	
31-49	6282-6285	the	_	
31-50	6286-6294	National	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[11]	
31-51	6295-6300	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[11]	
31-52	6301-6308	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[11]	
31-53	6309-6313	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[11]	
31-54	6314-6315	(	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[11]	
31-55	6315-6319	NART	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[11]	
31-56	6319-6320	)	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[11]	
31-57	6320-6321	.	_	

#Text=Handedness was assessed using the Annett Handedness Scale.
32-1	6322-6332	Handedness	_	
32-2	6333-6336	was	_	
32-3	6337-6345	assessed	_	
32-4	6346-6351	using	_	
32-5	6352-6355	the	_	
32-6	6356-6362	Annett	_	
32-7	6363-6373	Handedness	_	
32-8	6374-6379	Scale	_	
32-9	6379-6380	.	_	

#Text=Participants provided information on tobacco (cigarettes/day), alcohol (units/day), and cannabis use (0 = no use, 1 = experimental use, 2 = occasional use, 3 = moderate use, 4 = severe use).
33-1	6381-6393	Participants	_	
33-2	6394-6402	provided	_	
33-3	6403-6414	information	_	
33-4	6415-6417	on	_	
33-5	6418-6425	tobacco	_	
33-6	6426-6427	(	_	
33-7	6427-6437	cigarettes	_	
33-8	6437-6438	/	_	
33-9	6438-6441	day	_	
33-10	6441-6442	)	_	
33-11	6442-6443	,	_	
33-12	6444-6451	alcohol	_	
33-13	6452-6453	(	_	
33-14	6453-6458	units	_	
33-15	6458-6459	/	_	
33-16	6459-6462	day	_	
33-17	6462-6463	)	_	
33-18	6463-6464	,	_	
33-19	6465-6468	and	_	
33-20	6469-6477	cannabis	_	
33-21	6478-6481	use	_	
33-22	6482-6483	(	_	
33-23	6483-6484	0	_	
33-24	6485-6486	=	_	
33-25	6487-6489	no	_	
33-26	6490-6493	use	_	
33-27	6493-6494	,	_	
33-28	6495-6496	1	_	
33-29	6497-6498	=	_	
33-30	6499-6511	experimental	_	
33-31	6512-6515	use	_	
33-32	6515-6516	,	_	
33-33	6517-6518	2	_	
33-34	6519-6520	=	_	
33-35	6521-6531	occasional	_	
33-36	6532-6535	use	_	
33-37	6535-6536	,	_	
33-38	6537-6538	3	_	
33-39	6539-6540	=	_	
33-40	6541-6549	moderate	_	
33-41	6550-6553	use	_	
33-42	6553-6554	,	_	
33-43	6555-6556	4	_	
33-44	6557-6558	=	_	
33-45	6559-6565	severe	_	
33-46	6566-6569	use	_	
33-47	6569-6570	)	_	
33-48	6570-6571	.	_	

#Text=Novelty Salience Task
#Text=All participants underwent fMRI scanning on a 3T GE scanner at KCL using an event-related novelty salience task adapted from Bunzeck and Duzel.
34-1	6572-6579	Novelty	_	
34-2	6580-6588	Salience	_	
34-3	6589-6593	Task	_	
34-4	6594-6597	All	_	
34-5	6598-6610	participants	_	
34-6	6611-6620	underwent	_	
34-7	6621-6625	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
34-8	6626-6634	scanning	_	
34-9	6635-6637	on	_	
34-10	6638-6639	a	_	
34-11	6640-6642	3T	_	
34-12	6643-6645	GE	_	
34-13	6646-6653	scanner	_	
34-14	6654-6656	at	_	
34-15	6657-6660	KCL	_	
34-16	6661-6666	using	_	
34-17	6667-6669	an	_	
34-18	6670-6683	event-related	_	
34-19	6684-6691	novelty	_	
34-20	6692-6700	salience	_	
34-21	6701-6705	task	_	
34-22	6706-6713	adapted	_	
34-23	6714-6718	from	_	
34-24	6719-6726	Bunzeck	_	
34-25	6727-6730	and	_	
34-26	6731-6736	Duzel	_	
34-27	6736-6737	.	_	

#Text=Participants completed three 6-minute runs of a visual oddball paradigm (figure 1A).
35-1	6738-6750	Participants	_	
35-2	6751-6760	completed	_	
35-3	6761-6766	three	_	
35-4	6767-6768	6	_	
35-5	6768-6769	-	_	
35-6	6769-6775	minute	_	
35-7	6776-6780	runs	_	
35-8	6781-6783	of	_	
35-9	6784-6785	a	_	
35-10	6786-6792	visual	_	
35-11	6793-6800	oddball	_	
35-12	6801-6809	paradigm	_	
35-13	6810-6811	(	_	
35-14	6811-6817	figure	_	
35-15	6818-6820	1A	_	
35-16	6820-6821	)	_	
35-17	6821-6822	.	_	

#Text=In each of the 3 runs, there were 80 standards (same picture in 73% of trials), 10 target oddballs (same picture in 9% of trials, requiring a button press at each presentation), 10 neutral oddballs (same picture in 9% of trials), and 10 novel oddballs (a unique picture in 9% of trials representing a “pure novel stimulus” ), yielding a total of 360 stimuli across the entire 18-minute experiment (240 standards, 30 target oddballs, 30 neutral oddballs, and 30 novel oddballs).
36-1	6823-6825	In	_	
36-2	6826-6830	each	_	
36-3	6831-6833	of	_	
36-4	6834-6837	the	_	
36-5	6838-6839	3	_	
36-6	6840-6844	runs	_	
36-7	6844-6845	,	_	
36-8	6846-6851	there	_	
36-9	6852-6856	were	_	
36-10	6857-6859	80	_	
36-11	6860-6869	standards	_	
36-12	6870-6871	(	_	
36-13	6871-6875	same	_	
36-14	6876-6883	picture	_	
36-15	6884-6886	in	_	
36-16	6887-6890	73%	_	
36-17	6891-6893	of	_	
36-18	6894-6900	trials	_	
36-19	6900-6901	)	_	
36-20	6901-6902	,	_	
36-21	6903-6905	10	_	
36-22	6906-6912	target	_	
36-23	6913-6921	oddballs	_	
36-24	6922-6923	(	_	
36-25	6923-6927	same	_	
36-26	6928-6935	picture	_	
36-27	6936-6938	in	_	
36-28	6939-6941	9%	_	
36-29	6942-6944	of	_	
36-30	6945-6951	trials	_	
36-31	6951-6952	,	_	
36-32	6953-6962	requiring	_	
36-33	6963-6964	a	_	
36-34	6965-6971	button	_	
36-35	6972-6977	press	_	
36-36	6978-6980	at	_	
36-37	6981-6985	each	_	
36-38	6986-6998	presentation	_	
36-39	6998-6999	)	_	
36-40	6999-7000	,	_	
36-41	7001-7003	10	_	
36-42	7004-7011	neutral	_	
36-43	7012-7020	oddballs	_	
36-44	7021-7022	(	_	
36-45	7022-7026	same	_	
36-46	7027-7034	picture	_	
36-47	7035-7037	in	_	
36-48	7038-7040	9%	_	
36-49	7041-7043	of	_	
36-50	7044-7050	trials	_	
36-51	7050-7051	)	_	
36-52	7051-7052	,	_	
36-53	7053-7056	and	_	
36-54	7057-7059	10	_	
36-55	7060-7065	novel	_	
36-56	7066-7074	oddballs	_	
36-57	7075-7076	(	_	
36-58	7076-7077	a	_	
36-59	7078-7084	unique	_	
36-60	7085-7092	picture	_	
36-61	7093-7095	in	_	
36-62	7096-7098	9%	_	
36-63	7099-7101	of	_	
36-64	7102-7108	trials	_	
36-65	7109-7121	representing	_	
36-66	7122-7123	a	_	
36-67	7124-7125	“	_	
36-68	7125-7129	pure	_	
36-69	7130-7135	novel	_	
36-70	7136-7144	stimulus	_	
36-71	7144-7145	”	_	
36-72	7146-7147	)	_	
36-73	7147-7148	,	_	
36-74	7149-7157	yielding	_	
36-75	7158-7159	a	_	
36-76	7160-7165	total	_	
36-77	7166-7168	of	_	
36-78	7169-7172	360	_	
36-79	7173-7180	stimuli	_	
36-80	7181-7187	across	_	
36-81	7188-7191	the	_	
36-82	7192-7198	entire	_	
36-83	7199-7201	18	_	
36-84	7201-7202	-	_	
36-85	7202-7208	minute	_	
36-86	7209-7219	experiment	_	
36-87	7220-7221	(	_	
36-88	7221-7224	240	_	
36-89	7225-7234	standards	_	
36-90	7234-7235	,	_	
36-91	7236-7238	30	_	
36-92	7239-7245	target	_	
36-93	7246-7254	oddballs	_	
36-94	7254-7255	,	_	
36-95	7256-7258	30	_	
36-96	7259-7266	neutral	_	
36-97	7267-7275	oddballs	_	
36-98	7275-7276	,	_	
36-99	7277-7280	and	_	
36-100	7281-7283	30	_	
36-101	7284-7289	novel	_	
36-102	7290-7298	oddballs	_	
36-103	7298-7299	)	_	
36-104	7299-7300	.	_	

#Text=All pictures depicted black-and-white outdoor scenes.
37-1	7301-7304	All	_	
37-2	7305-7313	pictures	_	
37-3	7314-7322	depicted	_	
37-4	7323-7338	black-and-white	_	
37-5	7339-7346	outdoor	_	
37-6	7347-7353	scenes	_	
37-7	7353-7354	.	_	

#Text=The target stimulus, used solely to assess engagement with the task as in the original study (there was no measure of accuracy during novelty processing), was presented at the start of the experimental session for 4.5 seconds.
38-1	7355-7358	The	_	
38-2	7359-7365	target	_	
38-3	7366-7374	stimulus	_	
38-4	7374-7375	,	_	
38-5	7376-7380	used	_	
38-6	7381-7387	solely	_	
38-7	7388-7390	to	_	
38-8	7391-7397	assess	_	
38-9	7398-7408	engagement	_	
38-10	7409-7413	with	_	
38-11	7414-7417	the	_	
38-12	7418-7422	task	_	
38-13	7423-7425	as	_	
38-14	7426-7428	in	_	
38-15	7429-7432	the	_	
38-16	7433-7441	original	_	
38-17	7442-7447	study	_	
38-18	7448-7449	(	_	
38-19	7449-7454	there	_	
38-20	7455-7458	was	_	
38-21	7459-7461	no	_	
38-22	7462-7469	measure	_	
38-23	7470-7472	of	_	
38-24	7473-7481	accuracy	_	
38-25	7482-7488	during	_	
38-26	7489-7496	novelty	_	
38-27	7497-7507	processing	_	
38-28	7507-7508	)	_	
38-29	7508-7509	,	_	
38-30	7510-7513	was	_	
38-31	7514-7523	presented	_	
38-32	7524-7526	at	_	
38-33	7527-7530	the	_	
38-34	7531-7536	start	_	
38-35	7537-7539	of	_	
38-36	7540-7543	the	_	
38-37	7544-7556	experimental	_	
38-38	7557-7564	session	_	
38-39	7565-7568	for	_	
38-40	7569-7572	4.5	_	
38-41	7573-7580	seconds	_	
38-42	7580-7581	.	_	

#Text=Participants were asked to press a button with their right index finger every time it appeared (30 presentations in total).
39-1	7582-7594	Participants	_	
39-2	7595-7599	were	_	
39-3	7600-7605	asked	_	
39-4	7606-7608	to	_	
39-5	7609-7614	press	_	
39-6	7615-7616	a	_	
39-7	7617-7623	button	_	
39-8	7624-7628	with	_	
39-9	7629-7634	their	_	
39-10	7635-7640	right	_	
39-11	7641-7646	index	_	
39-12	7647-7653	finger	_	
39-13	7654-7659	every	_	
39-14	7660-7664	time	_	
39-15	7665-7667	it	_	
39-16	7668-7676	appeared	_	
39-17	7677-7678	(	_	
39-18	7678-7680	30	_	
39-19	7681-7694	presentations	_	
39-20	7695-7697	in	_	
39-21	7698-7703	total	_	
39-22	7703-7704	)	_	
39-23	7704-7705	.	_	

#Text=During the experiment, pictures were presented for 500 ms followed by a white fixation cross on a gray background with an inter-stimulus interval of 2.7 seconds, jittered between −300 ms and +300 ms (uniformly distributed).
40-1	7706-7712	During	_	
40-2	7713-7716	the	_	
40-3	7717-7727	experiment	_	
40-4	7727-7728	,	_	
40-5	7729-7737	pictures	_	
40-6	7738-7742	were	_	
40-7	7743-7752	presented	_	
40-8	7753-7756	for	_	
40-9	7757-7760	500	_	
40-10	7761-7763	ms	_	
40-11	7764-7772	followed	_	
40-12	7773-7775	by	_	
40-13	7776-7777	a	_	
40-14	7778-7783	white	_	
40-15	7784-7792	fixation	_	
40-16	7793-7798	cross	_	
40-17	7799-7801	on	_	
40-18	7802-7803	a	_	
40-19	7804-7808	gray	_	
40-20	7809-7819	background	_	
40-21	7820-7824	with	_	
40-22	7825-7827	an	_	
40-23	7828-7842	inter-stimulus	_	
40-24	7843-7851	interval	_	
40-25	7852-7854	of	_	
40-26	7855-7858	2.7	_	
40-27	7859-7866	seconds	_	
40-28	7866-7867	,	_	
40-29	7868-7876	jittered	_	
40-30	7877-7884	between	_	
40-31	7885-7886	−	_	
40-32	7886-7889	300	_	
40-33	7890-7892	ms	_	
40-34	7893-7896	and	_	
40-35	7897-7898	+	_	
40-36	7898-7901	300	_	
40-37	7902-7904	ms	_	
40-38	7905-7906	(	_	
40-39	7906-7915	uniformly	_	
40-40	7916-7927	distributed	_	
40-41	7927-7928	)	_	
40-42	7928-7929	.	_	

#Text=Clinical Follow-up
#Text=The entire CHR sample was followed up subsequent to scanning to determine clinical outcome (transition/non-transition to psychosis).
41-1	7930-7938	Clinical	_	
41-2	7939-7948	Follow-up	_	
41-3	7949-7952	The	_	
41-4	7953-7959	entire	_	
41-5	7960-7963	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk	
41-6	7964-7970	sample	_	
41-7	7971-7974	was	_	
41-8	7975-7983	followed	_	
41-9	7984-7986	up	_	
41-10	7987-7997	subsequent	_	
41-11	7998-8000	to	_	
41-12	8001-8009	scanning	_	
41-13	8010-8012	to	_	
41-14	8013-8022	determine	_	
41-15	8023-8031	clinical	_	
41-16	8032-8039	outcome	_	
41-17	8040-8041	(	_	
41-18	8041-8051	transition	_	
41-19	8051-8052	/	_	
41-20	8052-8066	non-transition	_	
41-21	8067-8069	to	_	
41-22	8070-8079	psychosis	_	
41-23	8079-8080	)	_	
41-24	8080-8081	.	_	

#Text=The mean interval between baseline and follow-up assessments was 59.7 months (SD = 15.4 mo).
42-1	8082-8085	The	_	
42-2	8086-8090	mean	_	
42-3	8091-8099	interval	_	
42-4	8100-8107	between	_	
42-5	8108-8116	baseline	_	
42-6	8117-8120	and	_	
42-7	8121-8130	follow-up	_	
42-8	8131-8142	assessments	_	
42-9	8143-8146	was	_	
42-10	8147-8151	59.7	_	
42-11	8152-8158	months	_	
42-12	8159-8160	(	_	
42-13	8160-8162	SD	_	
42-14	8163-8164	=	_	
42-15	8165-8169	15.4	_	
42-16	8170-8172	mo	_	
42-17	8172-8173	)	_	
42-18	8173-8174	.	_	

#Text=Transition to psychosis was determined using CAARMS Psychosis Threshold criteria and confirmed with the Structured Clinical Interview for Diagnosis, administered by a psychiatrist trained in its use.
43-1	8175-8185	Transition	_	
43-2	8186-8188	to	_	
43-3	8189-8198	psychosis	_	
43-4	8199-8202	was	_	
43-5	8203-8213	determined	_	
43-6	8214-8219	using	_	
43-7	8220-8226	CAARMS	_	
43-8	8227-8236	Psychosis	_	
43-9	8237-8246	Threshold	_	
43-10	8247-8255	criteria	_	
43-11	8256-8259	and	_	
43-12	8260-8269	confirmed	_	
43-13	8270-8274	with	_	
43-14	8275-8278	the	_	
43-15	8279-8289	Structured	_	
43-16	8290-8298	Clinical	_	
43-17	8299-8308	Interview	_	
43-18	8309-8312	for	_	
43-19	8313-8322	Diagnosis	_	
43-20	8322-8323	,	_	
43-21	8324-8336	administered	_	
43-22	8337-8339	by	_	
43-23	8340-8341	a	_	
43-24	8342-8354	psychiatrist	_	
43-25	8355-8362	trained	_	
43-26	8363-8365	in	_	
43-27	8366-8369	its	_	
43-28	8370-8373	use	_	
43-29	8373-8374	.	_	

#Text=Image Acquisition and Preprocessing
#Text=See supplementary material for details on fMRI acquisition and preprocessing.
44-1	8375-8380	Image	_	
44-2	8381-8392	Acquisition	_	
44-3	8393-8396	and	_	
44-4	8397-8410	Preprocessing	_	
44-5	8411-8414	See	_	
44-6	8415-8428	supplementary	_	
44-7	8429-8437	material	_	
44-8	8438-8441	for	_	
44-9	8442-8449	details	_	
44-10	8450-8452	on	_	
44-11	8453-8457	fMRI	_	
44-12	8458-8469	acquisition	_	
44-13	8470-8473	and	_	
44-14	8474-8487	preprocessing	_	
44-15	8487-8488	.	_	

#Text=Statistics
#Text=Demographic, Clinical, and Behavioral Data
#Text=Analyses of demographic data were performed in SPSS 24 (http://www-01.ibm.com/software/uk/analytics/spss/).
45-1	8489-8499	Statistics	_	
45-2	8500-8511	Demographic	_	
45-3	8511-8512	,	_	
45-4	8513-8521	Clinical	_	
45-5	8521-8522	,	_	
45-6	8523-8526	and	_	
45-7	8527-8537	Behavioral	_	
45-8	8538-8542	Data	_	
45-9	8543-8551	Analyses	_	
45-10	8552-8554	of	_	
45-11	8555-8566	demographic	_	
45-12	8567-8571	data	_	
45-13	8572-8576	were	_	
45-14	8577-8586	performed	_	
45-15	8587-8589	in	_	
45-16	8590-8594	SPSS	_	
45-17	8595-8597	24	_	
45-18	8598-8599	(	_	
45-19	8599-8603	http	_	
45-20	8603-8604	:	_	
45-21	8604-8605	/	_	
45-22	8605-8606	/	_	
45-23	8606-8609	www	_	
45-24	8609-8610	-	_	
45-25	8610-8612	01	_	
45-26	8612-8613	.	_	
45-27	8613-8620	ibm.com	_	
45-28	8620-8621	/	_	
45-29	8621-8629	software	_	
45-30	8629-8630	/	_	
45-31	8630-8632	uk	_	
45-32	8632-8633	/	_	
45-33	8633-8642	analytics	_	
45-34	8642-8643	/	_	
45-35	8643-8647	spss	_	
45-36	8647-8648	/	_	
45-37	8648-8649	)	_	
45-38	8649-8650	.	_	

#Text=The effect of group on these measures was examined using independent samples t-tests for parametric data and Chi-square tests for nonparametric data.
46-1	8651-8654	The	_	
46-2	8655-8661	effect	_	
46-3	8662-8664	of	_	
46-4	8665-8670	group	_	
46-5	8671-8673	on	_	
46-6	8674-8679	these	_	
46-7	8680-8688	measures	_	
46-8	8689-8692	was	_	
46-9	8693-8701	examined	_	
46-10	8702-8707	using	_	
46-11	8708-8719	independent	_	
46-12	8720-8727	samples	_	
46-13	8728-8735	t-tests	_	
46-14	8736-8739	for	_	
46-15	8740-8750	parametric	_	
46-16	8751-8755	data	_	
46-17	8756-8759	and	_	
46-18	8760-8770	Chi-square	_	
46-19	8771-8776	tests	_	
46-20	8777-8780	for	_	
46-21	8781-8794	nonparametric	_	
46-22	8795-8799	data	_	
46-23	8799-8800	.	_	

#Text=To examine the relationship between fMRI activation and transition to psychosis, the CHR sample was divided into 2 groups at follow-up: a transition to psychosis group (CHR-T) and a non-transition to psychosis group (CHR-NT).
47-1	8801-8803	To	_	
47-2	8804-8811	examine	_	
47-3	8812-8815	the	_	
47-4	8816-8828	relationship	_	
47-5	8829-8836	between	_	
47-6	8837-8841	fMRI	_	
47-7	8842-8852	activation	_	
47-8	8853-8856	and	_	
47-9	8857-8867	transition	_	
47-10	8868-8870	to	_	
47-11	8871-8880	psychosis	_	
47-12	8880-8881	,	_	
47-13	8882-8885	the	_	
47-14	8886-8889	CHR	_	
47-15	8890-8896	sample	_	
47-16	8897-8900	was	_	
47-17	8901-8908	divided	_	
47-18	8909-8913	into	_	
47-19	8914-8915	2	_	
47-20	8916-8922	groups	_	
47-21	8923-8925	at	_	
47-22	8926-8935	follow-up	_	
47-23	8935-8936	:	_	
47-24	8937-8938	a	_	
47-25	8939-8949	transition	_	
47-26	8950-8952	to	_	
47-27	8953-8962	psychosis	_	
47-28	8963-8968	group	_	
47-29	8969-8970	(	_	
47-30	8970-8975	CHR-T	_	
47-31	8975-8976	)	_	
47-32	8977-8980	and	_	
47-33	8981-8982	a	_	
47-34	8983-8997	non-transition	_	
47-35	8998-9000	to	_	
47-36	9001-9010	psychosis	_	
47-37	9011-9016	group	_	
47-38	9017-9018	(	_	
47-39	9018-9024	CHR-NT	_	
47-40	9024-9025	)	_	
47-41	9025-9026	.	_	

#Text=Analysis of behavioral data were performed in SPSS 24 for reaction time (RT), target recognition and error rates using separate 2-sample t-tests: HC vs CHR and CHR-NT vs CHR-T.
48-1	9027-9035	Analysis	_	
48-2	9036-9038	of	_	
48-3	9039-9049	behavioral	_	
48-4	9050-9054	data	_	
48-5	9055-9059	were	_	
48-6	9060-9069	performed	_	
48-7	9070-9072	in	_	
48-8	9073-9077	SPSS	_	
48-9	9078-9080	24	_	
48-10	9081-9084	for	_	
48-11	9085-9093	reaction	_	
48-12	9094-9098	time	_	
48-13	9099-9100	(	_	
48-14	9100-9102	RT	_	
48-15	9102-9103	)	_	
48-16	9103-9104	,	_	
48-17	9105-9111	target	_	
48-18	9112-9123	recognition	_	
48-19	9124-9127	and	_	
48-20	9128-9133	error	_	
48-21	9134-9139	rates	_	
48-22	9140-9145	using	_	
48-23	9146-9154	separate	_	
48-24	9155-9156	2	_	
48-25	9156-9157	-	_	
48-26	9157-9163	sample	_	
48-27	9164-9171	t-tests	_	
48-28	9171-9172	:	_	
48-29	9173-9175	HC	_	
48-30	9176-9178	vs	_	
48-31	9179-9182	CHR	_	
48-32	9183-9186	and	_	
48-33	9187-9193	CHR-NT	_	
48-34	9194-9196	vs	_	
48-35	9197-9202	CHR-T	_	
48-36	9202-9203	.	_	

#Text=Significant effects are reported at P < .05 with Bonferroni post hoc correction as appropriate (demographic data: age, sex, IQ, years of education, handedness, tobacco, alcohol, cannabis, antipsychotics, and antidepressant use—P < .05/10 = P < .005; clinical data: CAARMS positive, negative, total, GAF, HAM-A, and HAM-D—P < .05/6 = P < .008; behavior: targetness, errors, and RT—P < .05/3 = P < .017).
#Text=fMRI Data Analysis
#Text=Statistical analysis of the fMRI data was conducted using the general linear model in SPM12.
49-1	9204-9215	Significant	_	
49-2	9216-9223	effects	_	
49-3	9224-9227	are	_	
49-4	9228-9236	reported	_	
49-5	9237-9239	at	_	
49-6	9240-9241	P	_	
49-7	9242-9243	<	_	
49-8	9244-9247	.05	_	
49-9	9248-9252	with	_	
49-10	9253-9263	Bonferroni	_	
49-11	9264-9268	post	_	
49-12	9269-9272	hoc	_	
49-13	9273-9283	correction	_	
49-14	9284-9286	as	_	
49-15	9287-9298	appropriate	_	
49-16	9299-9300	(	_	
49-17	9300-9311	demographic	_	
49-18	9312-9316	data	_	
49-19	9316-9317	:	_	
49-20	9318-9321	age	_	
49-21	9321-9322	,	_	
49-22	9323-9326	sex	_	
49-23	9326-9327	,	_	
49-24	9328-9330	IQ	_	
49-25	9330-9331	,	_	
49-26	9332-9337	years	_	
49-27	9338-9340	of	_	
49-28	9341-9350	education	_	
49-29	9350-9351	,	_	
49-30	9352-9362	handedness	_	
49-31	9362-9363	,	_	
49-32	9364-9371	tobacco	_	
49-33	9371-9372	,	_	
49-34	9373-9380	alcohol	_	
49-35	9380-9381	,	_	
49-36	9382-9390	cannabis	_	
49-37	9390-9391	,	_	
49-38	9392-9406	antipsychotics	_	
49-39	9406-9407	,	_	
49-40	9408-9411	and	_	
49-41	9412-9426	antidepressant	_	
49-42	9427-9432	use—P	_	
49-43	9433-9434	<	_	
49-44	9435-9438	.05	_	
49-45	9438-9439	/	_	
49-46	9439-9441	10	_	
49-47	9442-9443	=	_	
49-48	9444-9445	P	_	
49-49	9446-9447	<	_	
49-50	9448-9452	.005	_	
49-51	9452-9453	;	_	
49-52	9454-9462	clinical	_	
49-53	9463-9467	data	_	
49-54	9467-9468	:	_	
49-55	9469-9475	CAARMS	_	
49-56	9476-9484	positive	_	
49-57	9484-9485	,	_	
49-58	9486-9494	negative	_	
49-59	9494-9495	,	_	
49-60	9496-9501	total	_	
49-61	9501-9502	,	_	
49-62	9503-9506	GAF	_	
49-63	9506-9507	,	_	
49-64	9508-9513	HAM-A	_	
49-65	9513-9514	,	_	
49-66	9515-9518	and	_	
49-67	9519-9526	HAM-D—P	_	
49-68	9527-9528	<	_	
49-69	9529-9532	.05	_	
49-70	9532-9533	/	_	
49-71	9533-9534	6	_	
49-72	9535-9536	=	_	
49-73	9537-9538	P	_	
49-74	9539-9540	<	_	
49-75	9541-9545	.008	_	
49-76	9545-9546	;	_	
49-77	9547-9555	behavior	_	
49-78	9555-9556	:	_	
49-79	9557-9567	targetness	_	
49-80	9567-9568	,	_	
49-81	9569-9575	errors	_	
49-82	9575-9576	,	_	
49-83	9577-9580	and	_	
49-84	9581-9585	RT—P	_	
49-85	9586-9587	<	_	
49-86	9588-9591	.05	_	
49-87	9591-9592	/	_	
49-88	9592-9593	3	_	
49-89	9594-9595	=	_	
49-90	9596-9597	P	_	
49-91	9598-9599	<	_	
49-92	9600-9604	.017	_	
49-93	9604-9605	)	_	
49-94	9605-9606	.	_	
49-95	9607-9611	fMRI	_	
49-96	9612-9616	Data	_	
49-97	9617-9625	Analysis	_	
49-98	9626-9637	Statistical	_	
49-99	9638-9646	analysis	_	
49-100	9647-9649	of	_	
49-101	9650-9653	the	_	
49-102	9654-9658	fMRI	_	
49-103	9659-9663	data	_	
49-104	9664-9667	was	_	
49-105	9668-9677	conducted	_	
49-106	9678-9683	using	_	
49-107	9684-9687	the	_	
49-108	9688-9695	general	_	
49-109	9696-9702	linear	_	
49-110	9703-9708	model	_	
49-111	9709-9711	in	_	
49-112	9712-9717	SPM12	_	
49-113	9717-9718	.	_	

#Text=Separate regressors of interest were specified for each trial type: Standard, Target, Neutral, and Novel.
50-1	9719-9727	Separate	_	
50-2	9728-9738	regressors	_	
50-3	9739-9741	of	_	
50-4	9742-9750	interest	_	
50-5	9751-9755	were	_	
50-6	9756-9765	specified	_	
50-7	9766-9769	for	_	
50-8	9770-9774	each	_	
50-9	9775-9780	trial	_	
50-10	9781-9785	type	_	
50-11	9785-9786	:	_	
50-12	9787-9795	Standard	_	
50-13	9795-9796	,	_	
50-14	9797-9803	Target	_	
50-15	9803-9804	,	_	
50-16	9805-9812	Neutral	_	
50-17	9812-9813	,	_	
50-18	9814-9817	and	_	
50-19	9818-9823	Novel	_	
50-20	9823-9824	.	_	

#Text=Realignment parameters (x, y, z, pitch, roll, yaw) were included in all first-level models as covariates of no interest to account for variance associated with head movement.
51-1	9825-9836	Realignment	_	
51-2	9837-9847	parameters	_	
51-3	9848-9849	(	_	
51-4	9849-9850	x	_	
51-5	9850-9851	,	_	
51-6	9852-9853	y	_	
51-7	9853-9854	,	_	
51-8	9855-9856	z	_	
51-9	9856-9857	,	_	
51-10	9858-9863	pitch	_	
51-11	9863-9864	,	_	
51-12	9865-9869	roll	_	
51-13	9869-9870	,	_	
51-14	9871-9874	yaw	_	
51-15	9874-9875	)	_	
51-16	9876-9880	were	_	
51-17	9881-9889	included	_	
51-18	9890-9892	in	_	
51-19	9893-9896	all	_	
51-20	9897-9908	first-level	_	
51-21	9909-9915	models	_	
51-22	9916-9918	as	_	
51-23	9919-9929	covariates	_	
51-24	9930-9932	of	_	
51-25	9933-9935	no	_	
51-26	9936-9944	interest	_	
51-27	9945-9947	to	_	
51-28	9948-9955	account	_	
51-29	9956-9959	for	_	
51-30	9960-9968	variance	_	
51-31	9969-9979	associated	_	
51-32	9980-9984	with	_	
51-33	9985-9989	head	_	
51-34	9990-9998	movement	_	
51-35	9998-9999	.	_	

#Text=All regressors were convolved with a canonical hemodynamic response function during the 500 ms in which trials were presented.
52-1	10000-10003	All	_	
52-2	10004-10014	regressors	_	
52-3	10015-10019	were	_	
52-4	10020-10029	convolved	_	
52-5	10030-10034	with	_	
52-6	10035-10036	a	_	
52-7	10037-10046	canonical	_	
52-8	10047-10058	hemodynamic	_	
52-9	10059-10067	response	_	
52-10	10068-10076	function	_	
52-11	10077-10083	during	_	
52-12	10084-10087	the	_	
52-13	10088-10091	500	_	
52-14	10092-10094	ms	_	
52-15	10095-10097	in	_	
52-16	10098-10103	which	_	
52-17	10104-10110	trials	_	
52-18	10111-10115	were	_	
52-19	10116-10125	presented	_	
52-20	10125-10126	.	_	

#Text=One contrast image was generated for each participant to examine activation related to pure stimulus novelty by contrasting all novel oddball trials against neutral oddball trials and was then submitted to second-level analysis.
53-1	10127-10130	One	_	
53-2	10131-10139	contrast	_	
53-3	10140-10145	image	_	
53-4	10146-10149	was	_	
53-5	10150-10159	generated	_	
53-6	10160-10163	for	_	
53-7	10164-10168	each	_	
53-8	10169-10180	participant	_	
53-9	10181-10183	to	_	
53-10	10184-10191	examine	_	
53-11	10192-10202	activation	_	
53-12	10203-10210	related	_	
53-13	10211-10213	to	_	
53-14	10214-10218	pure	_	
53-15	10219-10227	stimulus	_	
53-16	10228-10235	novelty	_	
53-17	10236-10238	by	_	
53-18	10239-10250	contrasting	_	
53-19	10251-10254	all	_	
53-20	10255-10260	novel	_	
53-21	10261-10268	oddball	_	
53-22	10269-10275	trials	_	
53-23	10276-10283	against	_	
53-24	10284-10291	neutral	_	
53-25	10292-10299	oddball	_	
53-26	10300-10306	trials	_	
53-27	10307-10310	and	_	
53-28	10311-10314	was	_	
53-29	10315-10319	then	_	
53-30	10320-10329	submitted	_	
53-31	10330-10332	to	_	
53-32	10333-10345	second-level	_	
53-33	10346-10354	analysis	_	
53-34	10354-10355	.	_	

#Text=For between-group comparisons between HC and CHR participants, a 2-sample t-test was performed using the first-level novel > neutral contrast images, covarying for age.
54-1	10356-10359	For	_	
54-2	10360-10373	between-group	_	
54-3	10374-10385	comparisons	_	
54-4	10386-10393	between	_	
54-5	10394-10396	HC	_	
54-6	10397-10400	and	_	
54-7	10401-10404	CHR	_	
54-8	10405-10417	participants	_	
54-9	10417-10418	,	_	
54-10	10419-10420	a	_	
54-11	10421-10422	2	_	
54-12	10422-10423	-	_	
54-13	10423-10429	sample	_	
54-14	10430-10436	t-test	_	
54-15	10437-10440	was	_	
54-16	10441-10450	performed	_	
54-17	10451-10456	using	_	
54-18	10457-10460	the	_	
54-19	10461-10472	first-level	_	
54-20	10473-10478	novel	_	
54-21	10479-10480	>	_	
54-22	10481-10488	neutral	_	
54-23	10489-10497	contrast	_	
54-24	10498-10504	images	_	
54-25	10504-10505	,	_	
54-26	10506-10515	covarying	_	
54-27	10516-10519	for	_	
54-28	10520-10523	age	_	
54-29	10523-10524	.	_	

#Text=We used an initial cluster defining threshold of P < .001 uncorrected to then enforce a voxel-wise height threshold of family-wise error (FWE) P < .05 after small volume correction (SVC) for region-of-interest (ROI) analyses, using a pre-specified bilateral mask comprising the hippocampus, striatum, and midbrain.
55-1	10525-10527	We	_	
55-2	10528-10532	used	_	
55-3	10533-10535	an	_	
55-4	10536-10543	initial	_	
55-5	10544-10551	cluster	_	
55-6	10552-10560	defining	_	
55-7	10561-10570	threshold	_	
55-8	10571-10573	of	_	
55-9	10574-10575	P	_	
55-10	10576-10577	<	_	
55-11	10578-10582	.001	_	
55-12	10583-10594	uncorrected	_	
55-13	10595-10597	to	_	
55-14	10598-10602	then	_	
55-15	10603-10610	enforce	_	
55-16	10611-10612	a	_	
55-17	10613-10623	voxel-wise	_	
55-18	10624-10630	height	_	
55-19	10631-10640	threshold	_	
55-20	10641-10643	of	_	
55-21	10644-10655	family-wise	_	
55-22	10656-10661	error	_	
55-23	10662-10663	(	_	
55-24	10663-10666	FWE	_	
55-25	10666-10667	)	_	
55-26	10668-10669	P	_	
55-27	10670-10671	<	_	
55-28	10672-10675	.05	_	
55-29	10676-10681	after	_	
55-30	10682-10687	small	_	
55-31	10688-10694	volume	_	
55-32	10695-10705	correction	_	
55-33	10706-10707	(	_	
55-34	10707-10710	SVC	_	
55-35	10710-10711	)	_	
55-36	10712-10715	for	_	
55-37	10716-10734	region-of-interest	_	
55-38	10735-10736	(	_	
55-39	10736-10739	ROI	_	
55-40	10739-10740	)	_	
55-41	10741-10749	analyses	_	
55-42	10749-10750	,	_	
55-43	10751-10756	using	_	
55-44	10757-10758	a	_	
55-45	10759-10772	pre-specified	_	
55-46	10773-10782	bilateral	_	
55-47	10783-10787	mask	_	
55-48	10788-10798	comprising	_	
55-49	10799-10802	the	_	
55-50	10803-10814	hippocampus	_	
55-51	10814-10815	,	_	
55-52	10816-10824	striatum	_	
55-53	10824-10825	,	_	
55-54	10826-10829	and	_	
55-55	10830-10838	midbrain	_	
55-56	10838-10839	.	_	

#Text=The striatum was chosen on the basis of its role in the aberrant salience hypothesis and previous fMRI studies documenting salience–related responses in this region.
56-1	10840-10843	The	_	
56-2	10844-10852	striatum	_	
56-3	10853-10856	was	_	
56-4	10857-10863	chosen	_	
56-5	10864-10866	on	_	
56-6	10867-10870	the	_	
56-7	10871-10876	basis	_	
56-8	10877-10879	of	_	
56-9	10880-10883	its	_	
56-10	10884-10888	role	_	
56-11	10889-10891	in	_	
56-12	10892-10895	the	_	
56-13	10896-10904	aberrant	_	
56-14	10905-10913	salience	_	
56-15	10914-10924	hypothesis	_	
56-16	10925-10928	and	_	
56-17	10929-10937	previous	_	
56-18	10938-10942	fMRI	_	
56-19	10943-10950	studies	_	
56-20	10951-10962	documenting	_	
56-21	10963-10979	salience–related	_	
56-22	10980-10989	responses	_	
56-23	10990-10992	in	_	
56-24	10993-10997	this	_	
56-25	10998-11004	region	_	
56-26	11004-11005	.	_	

#Text=The hippocampus was chosen based on preclinical evidence for its central role in psychosis through the regulation of dopamine signaling, and prior work indicating a relationship between aberrant hippocampal activity and the CHR state.
57-1	11006-11009	The	_	
57-2	11010-11021	hippocampus	_	
57-3	11022-11025	was	_	
57-4	11026-11032	chosen	_	
57-5	11033-11038	based	_	
57-6	11039-11041	on	_	
57-7	11042-11053	preclinical	_	
57-8	11054-11062	evidence	_	
57-9	11063-11066	for	_	
57-10	11067-11070	its	_	
57-11	11071-11078	central	_	
57-12	11079-11083	role	_	
57-13	11084-11086	in	_	
57-14	11087-11096	psychosis	_	
57-15	11097-11104	through	_	
57-16	11105-11108	the	_	
57-17	11109-11119	regulation	_	
57-18	11120-11122	of	_	
57-19	11123-11131	dopamine	_	
57-20	11132-11141	signaling	_	
57-21	11141-11142	,	_	
57-22	11143-11146	and	_	
57-23	11147-11152	prior	_	
57-24	11153-11157	work	_	
57-25	11158-11168	indicating	_	
57-26	11169-11170	a	_	
57-27	11171-11183	relationship	_	
57-28	11184-11191	between	_	
57-29	11192-11200	aberrant	_	
57-30	11201-11212	hippocampal	_	
57-31	11213-11221	activity	_	
57-32	11222-11225	and	_	
57-33	11226-11229	the	_	
57-34	11230-11233	CHR	_	
57-35	11234-11239	state	_	
57-36	11239-11240	.	_	

#Text=The midbrain was chosen since novel stimuli are associated with fMRI activations in this region as shown by Bunzeck and Duzel’s study using this task in healthy volunteers.
58-1	11241-11244	The	_	
58-2	11245-11253	midbrain	_	
58-3	11254-11257	was	_	
58-4	11258-11264	chosen	_	
58-5	11265-11270	since	_	
58-6	11271-11276	novel	_	
58-7	11277-11284	stimuli	_	
58-8	11285-11288	are	_	
58-9	11289-11299	associated	_	
58-10	11300-11304	with	_	
58-11	11305-11309	fMRI	_	
58-12	11310-11321	activations	_	
58-13	11322-11324	in	_	
58-14	11325-11329	this	_	
58-15	11330-11336	region	_	
58-16	11337-11339	as	_	
58-17	11340-11345	shown	_	
58-18	11346-11348	by	_	
58-19	11349-11356	Bunzeck	_	
58-20	11357-11360	and	_	
58-21	11361-11366	Duzel	_	
58-22	11366-11367	’	_	
58-23	11367-11368	s	_	
58-24	11369-11374	study	_	
58-25	11375-11380	using	_	
58-26	11381-11385	this	_	
58-27	11386-11390	task	_	
58-28	11391-11393	in	_	
58-29	11394-11401	healthy	_	
58-30	11402-11412	volunteers	_	
58-31	11412-11413	.	_	

#Text=The ROI mask was built using the WFU_Pitckatlas toolbox and comprised predefined anatomical masks of the striatum (caudate, pallidum, putamen) and the hippocampus from the automated anatomical labeling atlas, and a 6-mm sphere around the midbrain (ventral tegmental area/substantia nigra, VTA/SN) coordinates reported in the study with healthy volunteers (only right-sided as in Bunzeck & Duzel, xyz: 8, −20, −18; figure 1B).
59-1	11414-11417	The	_	
59-2	11418-11421	ROI	_	
59-3	11422-11426	mask	_	
59-4	11427-11430	was	_	
59-5	11431-11436	built	_	
59-6	11437-11442	using	_	
59-7	11443-11446	the	_	
59-8	11447-11461	WFU_Pitckatlas	_	
59-9	11462-11469	toolbox	_	
59-10	11470-11473	and	_	
59-11	11474-11483	comprised	_	
59-12	11484-11494	predefined	_	
59-13	11495-11505	anatomical	_	
59-14	11506-11511	masks	_	
59-15	11512-11514	of	_	
59-16	11515-11518	the	_	
59-17	11519-11527	striatum	_	
59-18	11528-11529	(	_	
59-19	11529-11536	caudate	_	
59-20	11536-11537	,	_	
59-21	11538-11546	pallidum	_	
59-22	11546-11547	,	_	
59-23	11548-11555	putamen	_	
59-24	11555-11556	)	_	
59-25	11557-11560	and	_	
59-26	11561-11564	the	_	
59-27	11565-11576	hippocampus	_	
59-28	11577-11581	from	_	
59-29	11582-11585	the	_	
59-30	11586-11595	automated	_	
59-31	11596-11606	anatomical	_	
59-32	11607-11615	labeling	_	
59-33	11616-11621	atlas	_	
59-34	11621-11622	,	_	
59-35	11623-11626	and	_	
59-36	11627-11628	a	_	
59-37	11629-11630	6	_	
59-38	11630-11631	-	_	
59-39	11631-11633	mm	_	
59-40	11634-11640	sphere	_	
59-41	11641-11647	around	_	
59-42	11648-11651	the	_	
59-43	11652-11660	midbrain	_	
59-44	11661-11662	(	_	
59-45	11662-11669	ventral	_	
59-46	11670-11679	tegmental	_	
59-47	11680-11684	area	_	
59-48	11684-11685	/	_	
59-49	11685-11695	substantia	_	
59-50	11696-11701	nigra	_	
59-51	11701-11702	,	_	
59-52	11703-11706	VTA	_	
59-53	11706-11707	/	_	
59-54	11707-11709	SN	_	
59-55	11709-11710	)	_	
59-56	11711-11722	coordinates	_	
59-57	11723-11731	reported	_	
59-58	11732-11734	in	_	
59-59	11735-11738	the	_	
59-60	11739-11744	study	_	
59-61	11745-11749	with	_	
59-62	11750-11757	healthy	_	
59-63	11758-11768	volunteers	_	
59-64	11769-11770	(	_	
59-65	11770-11774	only	_	
59-66	11775-11786	right-sided	_	
59-67	11787-11789	as	_	
59-68	11790-11792	in	_	
59-69	11793-11800	Bunzeck	_	
59-70	11801-11802	&	_	
59-71	11803-11808	Duzel	_	
59-72	11808-11809	,	_	
59-73	11810-11813	xyz	_	
59-74	11813-11814	:	_	
59-75	11815-11816	8	_	
59-76	11816-11817	,	_	
59-77	11818-11819	−	_	
59-78	11819-11821	20	_	
59-79	11821-11822	,	_	
59-80	11823-11824	−	_	
59-81	11824-11826	18	_	
59-82	11826-11827	;	_	
59-83	11828-11834	figure	_	
59-84	11835-11837	1B	_	
59-85	11837-11838	)	_	
59-86	11838-11839	.	_	

#Text=To investigate the relationship between functional activation in response to novelty and transition to psychosis, a 2-sample t-test was specified in SPM (CHR-NT vs CHR-T), adjusting for age.
60-1	11840-11842	To	_	
60-2	11843-11854	investigate	_	
60-3	11855-11858	the	_	
60-4	11859-11871	relationship	_	
60-5	11872-11879	between	_	
60-6	11880-11890	functional	_	
60-7	11891-11901	activation	_	
60-8	11902-11904	in	_	
60-9	11905-11913	response	_	
60-10	11914-11916	to	_	
60-11	11917-11924	novelty	_	
60-12	11925-11928	and	_	
60-13	11929-11939	transition	_	
60-14	11940-11942	to	_	
60-15	11943-11952	psychosis	_	
60-16	11952-11953	,	_	
60-17	11954-11955	a	_	
60-18	11956-11957	2	_	
60-19	11957-11958	-	_	
60-20	11958-11964	sample	_	
60-21	11965-11971	t-test	_	
60-22	11972-11975	was	_	
60-23	11976-11985	specified	_	
60-24	11986-11988	in	_	
60-25	11989-11992	SPM	_	
60-26	11993-11994	(	_	
60-27	11994-12000	CHR-NT	_	
60-28	12001-12003	vs	_	
60-29	12004-12009	CHR-T	_	
60-30	12009-12010	)	_	
60-31	12010-12011	,	_	
60-32	12012-12021	adjusting	_	
60-33	12022-12025	for	_	
60-34	12026-12029	age	_	
60-35	12029-12030	.	_	

#Text=The same ROI mask and significance threshold as above were applied (PFWE < .05 after SVC).
61-1	12031-12034	The	_	
61-2	12035-12039	same	_	
61-3	12040-12043	ROI	_	
61-4	12044-12048	mask	_	
61-5	12049-12052	and	_	
61-6	12053-12065	significance	_	
61-7	12066-12075	threshold	_	
61-8	12076-12078	as	_	
61-9	12079-12084	above	_	
61-10	12085-12089	were	_	
61-11	12090-12097	applied	_	
61-12	12098-12099	(	_	
61-13	12099-12103	PFWE	_	
61-14	12104-12105	<	_	
61-15	12106-12109	.05	_	
61-16	12110-12115	after	_	
61-17	12116-12119	SVC	_	
61-18	12119-12120	)	_	
61-19	12120-12121	.	_	

#Text=Potential confounding effects of substance use (alcohol, tobacco, cannabis) and levels of anxiety/depression (HAM-A/HAM-D) on the regions showing significant novelty-related group differences were examined with an additional ANCOVA in SPSS.
62-1	12122-12131	Potential	_	
62-2	12132-12143	confounding	_	
62-3	12144-12151	effects	_	
62-4	12152-12154	of	_	
62-5	12155-12164	substance	_	
62-6	12165-12168	use	_	
62-7	12169-12170	(	_	
62-8	12170-12177	alcohol	_	
62-9	12177-12178	,	_	
62-10	12179-12186	tobacco	_	
62-11	12186-12187	,	_	
62-12	12188-12196	cannabis	_	
62-13	12196-12197	)	_	
62-14	12198-12201	and	_	
62-15	12202-12208	levels	_	
62-16	12209-12211	of	_	
62-17	12212-12219	anxiety	_	
62-18	12219-12220	/	_	
62-19	12220-12230	depression	_	
62-20	12231-12232	(	_	
62-21	12232-12237	HAM-A	_	
62-22	12237-12238	/	_	
62-23	12238-12243	HAM-D	_	
62-24	12243-12244	)	_	
62-25	12245-12247	on	_	
62-26	12248-12251	the	_	
62-27	12252-12259	regions	_	
62-28	12260-12267	showing	_	
62-29	12268-12279	significant	_	
62-30	12280-12295	novelty-related	_	
62-31	12296-12301	group	_	
62-32	12302-12313	differences	_	
62-33	12314-12318	were	_	
62-34	12319-12327	examined	_	
62-35	12328-12332	with	_	
62-36	12333-12335	an	_	
62-37	12336-12346	additional	_	
62-38	12347-12353	ANCOVA	_	
62-39	12354-12356	in	_	
62-40	12357-12361	SPSS	_	
62-41	12361-12362	.	_	

#Text=Exploratory whole-brain voxel-wise analysis of fMRI data (comparing all CHR to HC subjects and CHR-NT to CHR-T subjects) is reported in the supplementary material.
63-1	12363-12374	Exploratory	_	
63-2	12375-12386	whole-brain	_	
63-3	12387-12397	voxel-wise	_	
63-4	12398-12406	analysis	_	
63-5	12407-12409	of	_	
63-6	12410-12414	fMRI	_	
63-7	12415-12419	data	_	
63-8	12420-12421	(	_	
63-9	12421-12430	comparing	_	
63-10	12431-12434	all	_	
63-11	12435-12438	CHR	_	
63-12	12439-12441	to	_	
63-13	12442-12444	HC	_	
63-14	12445-12453	subjects	_	
63-15	12454-12457	and	_	
63-16	12458-12464	CHR-NT	_	
63-17	12465-12467	to	_	
63-18	12468-12473	CHR-T	_	
63-19	12474-12482	subjects	_	
63-20	12482-12483	)	_	
63-21	12484-12486	is	_	
63-22	12487-12495	reported	_	
63-23	12496-12498	in	_	
63-24	12499-12502	the	_	
63-25	12503-12516	supplementary	_	
63-26	12517-12525	material	_	
63-27	12525-12526	.	_	

#Text=Dynamic Casual Modeling
#Text=Volumes of Interest and Time-Series Extraction
#Text=Based on preclinical evidence and data from a previous study of the task in healthy volunteers, we used DCM12 in SPM12 to compute effective connectivity within a circuit comprising the hippocampus, the striatum and the midbrain (figure 3A).
64-1	12527-12534	Dynamic	_	
64-2	12535-12541	Casual	_	
64-3	12542-12550	Modeling	_	
64-4	12551-12558	Volumes	_	
64-5	12559-12561	of	_	
64-6	12562-12570	Interest	_	
64-7	12571-12574	and	_	
64-8	12575-12586	Time-Series	_	
64-9	12587-12597	Extraction	_	
64-10	12598-12603	Based	_	
64-11	12604-12606	on	_	
64-12	12607-12618	preclinical	_	
64-13	12619-12627	evidence	_	
64-14	12628-12631	and	_	
64-15	12632-12636	data	_	
64-16	12637-12641	from	_	
64-17	12642-12643	a	_	
64-18	12644-12652	previous	_	
64-19	12653-12658	study	_	
64-20	12659-12661	of	_	
64-21	12662-12665	the	_	
64-22	12666-12670	task	_	
64-23	12671-12673	in	_	
64-24	12674-12681	healthy	_	
64-25	12682-12692	volunteers	_	
64-26	12692-12693	,	_	
64-27	12694-12696	we	_	
64-28	12697-12701	used	_	
64-29	12702-12707	DCM12	_	
64-30	12708-12710	in	_	
64-31	12711-12716	SPM12	_	
64-32	12717-12719	to	_	
64-33	12720-12727	compute	_	
64-34	12728-12737	effective	_	
64-35	12738-12750	connectivity	_	
64-36	12751-12757	within	_	
64-37	12758-12759	a	_	
64-38	12760-12767	circuit	_	
64-39	12768-12778	comprising	_	
64-40	12779-12782	the	_	
64-41	12783-12794	hippocampus	_	
64-42	12794-12795	,	_	
64-43	12796-12799	the	_	
64-44	12800-12808	striatum	_	
64-45	12809-12812	and	_	
64-46	12813-12816	the	_	
64-47	12817-12825	midbrain	_	
64-48	12826-12827	(	_	
64-49	12827-12833	figure	_	
64-50	12834-12836	3A	_	
64-51	12836-12837	)	_	
64-52	12837-12838	.	_	

#Text=The volumes of interest (VOIs) for these regions were defined using the maximally activated coordinates in the second-level fMRI analysis within our masked regions (figure 1B), following published rules for the application of DCM.
65-1	12839-12842	The	_	
65-2	12843-12850	volumes	_	
65-3	12851-12853	of	_	
65-4	12854-12862	interest	_	
65-5	12863-12864	(	_	
65-6	12864-12868	VOIs	_	
65-7	12868-12869	)	_	
65-8	12870-12873	for	_	
65-9	12874-12879	these	_	
65-10	12880-12887	regions	_	
65-11	12888-12892	were	_	
65-12	12893-12900	defined	_	
65-13	12901-12906	using	_	
65-14	12907-12910	the	_	
65-15	12911-12920	maximally	_	
65-16	12921-12930	activated	_	
65-17	12931-12942	coordinates	_	
65-18	12943-12945	in	_	
65-19	12946-12949	the	_	
65-20	12950-12962	second-level	_	
65-21	12963-12967	fMRI	_	
65-22	12968-12976	analysis	_	
65-23	12977-12983	within	_	
65-24	12984-12987	our	_	
65-25	12988-12994	masked	_	
65-26	12995-13002	regions	_	
65-27	13003-13004	(	_	
65-28	13004-13010	figure	_	
65-29	13011-13013	1B	_	
65-30	13013-13014	)	_	
65-31	13014-13015	,	_	
65-32	13016-13025	following	_	
65-33	13026-13035	published	_	
65-34	13036-13041	rules	_	
65-35	13042-13045	for	_	
65-36	13046-13049	the	_	
65-37	13050-13061	application	_	
65-38	13062-13064	of	_	
65-39	13065-13068	DCM	_	
65-40	13068-13069	.	_	

#Text=The VOI for the hippocampus was extracted from the group-level fMRI difference between CHR vs HCs (xyz: 38 −16 −14).
66-1	13070-13073	The	_	
66-2	13074-13077	VOI	_	
66-3	13078-13081	for	_	
66-4	13082-13085	the	_	
66-5	13086-13097	hippocampus	_	
66-6	13098-13101	was	_	
66-7	13102-13111	extracted	_	
66-8	13112-13116	from	_	
66-9	13117-13120	the	_	
66-10	13121-13132	group-level	_	
66-11	13133-13137	fMRI	_	
66-12	13138-13148	difference	_	
66-13	13149-13156	between	_	
66-14	13157-13160	CHR	_	
66-15	13161-13163	vs	_	
66-16	13164-13167	HCs	_	
66-17	13168-13169	(	_	
66-18	13169-13172	xyz	_	
66-19	13172-13173	:	_	
66-20	13174-13176	38	_	
66-21	13177-13178	−	_	
66-22	13178-13180	16	_	
66-23	13181-13182	−	_	
66-24	13182-13184	14	_	
66-25	13184-13185	)	_	
66-26	13185-13186	.	_	

#Text=As there was no significant group-level difference in either the striatum or midbrain, we used the coordinates of the task effect of novel > neutral across all participants with an 8-mm sphere for each region, allowing the center of the sphere to move to the nearest suprathreshold voxel (xyz: striatum, 28 20 −2; VTA/SN, 14 −24 −16; PUNC < .05).
67-1	13187-13189	As	_	
67-2	13190-13195	there	_	
67-3	13196-13199	was	_	
67-4	13200-13202	no	_	
67-5	13203-13214	significant	_	
67-6	13215-13226	group-level	_	
67-7	13227-13237	difference	_	
67-8	13238-13240	in	_	
67-9	13241-13247	either	_	
67-10	13248-13251	the	_	
67-11	13252-13260	striatum	_	
67-12	13261-13263	or	_	
67-13	13264-13272	midbrain	_	
67-14	13272-13273	,	_	
67-15	13274-13276	we	_	
67-16	13277-13281	used	_	
67-17	13282-13285	the	_	
67-18	13286-13297	coordinates	_	
67-19	13298-13300	of	_	
67-20	13301-13304	the	_	
67-21	13305-13309	task	_	
67-22	13310-13316	effect	_	
67-23	13317-13319	of	_	
67-24	13320-13325	novel	_	
67-25	13326-13327	>	_	
67-26	13328-13335	neutral	_	
67-27	13336-13342	across	_	
67-28	13343-13346	all	_	
67-29	13347-13359	participants	_	
67-30	13360-13364	with	_	
67-31	13365-13367	an	_	
67-32	13368-13369	8	_	
67-33	13369-13370	-	_	
67-34	13370-13372	mm	_	
67-35	13373-13379	sphere	_	
67-36	13380-13383	for	_	
67-37	13384-13388	each	_	
67-38	13389-13395	region	_	
67-39	13395-13396	,	_	
67-40	13397-13405	allowing	_	
67-41	13406-13409	the	_	
67-42	13410-13416	center	_	
67-43	13417-13419	of	_	
67-44	13420-13423	the	_	
67-45	13424-13430	sphere	_	
67-46	13431-13433	to	_	
67-47	13434-13438	move	_	
67-48	13439-13441	to	_	
67-49	13442-13445	the	_	
67-50	13446-13453	nearest	_	
67-51	13454-13468	suprathreshold	_	
67-52	13469-13474	voxel	_	
67-53	13475-13476	(	_	
67-54	13476-13479	xyz	_	
67-55	13479-13480	:	_	
67-56	13481-13489	striatum	_	
67-57	13489-13490	,	_	
67-58	13491-13493	28	_	
67-59	13494-13496	20	_	
67-60	13497-13498	−	_	
67-61	13498-13499	2	_	
67-62	13499-13500	;	_	
67-63	13501-13504	VTA	_	
67-64	13504-13505	/	_	
67-65	13505-13507	SN	_	
67-66	13507-13508	,	_	
67-67	13509-13511	14	_	
67-68	13512-13513	−	_	
67-69	13513-13515	24	_	
67-70	13516-13517	−	_	
67-71	13517-13519	16	_	
67-72	13519-13520	;	_	
67-73	13521-13525	PUNC	_	
67-74	13526-13527	<	_	
67-75	13528-13531	.05	_	
67-76	13531-13532	)	_	
67-77	13532-13533	.	_	

#Text=Group Comparisons With Parametric Empirical Bayes (PEB)
#Text=PEB, included in SPM12, allows evaluating group effects and between-subjects variability on DCM parameters (HC vs CHR; CHR-NT vs CHR-T).
68-1	13534-13539	Group	_	
68-2	13540-13551	Comparisons	_	
68-3	13552-13556	With	_	
68-4	13557-13567	Parametric	_	
68-5	13568-13577	Empirical	_	
68-6	13578-13583	Bayes	_	
68-7	13584-13585	(	_	
68-8	13585-13588	PEB	_	
68-9	13588-13589	)	_	
68-10	13590-13593	PEB	_	
68-11	13593-13594	,	_	
68-12	13595-13603	included	_	
68-13	13604-13606	in	_	
68-14	13607-13612	SPM12	_	
68-15	13612-13613	,	_	
68-16	13614-13620	allows	_	
68-17	13621-13631	evaluating	_	
68-18	13632-13637	group	_	
68-19	13638-13645	effects	_	
68-20	13646-13649	and	_	
68-21	13650-13666	between-subjects	_	
68-22	13667-13678	variability	_	
68-23	13679-13681	on	_	
68-24	13682-13685	DCM	_	
68-25	13686-13696	parameters	_	
68-26	13697-13698	(	_	
68-27	13698-13700	HC	_	
68-28	13701-13703	vs	_	
68-29	13704-13707	CHR	_	
68-30	13707-13708	;	_	
68-31	13709-13715	CHR-NT	_	
68-32	13716-13718	vs	_	
68-33	13719-13724	CHR-T	_	
68-34	13724-13725	)	_	
68-35	13725-13726	.	_	

#Text=PEB for DCM is performed by comparing the posterior density of any (reduced) model in terms of the posterior of its parent or full model.
69-1	13727-13730	PEB	_	
69-2	13731-13734	for	_	
69-3	13735-13738	DCM	_	
69-4	13739-13741	is	_	
69-5	13742-13751	performed	_	
69-6	13752-13754	by	_	
69-7	13755-13764	comparing	_	
69-8	13765-13768	the	_	
69-9	13769-13778	posterior	_	
69-10	13779-13786	density	_	
69-11	13787-13789	of	_	
69-12	13790-13793	any	_	
69-13	13794-13795	(	_	
69-14	13795-13802	reduced	_	
69-15	13802-13803	)	_	
69-16	13804-13809	model	_	
69-17	13810-13812	in	_	
69-18	13813-13818	terms	_	
69-19	13819-13821	of	_	
69-20	13822-13825	the	_	
69-21	13826-13835	posterior	_	
69-22	13836-13838	of	_	
69-23	13839-13842	its	_	
69-24	13843-13849	parent	_	
69-25	13850-13852	or	_	
69-26	13853-13857	full	_	
69-27	13858-13863	model	_	
69-28	13863-13864	.	_	

#Text=The first step is to estimate a full model (ie, with every connection switched “on”) for every subject.
70-1	13865-13868	The	_	
70-2	13869-13874	first	_	
70-3	13875-13879	step	_	
70-4	13880-13882	is	_	
70-5	13883-13885	to	_	
70-6	13886-13894	estimate	_	
70-7	13895-13896	a	_	
70-8	13897-13901	full	_	
70-9	13902-13907	model	_	
70-10	13908-13909	(	_	
70-11	13909-13911	ie	_	
70-12	13911-13912	,	_	
70-13	13913-13917	with	_	
70-14	13918-13923	every	_	
70-15	13924-13934	connection	_	
70-16	13935-13943	switched	_	
70-17	13944-13945	“	_	
70-18	13945-13947	on	_	
70-19	13947-13948	”	_	
70-20	13948-13949	)	_	
70-21	13950-13953	for	_	
70-22	13954-13959	every	_	
70-23	13960-13967	subject	_	
70-24	13967-13968	.	_	

#Text=Then, a nested model is constructed (ie, with certain conditions switched “off”), which allows the expression of the posterior density of any (reduced) model in terms of the posterior of its parent or full model.
71-1	13969-13973	Then	_	
71-2	13973-13974	,	_	
71-3	13975-13976	a	_	
71-4	13977-13983	nested	_	
71-5	13984-13989	model	_	
71-6	13990-13992	is	_	
71-7	13993-14004	constructed	_	
71-8	14005-14006	(	_	
71-9	14006-14008	ie	_	
71-10	14008-14009	,	_	
71-11	14010-14014	with	_	
71-12	14015-14022	certain	_	
71-13	14023-14033	conditions	_	
71-14	14034-14042	switched	_	
71-15	14043-14044	“	_	
71-16	14044-14047	off	_	
71-17	14047-14048	”	_	
71-18	14048-14049	)	_	
71-19	14049-14050	,	_	
71-20	14051-14056	which	_	
71-21	14057-14063	allows	_	
71-22	14064-14067	the	_	
71-23	14068-14078	expression	_	
71-24	14079-14081	of	_	
71-25	14082-14085	the	_	
71-26	14086-14095	posterior	_	
71-27	14096-14103	density	_	
71-28	14104-14106	of	_	
71-29	14107-14110	any	_	
71-30	14111-14112	(	_	
71-31	14112-14119	reduced	_	
71-32	14119-14120	)	_	
71-33	14121-14126	model	_	
71-34	14127-14129	in	_	
71-35	14130-14135	terms	_	
71-36	14136-14138	of	_	
71-37	14139-14142	the	_	
71-38	14143-14152	posterior	_	
71-39	14153-14155	of	_	
71-40	14156-14159	its	_	
71-41	14160-14166	parent	_	
71-42	14167-14169	or	_	
71-43	14170-14174	full	_	
71-44	14175-14180	model	_	
71-45	14180-14181	.	_	

#Text=This process affords an efficient way to evaluate posterior densities under empirical priors.
72-1	14182-14186	This	_	
72-2	14187-14194	process	_	
72-3	14195-14202	affords	_	
72-4	14203-14205	an	_	
72-5	14206-14215	efficient	_	
72-6	14216-14219	way	_	
72-7	14220-14222	to	_	
72-8	14223-14231	evaluate	_	
72-9	14232-14241	posterior	_	
72-10	14242-14251	densities	_	
72-11	14252-14257	under	_	
72-12	14258-14267	empirical	_	
72-13	14268-14274	priors	_	
72-14	14274-14275	.	_	

#Text=It is then possible to apply Bayesian model reduction to the posterior densities over the second-level parameters to find out where between-subject effects are expressed.
73-1	14276-14278	It	_	
73-2	14279-14281	is	_	
73-3	14282-14286	then	_	
73-4	14287-14295	possible	_	
73-5	14296-14298	to	_	
73-6	14299-14304	apply	_	
73-7	14305-14313	Bayesian	_	
73-8	14314-14319	model	_	
73-9	14320-14329	reduction	_	
73-10	14330-14332	to	_	
73-11	14333-14336	the	_	
73-12	14337-14346	posterior	_	
73-13	14347-14356	densities	_	
73-14	14357-14361	over	_	
73-15	14362-14365	the	_	
73-16	14366-14378	second-level	_	
73-17	14379-14389	parameters	_	
73-18	14390-14392	to	_	
73-19	14393-14397	find	_	
73-20	14398-14401	out	_	
73-21	14402-14407	where	_	
73-22	14408-14423	between-subject	_	
73-23	14424-14431	effects	_	
73-24	14432-14435	are	_	
73-25	14436-14445	expressed	_	
73-26	14445-14446	.	_	

#Text=Results are given by the group effect on the Posterior Probabilities (P) and the Bayesian Confidence Interval.
74-1	14447-14454	Results	_	
74-2	14455-14458	are	_	
74-3	14459-14464	given	_	
74-4	14465-14467	by	_	
74-5	14468-14471	the	_	
74-6	14472-14477	group	_	
74-7	14478-14484	effect	_	
74-8	14485-14487	on	_	
74-9	14488-14491	the	_	
74-10	14492-14501	Posterior	_	
74-11	14502-14515	Probabilities	_	
74-12	14516-14517	(	_	
74-13	14517-14518	P	_	
74-14	14518-14519	)	_	
74-15	14520-14523	and	_	
74-16	14524-14527	the	_	
74-17	14528-14536	Bayesian	_	
74-18	14537-14547	Confidence	_	
74-19	14548-14556	Interval	_	
74-20	14556-14557	.	_	

#Text=Group differences were thresholded with a P > .5 obtained as recommended by DCM’s developers (https://arxiv.org/pdf/1902.10604.pdf) and following Kass & Raftery.
75-1	14558-14563	Group	_	
75-2	14564-14575	differences	_	
75-3	14576-14580	were	_	
75-4	14581-14592	thresholded	_	
75-5	14593-14597	with	_	
75-6	14598-14599	a	_	
75-7	14600-14601	P	_	
75-8	14602-14603	>	_	
75-9	14604-14606	.5	_	
75-10	14607-14615	obtained	_	
75-11	14616-14618	as	_	
75-12	14619-14630	recommended	_	
75-13	14631-14633	by	_	
75-14	14634-14637	DCM	_	
75-15	14637-14638	’	_	
75-16	14638-14639	s	_	
75-17	14640-14650	developers	_	
75-18	14651-14652	(	_	
75-19	14652-14657	https	_	
75-20	14657-14658	:	_	
75-21	14658-14659	/	_	
75-22	14659-14660	/	_	
75-23	14660-14669	arxiv.org	_	
75-24	14669-14670	/	_	
75-25	14670-14673	pdf	_	
75-26	14673-14674	/	_	
75-27	14674-14684	1902.10604	_	
75-28	14684-14685	.	_	
75-29	14685-14688	pdf	_	
75-30	14688-14689	)	_	
75-31	14690-14693	and	_	
75-32	14694-14703	following	_	
75-33	14704-14708	Kass	_	
75-34	14709-14710	&	_	
75-35	14711-14718	Raftery	_	
75-36	14718-14719	.	_	

#Text=Although comparing Bayes Factor to P-values is not straightforward, it could be argued that it is equivalent to P < 0.05.
76-1	14720-14728	Although	_	
76-2	14729-14738	comparing	_	
76-3	14739-14744	Bayes	_	
76-4	14745-14751	Factor	_	
76-5	14752-14754	to	_	
76-6	14755-14763	P-values	_	
76-7	14764-14766	is	_	
76-8	14767-14770	not	_	
76-9	14771-14786	straightforward	_	
76-10	14786-14787	,	_	
76-11	14788-14790	it	_	
76-12	14791-14796	could	_	
76-13	14797-14799	be	_	
76-14	14800-14806	argued	_	
76-15	14807-14811	that	_	
76-16	14812-14814	it	_	
76-17	14815-14817	is	_	
76-18	14818-14828	equivalent	_	
76-19	14829-14831	to	_	
76-20	14832-14833	P	_	
76-21	14834-14835	<	_	
76-22	14836-14840	0.05	_	
76-23	14840-14841	.	_	

#Text=The present study examined how the connections between the anterior hippocampus, ventral striatum and VTA/SN were modulated by stimulus novelty (novel > neutral oddball trials) by generating a second model space which included a full model, to then create 4 different models with each connection switched “off” (nested models; figure 3A).
77-1	14842-14845	The	_	
77-2	14846-14853	present	_	
77-3	14854-14859	study	_	
77-4	14860-14868	examined	_	
77-5	14869-14872	how	_	
77-6	14873-14876	the	_	
77-7	14877-14888	connections	_	
77-8	14889-14896	between	_	
77-9	14897-14900	the	_	
77-10	14901-14909	anterior	_	
77-11	14910-14921	hippocampus	_	
77-12	14921-14922	,	_	
77-13	14923-14930	ventral	_	
77-14	14931-14939	striatum	_	
77-15	14940-14943	and	_	
77-16	14944-14947	VTA	_	
77-17	14947-14948	/	_	
77-18	14948-14950	SN	_	
77-19	14951-14955	were	_	
77-20	14956-14965	modulated	_	
77-21	14966-14968	by	_	
77-22	14969-14977	stimulus	_	
77-23	14978-14985	novelty	_	
77-24	14986-14987	(	_	
77-25	14987-14992	novel	_	
77-26	14993-14994	>	_	
77-27	14995-15002	neutral	_	
77-28	15003-15010	oddball	_	
77-29	15011-15017	trials	_	
77-30	15017-15018	)	_	
77-31	15019-15021	by	_	
77-32	15022-15032	generating	_	
77-33	15033-15034	a	_	
77-34	15035-15041	second	_	
77-35	15042-15047	model	_	
77-36	15048-15053	space	_	
77-37	15054-15059	which	_	
77-38	15060-15068	included	_	
77-39	15069-15070	a	_	
77-40	15071-15075	full	_	
77-41	15076-15081	model	_	
77-42	15081-15082	,	_	
77-43	15083-15085	to	_	
77-44	15086-15090	then	_	
77-45	15091-15097	create	_	
77-46	15098-15099	4	_	
77-47	15100-15109	different	_	
77-48	15110-15116	models	_	
77-49	15117-15121	with	_	
77-50	15122-15126	each	_	
77-51	15127-15137	connection	_	
77-52	15138-15146	switched	_	
77-53	15147-15148	“	_	
77-54	15148-15151	off	_	
77-55	15151-15152	”	_	
77-56	15153-15154	(	_	
77-57	15154-15160	nested	_	
77-58	15161-15167	models	_	
77-59	15167-15168	;	_	
77-60	15169-15175	figure	_	
77-61	15176-15178	3A	_	
77-62	15178-15179	)	_	
77-63	15179-15180	.	_	

#Text=Group differences were then verified by comparing the evidence between the full model and the nested model.
78-1	15181-15186	Group	_	
78-2	15187-15198	differences	_	
78-3	15199-15203	were	_	
78-4	15204-15208	then	_	
78-5	15209-15217	verified	_	
78-6	15218-15220	by	_	
78-7	15221-15230	comparing	_	
78-8	15231-15234	the	_	
78-9	15235-15243	evidence	_	
78-10	15244-15251	between	_	
78-11	15252-15255	the	_	
78-12	15256-15260	full	_	
78-13	15261-15266	model	_	
78-14	15267-15270	and	_	
78-15	15271-15274	the	_	
78-16	15275-15281	nested	_	
78-17	15282-15287	model	_	
78-18	15287-15288	.	_	

#Text=Group variables were de-meaned before being entered in the PEB model, to account for the different sample sizes of our study groups.
79-1	15289-15294	Group	_	
79-2	15295-15304	variables	_	
79-3	15305-15309	were	_	
79-4	15310-15319	de-meaned	_	
79-5	15320-15326	before	_	
79-6	15327-15332	being	_	
79-7	15333-15340	entered	_	
79-8	15341-15343	in	_	
79-9	15344-15347	the	_	
79-10	15348-15351	PEB	_	
79-11	15352-15357	model	_	
79-12	15357-15358	,	_	
79-13	15359-15361	to	_	
79-14	15362-15369	account	_	
79-15	15370-15373	for	_	
79-16	15374-15377	the	_	
79-17	15378-15387	different	_	
79-18	15388-15394	sample	_	
79-19	15395-15400	sizes	_	
79-20	15401-15403	of	_	
79-21	15404-15407	our	_	
79-22	15408-15413	study	_	
79-23	15414-15420	groups	_	
79-24	15420-15421	.	_	

#Text=Age was included as a covariate on all PEB analyses.
80-1	15422-15425	Age	_	
80-2	15426-15429	was	_	
80-3	15430-15438	included	_	
80-4	15439-15441	as	_	
80-5	15442-15443	a	_	
80-6	15444-15453	covariate	_	
80-7	15454-15456	on	_	
80-8	15457-15460	all	_	
80-9	15461-15464	PEB	_	
80-10	15465-15473	analyses	_	
80-11	15473-15474	.	_	

#Text=Additional exploratory analyses within the CHR group and its subgroups according to transition status were conducted to examine potential associations between severity of positive prodromal symptoms and fMRI response to novelty/DCM connectivity strengths (supplementary eFigure 1).
81-1	15475-15485	Additional	_	
81-2	15486-15497	exploratory	_	
81-3	15498-15506	analyses	_	
81-4	15507-15513	within	_	
81-5	15514-15517	the	_	
81-6	15518-15521	CHR	_	
81-7	15522-15527	group	_	
81-8	15528-15531	and	_	
81-9	15532-15535	its	_	
81-10	15536-15545	subgroups	_	
81-11	15546-15555	according	_	
81-12	15556-15558	to	_	
81-13	15559-15569	transition	_	
81-14	15570-15576	status	_	
81-15	15577-15581	were	_	
81-16	15582-15591	conducted	_	
81-17	15592-15594	to	_	
81-18	15595-15602	examine	_	
81-19	15603-15612	potential	_	
81-20	15613-15625	associations	_	
81-21	15626-15633	between	_	
81-22	15634-15642	severity	_	
81-23	15643-15645	of	_	
81-24	15646-15654	positive	_	
81-25	15655-15664	prodromal	_	
81-26	15665-15673	symptoms	_	
81-27	15674-15677	and	_	
81-28	15678-15682	fMRI	_	
81-29	15683-15691	response	_	
81-30	15692-15694	to	_	
81-31	15695-15702	novelty	_	
81-32	15702-15703	/	_	
81-33	15703-15706	DCM	_	
81-34	15707-15719	connectivity	_	
81-35	15720-15729	strengths	_	
81-36	15730-15731	(	_	
81-37	15731-15744	supplementary	_	
81-38	15745-15752	eFigure	_	
81-39	15753-15754	1	_	
81-40	15754-15755	)	_	
81-41	15755-15756	.	_	

#Text=Results
#Text=Demographic and Clinical Data
#Text=Nine CHR participants were excluded from the final analyses due to incomplete fMRI data (n = 3), or excessive movement (n = 6).
82-1	15757-15764	Results	_	
82-2	15765-15776	Demographic	_	
82-3	15777-15780	and	_	
82-4	15781-15789	Clinical	_	
82-5	15790-15794	Data	_	
82-6	15795-15799	Nine	_	
82-7	15800-15803	CHR	_	
82-8	15804-15816	participants	_	
82-9	15817-15821	were	_	
82-10	15822-15830	excluded	_	
82-11	15831-15835	from	_	
82-12	15836-15839	the	_	
82-13	15840-15845	final	_	
82-14	15846-15854	analyses	_	
82-15	15855-15858	due	_	
82-16	15859-15861	to	_	
82-17	15862-15872	incomplete	_	
82-18	15873-15877	fMRI	_	
82-19	15878-15882	data	_	
82-20	15883-15884	(	_	
82-21	15884-15885	n	_	
82-22	15886-15887	=	_	
82-23	15888-15889	3	_	
82-24	15889-15890	)	_	
82-25	15890-15891	,	_	
82-26	15892-15894	or	_	
82-27	15895-15904	excessive	_	
82-28	15905-15913	movement	_	
82-29	15914-15915	(	_	
82-30	15915-15916	n	_	
82-31	15917-15918	=	_	
82-32	15919-15920	6	_	
82-33	15920-15921	)	_	
82-34	15921-15922	.	_	

#Text=The analyzed sample thus comprised 76 CHR participants and 31 HCs.
83-1	15923-15926	The	_	
83-2	15927-15935	analyzed	_	
83-3	15936-15942	sample	_	
83-4	15943-15947	thus	_	
83-5	15948-15957	comprised	_	
83-6	15958-15960	76	_	
83-7	15961-15964	CHR	_	
83-8	15965-15977	participants	_	
83-9	15978-15981	and	_	
83-10	15982-15984	31	_	
83-11	15985-15988	HCs	_	
83-12	15988-15989	.	_	

#Text=Detailed examination of potential movement confounds is reported in supplementary eTable 1 and eFigure 2.
84-1	15990-15998	Detailed	_	
84-2	15999-16010	examination	_	
84-3	16011-16013	of	_	
84-4	16014-16023	potential	_	
84-5	16024-16032	movement	_	
84-6	16033-16042	confounds	_	
84-7	16043-16045	is	_	
84-8	16046-16054	reported	_	
84-9	16055-16057	in	_	
84-10	16058-16071	supplementary	_	
84-11	16072-16078	eTable	_	
84-12	16079-16080	1	_	
84-13	16081-16084	and	_	
84-14	16085-16092	eFigure	_	
84-15	16093-16094	2	_	
84-16	16094-16095	.	_	

#Text=All of the CHR participants met the CAARMS Attenuated Psychotic Symptoms criteria.
85-1	16096-16099	All	_	
85-2	16100-16102	of	_	
85-3	16103-16106	the	_	
85-4	16107-16110	CHR	_	
85-5	16111-16123	participants	_	
85-6	16124-16127	met	_	
85-7	16128-16131	the	_	
85-8	16132-16138	CAARMS	_	
85-9	16139-16149	Attenuated	_	
85-10	16150-16159	Psychotic	_	
85-11	16160-16168	Symptoms	_	
85-12	16169-16177	criteria	_	
85-13	16177-16178	.	_	

#Text=A minority additionally fulfilled the BLIPS (n = 5) or schizotypal personality disorder/familial risk criteria (n = 2).
86-1	16179-16180	A	_	
86-2	16181-16189	minority	_	
86-3	16190-16202	additionally	_	
86-4	16203-16212	fulfilled	_	
86-5	16213-16216	the	_	
86-6	16217-16222	BLIPS	_	
86-7	16223-16224	(	_	
86-8	16224-16225	n	_	
86-9	16226-16227	=	_	
86-10	16228-16229	5	_	
86-11	16229-16230	)	_	
86-12	16231-16233	or	_	
86-13	16234-16245	schizotypal	_	
86-14	16246-16257	personality	_	
86-15	16258-16266	disorder	_	
86-16	16266-16267	/	_	
86-17	16267-16275	familial	_	
86-18	16276-16280	risk	_	
86-19	16281-16289	criteria	_	
86-20	16290-16291	(	_	
86-21	16291-16292	n	_	
86-22	16293-16294	=	_	
86-23	16295-16296	2	_	
86-24	16296-16297	)	_	
86-25	16297-16298	.	_	

#Text=At the time of scanning, most (67/76; 88%) CHR participants were naïve to antipsychotic medication.
87-1	16299-16301	At	_	
87-2	16302-16305	the	_	
87-3	16306-16310	time	_	
87-4	16311-16313	of	_	
87-5	16314-16322	scanning	_	
87-6	16322-16323	,	_	
87-7	16324-16328	most	_	
87-8	16329-16330	(	_	
87-9	16330-16332	67	_	
87-10	16332-16333	/	_	
87-11	16333-16335	76	_	
87-12	16335-16336	;	_	
87-13	16337-16340	88%	_	
87-14	16340-16341	)	_	
87-15	16342-16345	CHR	_	
87-16	16346-16358	participants	_	
87-17	16359-16363	were	_	
87-18	16364-16369	naïve	_	
87-19	16370-16372	to	_	
87-20	16373-16386	antipsychotic	_	
87-21	16387-16397	medication	_	
87-22	16397-16398	.	_	

#Text=The remainder were taking low doses of antipsychotics (<1.5 mg haloperidol equivalents per day).
88-1	16399-16402	The	_	
88-2	16403-16412	remainder	_	
88-3	16413-16417	were	_	
88-4	16418-16424	taking	_	
88-5	16425-16428	low	_	
88-6	16429-16434	doses	_	
88-7	16435-16437	of	_	
88-8	16438-16452	antipsychotics	_	
88-9	16453-16454	(	_	
88-10	16454-16455	<	_	
88-11	16455-16458	1.5	_	
88-12	16459-16461	mg	_	
88-13	16462-16473	haloperidol	_	
88-14	16474-16485	equivalents	_	
88-15	16486-16489	per	_	
88-16	16490-16493	day	_	
88-17	16493-16494	)	_	
88-18	16494-16495	.	_	

#Text=The majority of CHR participants were also anti-depressant free at the time of scanning (48/76; 63%).
89-1	16496-16499	The	_	
89-2	16500-16508	majority	_	
89-3	16509-16511	of	_	
89-4	16512-16515	CHR	_	
89-5	16516-16528	participants	_	
89-6	16529-16533	were	_	
89-7	16534-16538	also	_	
89-8	16539-16554	anti-depressant	_	
89-9	16555-16559	free	_	
89-10	16560-16562	at	_	
89-11	16563-16566	the	_	
89-12	16567-16571	time	_	
89-13	16572-16574	of	_	
89-14	16575-16583	scanning	_	
89-15	16584-16585	(	_	
89-16	16585-16587	48	_	
89-17	16587-16588	/	_	
89-18	16588-16590	76	_	
89-19	16590-16591	;	_	
89-20	16592-16595	63%	_	
89-21	16595-16596	)	_	
89-22	16596-16597	.	_	

#Text=The HC and CHR groups did not differ significantly in gender, handedness, estimated IQ, years of education, alcohol, or cannabis use.
90-1	16598-16601	The	_	
90-2	16602-16604	HC	_	
90-3	16605-16608	and	_	
90-4	16609-16612	CHR	_	
90-5	16613-16619	groups	_	
90-6	16620-16623	did	_	
90-7	16624-16627	not	_	
90-8	16628-16634	differ	_	
90-9	16635-16648	significantly	_	
90-10	16649-16651	in	_	
90-11	16652-16658	gender	_	
90-12	16658-16659	,	_	
90-13	16660-16670	handedness	_	
90-14	16670-16671	,	_	
90-15	16672-16681	estimated	_	
90-16	16682-16684	IQ	_	
90-17	16684-16685	,	_	
90-18	16686-16691	years	_	
90-19	16692-16694	of	_	
90-20	16695-16704	education	_	
90-21	16704-16705	,	_	
90-22	16706-16713	alcohol	_	
90-23	16713-16714	,	_	
90-24	16715-16717	or	_	
90-25	16718-16726	cannabis	_	
90-26	16727-16730	use	_	
90-27	16730-16731	.	_	

#Text=However, the CHR group was younger and smoked more tobacco.
91-1	16732-16739	However	_	
91-2	16739-16740	,	_	
91-3	16741-16744	the	_	
91-4	16745-16748	CHR	_	
91-5	16749-16754	group	_	
91-6	16755-16758	was	_	
91-7	16759-16766	younger	_	
91-8	16767-16770	and	_	
91-9	16771-16777	smoked	_	
91-10	16778-16782	more	_	
91-11	16783-16790	tobacco	_	
91-12	16790-16791	.	_	

#Text=As would be expected, they showed higher levels of anxiety and depressive symptoms (HAM-A/HAM-D scores) and had lower levels of overall functioning compared to HCs (GAF score; table 1).
92-1	16792-16794	As	_	
92-2	16795-16800	would	_	
92-3	16801-16803	be	_	
92-4	16804-16812	expected	_	
92-5	16812-16813	,	_	
92-6	16814-16818	they	_	
92-7	16819-16825	showed	_	
92-8	16826-16832	higher	_	
92-9	16833-16839	levels	_	
92-10	16840-16842	of	_	
92-11	16843-16850	anxiety	_	
92-12	16851-16854	and	_	
92-13	16855-16865	depressive	_	
92-14	16866-16874	symptoms	_	
92-15	16875-16876	(	_	
92-16	16876-16881	HAM-A	_	
92-17	16881-16882	/	_	
92-18	16882-16887	HAM-D	_	
92-19	16888-16894	scores	_	
92-20	16894-16895	)	_	
92-21	16896-16899	and	_	
92-22	16900-16903	had	_	
92-23	16904-16909	lower	_	
92-24	16910-16916	levels	_	
92-25	16917-16919	of	_	
92-26	16920-16927	overall	_	
92-27	16928-16939	functioning	_	
92-28	16940-16948	compared	_	
92-29	16949-16951	to	_	
92-30	16952-16955	HCs	_	
92-31	16956-16957	(	_	
92-32	16957-16960	GAF	_	
92-33	16961-16966	score	_	
92-34	16966-16967	;	_	
92-35	16968-16973	table	_	
92-36	16974-16975	1	_	
92-37	16975-16976	)	_	
92-38	16976-16977	.	_	

#Text=Thirteen of the CHR participants (17%) developed a psychotic disorder within the follow-up period of 59.7 months (CHR-T), while 63 participants did not (CHR-NT).
93-1	16978-16986	Thirteen	_	
93-2	16987-16989	of	_	
93-3	16990-16993	the	_	
93-4	16994-16997	CHR	_	
93-5	16998-17010	participants	_	
93-6	17011-17012	(	_	
93-7	17012-17015	17%	_	
93-8	17015-17016	)	_	
93-9	17017-17026	developed	_	
93-10	17027-17028	a	_	
93-11	17029-17038	psychotic	_	
93-12	17039-17047	disorder	_	
93-13	17048-17054	within	_	
93-14	17055-17058	the	_	
93-15	17059-17068	follow-up	_	
93-16	17069-17075	period	_	
93-17	17076-17078	of	_	
93-18	17079-17083	59.7	_	
93-19	17084-17090	months	_	
93-20	17091-17092	(	_	
93-21	17092-17097	CHR-T	_	
93-22	17097-17098	)	_	
93-23	17098-17099	,	_	
93-24	17100-17105	while	_	
93-25	17106-17108	63	_	
93-26	17109-17121	participants	_	
93-27	17122-17125	did	_	
93-28	17126-17129	not	_	
93-29	17130-17131	(	_	
93-30	17131-17137	CHR-NT	_	
93-31	17137-17138	)	_	
93-32	17138-17139	.	_	

#Text=There were no significant differences in demographic or clinical variables at baseline between these groups (table 1).
94-1	17140-17145	There	_	
94-2	17146-17150	were	_	
94-3	17151-17153	no	_	
94-4	17154-17165	significant	_	
94-5	17166-17177	differences	_	
94-6	17178-17180	in	_	
94-7	17181-17192	demographic	_	
94-8	17193-17195	or	_	
94-9	17196-17204	clinical	_	
94-10	17205-17214	variables	_	
94-11	17215-17217	at	_	
94-12	17218-17226	baseline	_	
94-13	17227-17234	between	_	
94-14	17235-17240	these	_	
94-15	17241-17247	groups	_	
94-16	17248-17249	(	_	
94-17	17249-17254	table	_	
94-18	17255-17256	1	_	
94-19	17256-17257	)	_	
94-20	17257-17258	.	_	

#Text=Behavioral Data
#Text=The groups did not differ in their engagement with the fMRI task (mean RT or recognition of target stimuli; supplementary eTable 2).
#Text=fMRI Data
#Text=Effect of Task
#Text=Across groups, pure stimulus novelty was associated with activation in the anterior hippocampus, ventral striatum and midbrain bilaterally (PFWE < .05 after SVC; table 2, figure 2A).
95-1	17259-17269	Behavioral	_	
95-2	17270-17274	Data	_	
95-3	17275-17278	The	_	
95-4	17279-17285	groups	_	
95-5	17286-17289	did	_	
95-6	17290-17293	not	_	
95-7	17294-17300	differ	_	
95-8	17301-17303	in	_	
95-9	17304-17309	their	_	
95-10	17310-17320	engagement	_	
95-11	17321-17325	with	_	
95-12	17326-17329	the	_	
95-13	17330-17334	fMRI	_	
95-14	17335-17339	task	_	
95-15	17340-17341	(	_	
95-16	17341-17345	mean	_	
95-17	17346-17348	RT	_	
95-18	17349-17351	or	_	
95-19	17352-17363	recognition	_	
95-20	17364-17366	of	_	
95-21	17367-17373	target	_	
95-22	17374-17381	stimuli	_	
95-23	17381-17382	;	_	
95-24	17383-17396	supplementary	_	
95-25	17397-17403	eTable	_	
95-26	17404-17405	2	_	
95-27	17405-17406	)	_	
95-28	17406-17407	.	_	
95-29	17408-17412	fMRI	_	
95-30	17413-17417	Data	_	
95-31	17418-17424	Effect	_	
95-32	17425-17427	of	_	
95-33	17428-17432	Task	_	
95-34	17433-17439	Across	_	
95-35	17440-17446	groups	_	
95-36	17446-17447	,	_	
95-37	17448-17452	pure	_	
95-38	17453-17461	stimulus	_	
95-39	17462-17469	novelty	_	
95-40	17470-17473	was	_	
95-41	17474-17484	associated	_	
95-42	17485-17489	with	_	
95-43	17490-17500	activation	_	
95-44	17501-17503	in	_	
95-45	17504-17507	the	_	
95-46	17508-17516	anterior	_	
95-47	17517-17528	hippocampus	_	
95-48	17528-17529	,	_	
95-49	17530-17537	ventral	_	
95-50	17538-17546	striatum	_	
95-51	17547-17550	and	_	
95-52	17551-17559	midbrain	_	
95-53	17560-17571	bilaterally	_	
95-54	17572-17573	(	_	
95-55	17573-17577	PFWE	_	
95-56	17578-17579	<	_	
95-57	17580-17583	.05	_	
95-58	17584-17589	after	_	
95-59	17590-17593	SVC	_	
95-60	17593-17594	;	_	
95-61	17595-17600	table	_	
95-62	17601-17602	2	_	
95-63	17602-17603	,	_	
95-64	17604-17610	figure	_	
95-65	17611-17613	2A	_	
95-66	17613-17614	)	_	
95-67	17614-17615	.	_	

#Text=Group Differences: All CHRs vs HCs
#Text=In CHR participants, relative to HC, pure stimulus novelty (novel > neutral oddball trial) was associated with significantly less activation in the anterior portion of the right hippocampus than in HCs (PFWE = .041; xyz = 38 −16 −14; Z = 3.42, Hedges’ g = 0.543; figures 2B and C).
96-1	17616-17621	Group	_	
96-2	17622-17633	Differences	_	
96-3	17633-17634	:	_	
96-4	17635-17638	All	_	
96-5	17639-17643	CHRs	_	
96-6	17644-17646	vs	_	
96-7	17647-17650	HCs	_	
96-8	17651-17653	In	_	
96-9	17654-17657	CHR	_	
96-10	17658-17670	participants	_	
96-11	17670-17671	,	_	
96-12	17672-17680	relative	_	
96-13	17681-17683	to	_	
96-14	17684-17686	HC	_	
96-15	17686-17687	,	_	
96-16	17688-17692	pure	_	
96-17	17693-17701	stimulus	_	
96-18	17702-17709	novelty	_	
96-19	17710-17711	(	_	
96-20	17711-17716	novel	_	
96-21	17717-17718	>	_	
96-22	17719-17726	neutral	_	
96-23	17727-17734	oddball	_	
96-24	17735-17740	trial	_	
96-25	17740-17741	)	_	
96-26	17742-17745	was	_	
96-27	17746-17756	associated	_	
96-28	17757-17761	with	_	
96-29	17762-17775	significantly	_	
96-30	17776-17780	less	_	
96-31	17781-17791	activation	_	
96-32	17792-17794	in	_	
96-33	17795-17798	the	_	
96-34	17799-17807	anterior	_	
96-35	17808-17815	portion	_	
96-36	17816-17818	of	_	
96-37	17819-17822	the	_	
96-38	17823-17828	right	_	
96-39	17829-17840	hippocampus	_	
96-40	17841-17845	than	_	
96-41	17846-17848	in	_	
96-42	17849-17852	HCs	_	
96-43	17853-17854	(	_	
96-44	17854-17858	PFWE	_	
96-45	17859-17860	=	_	
96-46	17861-17865	.041	_	
96-47	17865-17866	;	_	
96-48	17867-17870	xyz	_	
96-49	17871-17872	=	_	
96-50	17873-17875	38	_	
96-51	17876-17877	−	_	
96-52	17877-17879	16	_	
96-53	17880-17881	−	_	
96-54	17881-17883	14	_	
96-55	17883-17884	;	_	
96-56	17885-17886	Z	_	
96-57	17887-17888	=	_	
96-58	17889-17893	3.42	_	
96-59	17893-17894	,	_	
96-60	17895-17901	Hedges	_	
96-61	17901-17902	’	_	
96-62	17903-17904	g	_	
96-63	17905-17906	=	_	
96-64	17907-17912	0.543	_	
96-65	17912-17913	;	_	
96-66	17914-17921	figures	_	
96-67	17922-17924	2B	_	
96-68	17925-17928	and	_	
96-69	17929-17930	C	_	
96-70	17930-17931	)	_	
96-71	17931-17932	.	_	

#Text=There were no areas where CHR participants showed greater activation than HC.
97-1	17933-17938	There	_	
97-2	17939-17943	were	_	
97-3	17944-17946	no	_	
97-4	17947-17952	areas	_	
97-5	17953-17958	where	_	
97-6	17959-17962	CHR	_	
97-7	17963-17975	participants	_	
97-8	17976-17982	showed	_	
97-9	17983-17990	greater	_	
97-10	17991-18001	activation	_	
97-11	18002-18006	than	_	
97-12	18007-18009	HC	_	
97-13	18009-18010	.	_	

#Text=These findings remained unchanged after adding sex as additional covariate of no interest in the analysis (HC > CHR: right hippocampus, PFWE = .033; xyz = 38 −16 −14; Z = 3.49, Hedges’ g = 0.544; CHR > HC no suprathreshold voxels).
98-1	18011-18016	These	_	
98-2	18017-18025	findings	_	
98-3	18026-18034	remained	_	
98-4	18035-18044	unchanged	_	
98-5	18045-18050	after	_	
98-6	18051-18057	adding	_	
98-7	18058-18061	sex	_	
98-8	18062-18064	as	_	
98-9	18065-18075	additional	_	
98-10	18076-18085	covariate	_	
98-11	18086-18088	of	_	
98-12	18089-18091	no	_	
98-13	18092-18100	interest	_	
98-14	18101-18103	in	_	
98-15	18104-18107	the	_	
98-16	18108-18116	analysis	_	
98-17	18117-18118	(	_	
98-18	18118-18120	HC	_	
98-19	18121-18122	>	_	
98-20	18123-18126	CHR	_	
98-21	18126-18127	:	_	
98-22	18128-18133	right	_	
98-23	18134-18145	hippocampus	_	
98-24	18145-18146	,	_	
98-25	18147-18151	PFWE	_	
98-26	18152-18153	=	_	
98-27	18154-18158	.033	_	
98-28	18158-18159	;	_	
98-29	18160-18163	xyz	_	
98-30	18164-18165	=	_	
98-31	18166-18168	38	_	
98-32	18169-18170	−	_	
98-33	18170-18172	16	_	
98-34	18173-18174	−	_	
98-35	18174-18176	14	_	
98-36	18176-18177	;	_	
98-37	18178-18179	Z	_	
98-38	18180-18181	=	_	
98-39	18182-18186	3.49	_	
98-40	18186-18187	,	_	
98-41	18188-18194	Hedges	_	
98-42	18194-18195	’	_	
98-43	18196-18197	g	_	
98-44	18198-18199	=	_	
98-45	18200-18205	0.544	_	
98-46	18205-18206	;	_	
98-47	18207-18210	CHR	_	
98-48	18211-18212	>	_	
98-49	18213-18215	HC	_	
98-50	18216-18218	no	_	
98-51	18219-18233	suprathreshold	_	
98-52	18234-18240	voxels	_	
98-53	18240-18241	)	_	
98-54	18241-18242	.	_	

#Text=Because resting-state neuroimaging studies in CHR groups have reported increased hippocampal perfusion/metabolism, we tested whether the reduced activation of the right anterior hippocampus in CHR relative to HC during pure stimulus novelty reflected an increased response to the neutral comparator stimuli that fMRI studies traditionally use.
99-1	18243-18250	Because	_	
99-2	18251-18264	resting-state	_	
99-3	18265-18277	neuroimaging	_	
99-4	18278-18285	studies	_	
99-5	18286-18288	in	_	
99-6	18289-18292	CHR	_	
99-7	18293-18299	groups	_	
99-8	18300-18304	have	_	
99-9	18305-18313	reported	_	
99-10	18314-18323	increased	_	
99-11	18324-18335	hippocampal	_	
99-12	18336-18345	perfusion	_	
99-13	18345-18346	/	_	
99-14	18346-18356	metabolism	_	
99-15	18356-18357	,	_	
99-16	18358-18360	we	_	
99-17	18361-18367	tested	_	
99-18	18368-18375	whether	_	
99-19	18376-18379	the	_	
99-20	18380-18387	reduced	_	
99-21	18388-18398	activation	_	
99-22	18399-18401	of	_	
99-23	18402-18405	the	_	
99-24	18406-18411	right	_	
99-25	18412-18420	anterior	_	
99-26	18421-18432	hippocampus	_	
99-27	18433-18435	in	_	
99-28	18436-18439	CHR	_	
99-29	18440-18448	relative	_	
99-30	18449-18451	to	_	
99-31	18452-18454	HC	_	
99-32	18455-18461	during	_	
99-33	18462-18466	pure	_	
99-34	18467-18475	stimulus	_	
99-35	18476-18483	novelty	_	
99-36	18484-18493	reflected	_	
99-37	18494-18496	an	_	
99-38	18497-18506	increased	_	
99-39	18507-18515	response	_	
99-40	18516-18518	to	_	
99-41	18519-18522	the	_	
99-42	18523-18530	neutral	_	
99-43	18531-18541	comparator	_	
99-44	18542-18549	stimuli	_	
99-45	18550-18554	that	_	
99-46	18555-18559	fMRI	_	
99-47	18560-18567	studies	_	
99-48	18568-18581	traditionally	_	
99-49	18582-18585	use	_	
99-50	18585-18586	.	_	

#Text=This supplementary analysis involved the contrast of neutral oddballs vs standards, reflecting activation related to unexpected, as opposed to novel stimuli, and revealed an increased hippocampal response in CHR relative to HC at a lenient threshold (P = .004 uncorrected, xyz = 36 −24 −16; kE = 20; Z = 2.66; Hedges’ g = 0.186; figure 1).
100-1	18587-18591	This	_	
100-2	18592-18605	supplementary	_	
100-3	18606-18614	analysis	_	
100-4	18615-18623	involved	_	
100-5	18624-18627	the	_	
100-6	18628-18636	contrast	_	
100-7	18637-18639	of	_	
100-8	18640-18647	neutral	_	
100-9	18648-18656	oddballs	_	
100-10	18657-18659	vs	_	
100-11	18660-18669	standards	_	
100-12	18669-18670	,	_	
100-13	18671-18681	reflecting	_	
100-14	18682-18692	activation	_	
100-15	18693-18700	related	_	
100-16	18701-18703	to	_	
100-17	18704-18714	unexpected	_	
100-18	18714-18715	,	_	
100-19	18716-18718	as	_	
100-20	18719-18726	opposed	_	
100-21	18727-18729	to	_	
100-22	18730-18735	novel	_	
100-23	18736-18743	stimuli	_	
100-24	18743-18744	,	_	
100-25	18745-18748	and	_	
100-26	18749-18757	revealed	_	
100-27	18758-18760	an	_	
100-28	18761-18770	increased	_	
100-29	18771-18782	hippocampal	_	
100-30	18783-18791	response	_	
100-31	18792-18794	in	_	
100-32	18795-18798	CHR	_	
100-33	18799-18807	relative	_	
100-34	18808-18810	to	_	
100-35	18811-18813	HC	_	
100-36	18814-18816	at	_	
100-37	18817-18818	a	_	
100-38	18819-18826	lenient	_	
100-39	18827-18836	threshold	_	
100-40	18837-18838	(	_	
100-41	18838-18839	P	_	
100-42	18840-18841	=	_	
100-43	18842-18846	.004	_	
100-44	18847-18858	uncorrected	_	
100-45	18858-18859	,	_	
100-46	18860-18863	xyz	_	
100-47	18864-18865	=	_	
100-48	18866-18868	36	_	
100-49	18869-18870	−	_	
100-50	18870-18872	24	_	
100-51	18873-18874	−	_	
100-52	18874-18876	16	_	
100-53	18876-18877	;	_	
100-54	18878-18880	kE	_	
100-55	18881-18882	=	_	
100-56	18883-18885	20	_	
100-57	18885-18886	;	_	
100-58	18887-18888	Z	_	
100-59	18889-18890	=	_	
100-60	18891-18895	2.66	_	
100-61	18895-18896	;	_	
100-62	18897-18903	Hedges	_	
100-63	18903-18904	’	_	
100-64	18905-18906	g	_	
100-65	18907-18908	=	_	
100-66	18909-18914	0.186	_	
100-67	18914-18915	;	_	
100-68	18916-18922	figure	_	
100-69	18923-18924	1	_	
100-70	18924-18925	)	_	
100-71	18925-18926	.	_	

#Text=Group Differences: Transition to Psychosis
#Text=There were no significant differences in activation between the CHR-T subgroup and either the CHR-NT subgroup or HCs.
101-1	18927-18932	Group	_	
101-2	18933-18944	Differences	_	
101-3	18944-18945	:	_	
101-4	18946-18956	Transition	_	
101-5	18957-18959	to	_	
101-6	18960-18969	Psychosis	_	
101-7	18970-18975	There	_	
101-8	18976-18980	were	_	
101-9	18981-18983	no	_	
101-10	18984-18995	significant	_	
101-11	18996-19007	differences	_	
101-12	19008-19010	in	_	
101-13	19011-19021	activation	_	
101-14	19022-19029	between	_	
101-15	19030-19033	the	_	
101-16	19034-19039	CHR-T	_	
101-17	19040-19048	subgroup	_	
101-18	19049-19052	and	_	
101-19	19053-19059	either	_	
101-20	19060-19063	the	_	
101-21	19064-19070	CHR-NT	_	
101-22	19071-19079	subgroup	_	
101-23	19080-19082	or	_	
101-24	19083-19086	HCs	_	
101-25	19086-19087	.	_	

#Text=However, as in the total CHR sample, a lower right anterior hippocampal response to novel > neutral stimuli was evident when CHR-NT were compared with HC (PFWE = .018; xyz = 38 −16 −14; Z = 3.68, Hedges’ g = 0.626).
102-1	19088-19095	However	_	
102-2	19095-19096	,	_	
102-3	19097-19099	as	_	
102-4	19100-19102	in	_	
102-5	19103-19106	the	_	
102-6	19107-19112	total	_	
102-7	19113-19116	CHR	_	
102-8	19117-19123	sample	_	
102-9	19123-19124	,	_	
102-10	19125-19126	a	_	
102-11	19127-19132	lower	_	
102-12	19133-19138	right	_	
102-13	19139-19147	anterior	_	
102-14	19148-19159	hippocampal	_	
102-15	19160-19168	response	_	
102-16	19169-19171	to	_	
102-17	19172-19177	novel	_	
102-18	19178-19179	>	_	
102-19	19180-19187	neutral	_	
102-20	19188-19195	stimuli	_	
102-21	19196-19199	was	_	
102-22	19200-19207	evident	_	
102-23	19208-19212	when	_	
102-24	19213-19219	CHR-NT	_	
102-25	19220-19224	were	_	
102-26	19225-19233	compared	_	
102-27	19234-19238	with	_	
102-28	19239-19241	HC	_	
102-29	19242-19243	(	_	
102-30	19243-19247	PFWE	_	
102-31	19248-19249	=	_	
102-32	19250-19254	.018	_	
102-33	19254-19255	;	_	
102-34	19256-19259	xyz	_	
102-35	19260-19261	=	_	
102-36	19262-19264	38	_	
102-37	19265-19266	−	_	
102-38	19266-19268	16	_	
102-39	19269-19270	−	_	
102-40	19270-19272	14	_	
102-41	19272-19273	;	_	
102-42	19274-19275	Z	_	
102-43	19276-19277	=	_	
102-44	19278-19282	3.68	_	
102-45	19282-19283	,	_	
102-46	19284-19290	Hedges	_	
102-47	19290-19291	’	_	
102-48	19292-19293	g	_	
102-49	19294-19295	=	_	
102-50	19296-19301	0.626	_	
102-51	19301-19302	)	_	
102-52	19302-19303	.	_	

#Text=These findings remained unchanged after additionally adjusting the analysis for sex (HC > CHR-NT: right hippocampus, PFWE = 0.013; xyz = 38 −16 −14; Z = 3.76, Hedges’ g = 0.488; HC <> CHR-T or CHR-NT <> CHR-T: no suprathreshold voxels).
103-1	19304-19309	These	_	
103-2	19310-19318	findings	_	
103-3	19319-19327	remained	_	
103-4	19328-19337	unchanged	_	
103-5	19338-19343	after	_	
103-6	19344-19356	additionally	_	
103-7	19357-19366	adjusting	_	
103-8	19367-19370	the	_	
103-9	19371-19379	analysis	_	
103-10	19380-19383	for	_	
103-11	19384-19387	sex	_	
103-12	19388-19389	(	_	
103-13	19389-19391	HC	_	
103-14	19392-19393	>	_	
103-15	19394-19400	CHR-NT	_	
103-16	19400-19401	:	_	
103-17	19402-19407	right	_	
103-18	19408-19419	hippocampus	_	
103-19	19419-19420	,	_	
103-20	19421-19425	PFWE	_	
103-21	19426-19427	=	_	
103-22	19428-19433	0.013	_	
103-23	19433-19434	;	_	
103-24	19435-19438	xyz	_	
103-25	19439-19440	=	_	
103-26	19441-19443	38	_	
103-27	19444-19445	−	_	
103-28	19445-19447	16	_	
103-29	19448-19449	−	_	
103-30	19449-19451	14	_	
103-31	19451-19452	;	_	
103-32	19453-19454	Z	_	
103-33	19455-19456	=	_	
103-34	19457-19461	3.76	_	
103-35	19461-19462	,	_	
103-36	19463-19469	Hedges	_	
103-37	19469-19470	’	_	
103-38	19471-19472	g	_	
103-39	19473-19474	=	_	
103-40	19475-19480	0.488	_	
103-41	19480-19481	;	_	
103-42	19482-19484	HC	_	
103-43	19485-19486	<	_	
103-44	19486-19487	>	_	
103-45	19488-19493	CHR-T	_	
103-46	19494-19496	or	_	
103-47	19497-19503	CHR-NT	_	
103-48	19504-19505	<	_	
103-49	19505-19506	>	_	
103-50	19507-19512	CHR-T	_	
103-51	19512-19513	:	_	
103-52	19514-19516	no	_	
103-53	19517-19531	suprathreshold	_	
103-54	19532-19538	voxels	_	
103-55	19538-19539	)	_	
103-56	19539-19540	.	_	

#Text=Clinical follow-up information (transition/non-transition) was not available for 6 of the 76 CHR individuals; repeating the transition analysis with these 6 individuals excluded from the CHR-NT group did not change the results (HC > CHR-NT: right hippocampus, PFWE = .019; xyz = 38 −16 −14; Z = 3.64, Hedges’ g = 0.621; HC <> CHR-T or CHR-NT <> CHR-T: no suprathreshold voxels).
104-1	19541-19549	Clinical	_	
104-2	19550-19559	follow-up	_	
104-3	19560-19571	information	_	
104-4	19572-19573	(	_	
104-5	19573-19583	transition	_	
104-6	19583-19584	/	_	
104-7	19584-19598	non-transition	_	
104-8	19598-19599	)	_	
104-9	19600-19603	was	_	
104-10	19604-19607	not	_	
104-11	19608-19617	available	_	
104-12	19618-19621	for	_	
104-13	19622-19623	6	_	
104-14	19624-19626	of	_	
104-15	19627-19630	the	_	
104-16	19631-19633	76	_	
104-17	19634-19637	CHR	_	
104-18	19638-19649	individuals	_	
104-19	19649-19650	;	_	
104-20	19651-19660	repeating	_	
104-21	19661-19664	the	_	
104-22	19665-19675	transition	_	
104-23	19676-19684	analysis	_	
104-24	19685-19689	with	_	
104-25	19690-19695	these	_	
104-26	19696-19697	6	_	
104-27	19698-19709	individuals	_	
104-28	19710-19718	excluded	_	
104-29	19719-19723	from	_	
104-30	19724-19727	the	_	
104-31	19728-19734	CHR-NT	_	
104-32	19735-19740	group	_	
104-33	19741-19744	did	_	
104-34	19745-19748	not	_	
104-35	19749-19755	change	_	
104-36	19756-19759	the	_	
104-37	19760-19767	results	_	
104-38	19768-19769	(	_	
104-39	19769-19771	HC	_	
104-40	19772-19773	>	_	
104-41	19774-19780	CHR-NT	_	
104-42	19780-19781	:	_	
104-43	19782-19787	right	_	
104-44	19788-19799	hippocampus	_	
104-45	19799-19800	,	_	
104-46	19801-19805	PFWE	_	
104-47	19806-19807	=	_	
104-48	19808-19812	.019	_	
104-49	19812-19813	;	_	
104-50	19814-19817	xyz	_	
104-51	19818-19819	=	_	
104-52	19820-19822	38	_	
104-53	19823-19824	−	_	
104-54	19824-19826	16	_	
104-55	19827-19828	−	_	
104-56	19828-19830	14	_	
104-57	19830-19831	;	_	
104-58	19832-19833	Z	_	
104-59	19834-19835	=	_	
104-60	19836-19840	3.64	_	
104-61	19840-19841	,	_	
104-62	19842-19848	Hedges	_	
104-63	19848-19849	’	_	
104-64	19850-19851	g	_	
104-65	19852-19853	=	_	
104-66	19854-19859	0.621	_	
104-67	19859-19860	;	_	
104-68	19861-19863	HC	_	
104-69	19864-19865	<	_	
104-70	19865-19866	>	_	
104-71	19867-19872	CHR-T	_	
104-72	19873-19875	or	_	
104-73	19876-19882	CHR-NT	_	
104-74	19883-19884	<	_	
104-75	19884-19885	>	_	
104-76	19886-19891	CHR-T	_	
104-77	19891-19892	:	_	
104-78	19893-19895	no	_	
104-79	19896-19910	suprathreshold	_	
104-80	19911-19917	voxels	_	
104-81	19917-19918	)	_	
104-82	19918-19919	.	_	

#Text=Analysis of Potential Confounders
#Text=A secondary analysis assessed the potentially confounding effects of substance use (alcohol, cigarettes, and cannabis) and levels of anxiety/depression (HAM-A/HAM-D) on the group difference in right anterior hippocampus activation.
105-1	19920-19928	Analysis	_	
105-2	19929-19931	of	_	
105-3	19932-19941	Potential	_	
105-4	19942-19953	Confounders	_	
105-5	19954-19955	A	_	
105-6	19956-19965	secondary	_	
105-7	19966-19974	analysis	_	
105-8	19975-19983	assessed	_	
105-9	19984-19987	the	_	
105-10	19988-19999	potentially	_	
105-11	20000-20011	confounding	_	
105-12	20012-20019	effects	_	
105-13	20020-20022	of	_	
105-14	20023-20032	substance	_	
105-15	20033-20036	use	_	
105-16	20037-20038	(	_	
105-17	20038-20045	alcohol	_	
105-18	20045-20046	,	_	
105-19	20047-20057	cigarettes	_	
105-20	20057-20058	,	_	
105-21	20059-20062	and	_	
105-22	20063-20071	cannabis	_	
105-23	20071-20072	)	_	
105-24	20073-20076	and	_	
105-25	20077-20083	levels	_	
105-26	20084-20086	of	_	
105-27	20087-20094	anxiety	_	
105-28	20094-20095	/	_	
105-29	20095-20105	depression	_	
105-30	20106-20107	(	_	
105-31	20107-20112	HAM-A	_	
105-32	20112-20113	/	_	
105-33	20113-20118	HAM-D	_	
105-34	20118-20119	)	_	
105-35	20120-20122	on	_	
105-36	20123-20126	the	_	
105-37	20127-20132	group	_	
105-38	20133-20143	difference	_	
105-39	20144-20146	in	_	
105-40	20147-20152	right	_	
105-41	20153-20161	anterior	_	
105-42	20162-20173	hippocampus	_	
105-43	20174-20184	activation	_	
105-44	20184-20185	.	_	

#Text=The group effect remained significant (F1,80 = 5.486, P = .022, Hedges’ g = 0.742; supplementaty eTable 3).
106-1	20186-20189	The	_	
106-2	20190-20195	group	_	
106-3	20196-20202	effect	_	
106-4	20203-20211	remained	_	
106-5	20212-20223	significant	_	
106-6	20224-20225	(	_	
106-7	20225-20230	F1,80	_	
106-8	20231-20232	=	_	
106-9	20233-20238	5.486	_	
106-10	20238-20239	,	_	
106-11	20240-20241	P	_	
106-12	20242-20243	=	_	
106-13	20244-20248	.022	_	
106-14	20248-20249	,	_	
106-15	20250-20256	Hedges	_	
106-16	20256-20257	’	_	
106-17	20258-20259	g	_	
106-18	20260-20261	=	_	
106-19	20262-20267	0.742	_	
106-20	20267-20268	;	_	
106-21	20269-20282	supplementaty	_	
106-22	20283-20289	eTable	_	
106-23	20290-20291	3	_	
106-24	20291-20292	)	_	
106-25	20292-20293	.	_	

#Text=We also examined whether antipsychotic medication could have affected the results by repeating the analysis after the 9 CHR participants who were receiving antipsychotics had been excluded from the SPM design.
107-1	20294-20296	We	_	
107-2	20297-20301	also	_	
107-3	20302-20310	examined	_	
107-4	20311-20318	whether	_	
107-5	20319-20332	antipsychotic	_	
107-6	20333-20343	medication	_	
107-7	20344-20349	could	_	
107-8	20350-20354	have	_	
107-9	20355-20363	affected	_	
107-10	20364-20367	the	_	
107-11	20368-20375	results	_	
107-12	20376-20378	by	_	
107-13	20379-20388	repeating	_	
107-14	20389-20392	the	_	
107-15	20393-20401	analysis	_	
107-16	20402-20407	after	_	
107-17	20408-20411	the	_	
107-18	20412-20413	9	_	
107-19	20414-20417	CHR	_	
107-20	20418-20430	participants	_	
107-21	20431-20434	who	_	
107-22	20435-20439	were	_	
107-23	20440-20449	receiving	_	
107-24	20450-20464	antipsychotics	_	
107-25	20465-20468	had	_	
107-26	20469-20473	been	_	
107-27	20474-20482	excluded	_	
107-28	20483-20487	from	_	
107-29	20488-20491	the	_	
107-30	20492-20495	SPM	_	
107-31	20496-20502	design	_	
107-32	20502-20503	.	_	

#Text=Again, the group difference in the right anterior hippocampus remained significant (PFWE = .042; xyz = 38, −18 −14; Z = 3.43, Hedges’ g = 0.591).
108-1	20504-20509	Again	_	
108-2	20509-20510	,	_	
108-3	20511-20514	the	_	
108-4	20515-20520	group	_	
108-5	20521-20531	difference	_	
108-6	20532-20534	in	_	
108-7	20535-20538	the	_	
108-8	20539-20544	right	_	
108-9	20545-20553	anterior	_	
108-10	20554-20565	hippocampus	_	
108-11	20566-20574	remained	_	
108-12	20575-20586	significant	_	
108-13	20587-20588	(	_	
108-14	20588-20592	PFWE	_	
108-15	20593-20594	=	_	
108-16	20595-20599	.042	_	
108-17	20599-20600	;	_	
108-18	20601-20604	xyz	_	
108-19	20605-20606	=	_	
108-20	20607-20609	38	_	
108-21	20609-20610	,	_	
108-22	20611-20612	−	_	
108-23	20612-20614	18	_	
108-24	20615-20616	−	_	
108-25	20616-20618	14	_	
108-26	20618-20619	;	_	
108-27	20620-20621	Z	_	
108-28	20622-20623	=	_	
108-29	20624-20628	3.43	_	
108-30	20628-20629	,	_	
108-31	20630-20636	Hedges	_	
108-32	20636-20637	’	_	
108-33	20638-20639	g	_	
108-34	20640-20641	=	_	
108-35	20642-20647	0.591	_	
108-36	20647-20648	)	_	
108-37	20648-20649	.	_	

#Text=Finally, comparing CHR participants with (n = 28) vs CHR participants without (n = 48) antidepressants showed no suprathreshold effects at PFWE < .05.
109-1	20650-20657	Finally	_	
109-2	20657-20658	,	_	
109-3	20659-20668	comparing	_	
109-4	20669-20672	CHR	_	
109-5	20673-20685	participants	_	
109-6	20686-20690	with	_	
109-7	20691-20692	(	_	
109-8	20692-20693	n	_	
109-9	20694-20695	=	_	
109-10	20696-20698	28	_	
109-11	20698-20699	)	_	
109-12	20700-20702	vs	_	
109-13	20703-20706	CHR	_	
109-14	20707-20719	participants	_	
109-15	20720-20727	without	_	
109-16	20728-20729	(	_	
109-17	20729-20730	n	_	
109-18	20731-20732	=	_	
109-19	20733-20735	48	_	
109-20	20735-20736	)	_	
109-21	20737-20752	antidepressants	_	
109-22	20753-20759	showed	_	
109-23	20760-20762	no	_	
109-24	20763-20777	suprathreshold	_	
109-25	20778-20785	effects	_	
109-26	20786-20788	at	_	
109-27	20789-20793	PFWE	_	
109-28	20794-20795	<	_	
109-29	20796-20799	.05	_	
109-30	20799-20800	.	_	

#Text=Exploratory whole-brain fMRI results (comparing all CHR with HC subjects and CHR-NT with CHR-NT subjects) are reported in the supplementary eTable 4 and eFigure 3.
110-1	20801-20812	Exploratory	_	
110-2	20813-20824	whole-brain	_	
110-3	20825-20829	fMRI	_	
110-4	20830-20837	results	_	
110-5	20838-20839	(	_	
110-6	20839-20848	comparing	_	
110-7	20849-20852	all	_	
110-8	20853-20856	CHR	_	
110-9	20857-20861	with	_	
110-10	20862-20864	HC	_	
110-11	20865-20873	subjects	_	
110-12	20874-20877	and	_	
110-13	20878-20884	CHR-NT	_	
110-14	20885-20889	with	_	
110-15	20890-20896	CHR-NT	_	
110-16	20897-20905	subjects	_	
110-17	20905-20906	)	_	
110-18	20907-20910	are	_	
110-19	20911-20919	reported	_	
110-20	20920-20922	in	_	
110-21	20923-20926	the	_	
110-22	20927-20940	supplementary	_	
110-23	20941-20947	eTable	_	
110-24	20948-20949	4	_	
110-25	20950-20953	and	_	
110-26	20954-20961	eFigure	_	
110-27	20962-20963	3	_	
110-28	20963-20964	.	_	

#Text=Effective Connectivity: All CHRs vs HCs
#Text=For the comparison of HC vs CHR groups, PEB revealed group differences in the modulatory effect of pure stimulus novelty on hippocampal-striatal-midbrain connections.
111-1	20965-20974	Effective	_	
111-2	20975-20987	Connectivity	_	
111-3	20987-20988	:	_	
111-4	20989-20992	All	_	
111-5	20993-20997	CHRs	_	
111-6	20998-21000	vs	_	
111-7	21001-21004	HCs	_	
111-8	21005-21008	For	_	
111-9	21009-21012	the	_	
111-10	21013-21023	comparison	_	
111-11	21024-21026	of	_	
111-12	21027-21029	HC	_	
111-13	21030-21032	vs	_	
111-14	21033-21036	CHR	_	
111-15	21037-21043	groups	_	
111-16	21043-21044	,	_	
111-17	21045-21048	PEB	_	
111-18	21049-21057	revealed	_	
111-19	21058-21063	group	_	
111-20	21064-21075	differences	_	
111-21	21076-21078	in	_	
111-22	21079-21082	the	_	
111-23	21083-21093	modulatory	_	
111-24	21094-21100	effect	_	
111-25	21101-21103	of	_	
111-26	21104-21108	pure	_	
111-27	21109-21117	stimulus	_	
111-28	21118-21125	novelty	_	
111-29	21126-21128	on	_	
111-30	21129-21158	hippocampal-striatal-midbrain	_	
111-31	21159-21170	connections	_	
111-32	21170-21171	.	_	

#Text=The CHR group showed relatively reduced connectivity from VTA/SN to striatum (P = .52), but greater connectivity from hippocampus to striatum (P = .64) and from VTA/SN to hippocampus (P = .68; figure 3B).
112-1	21172-21175	The	_	
112-2	21176-21179	CHR	_	
112-3	21180-21185	group	_	
112-4	21186-21192	showed	_	
112-5	21193-21203	relatively	_	
112-6	21204-21211	reduced	_	
112-7	21212-21224	connectivity	_	
112-8	21225-21229	from	_	
112-9	21230-21233	VTA	_	
112-10	21233-21234	/	_	
112-11	21234-21236	SN	_	
112-12	21237-21239	to	_	
112-13	21240-21248	striatum	_	
112-14	21249-21250	(	_	
112-15	21250-21251	P	_	
112-16	21252-21253	=	_	
112-17	21254-21257	.52	_	
112-18	21257-21258	)	_	
112-19	21258-21259	,	_	
112-20	21260-21263	but	_	
112-21	21264-21271	greater	_	
112-22	21272-21284	connectivity	_	
112-23	21285-21289	from	_	
112-24	21290-21301	hippocampus	_	
112-25	21302-21304	to	_	
112-26	21305-21313	striatum	_	
112-27	21314-21315	(	_	
112-28	21315-21316	P	_	
112-29	21317-21318	=	_	
112-30	21319-21322	.64	_	
112-31	21322-21323	)	_	
112-32	21324-21327	and	_	
112-33	21328-21332	from	_	
112-34	21333-21336	VTA	_	
112-35	21336-21337	/	_	
112-36	21337-21339	SN	_	
112-37	21340-21342	to	_	
112-38	21343-21354	hippocampus	_	
112-39	21355-21356	(	_	
112-40	21356-21357	P	_	
112-41	21358-21359	=	_	
112-42	21360-21363	.68	_	
112-43	21363-21364	;	_	
112-44	21365-21371	figure	_	
112-45	21372-21374	3B	_	
112-46	21374-21375	)	_	
112-47	21375-21376	.	_	

#Text=These findings remained largely unchanged after additionally adjusting the analysis for sex (VTA/SN to hippocampus P = .74; hippocampus to striatum P = .63; although VTA/SN to striatum P = .47).
113-1	21377-21382	These	_	
113-2	21383-21391	findings	_	
113-3	21392-21400	remained	_	
113-4	21401-21408	largely	_	
113-5	21409-21418	unchanged	_	
113-6	21419-21424	after	_	
113-7	21425-21437	additionally	_	
113-8	21438-21447	adjusting	_	
113-9	21448-21451	the	_	
113-10	21452-21460	analysis	_	
113-11	21461-21464	for	_	
113-12	21465-21468	sex	_	
113-13	21469-21470	(	_	
113-14	21470-21473	VTA	_	
113-15	21473-21474	/	_	
113-16	21474-21476	SN	_	
113-17	21477-21479	to	_	
113-18	21480-21491	hippocampus	_	
113-19	21492-21493	P	_	
113-20	21494-21495	=	_	
113-21	21496-21499	.74	_	
113-22	21499-21500	;	_	
113-23	21501-21512	hippocampus	_	
113-24	21513-21515	to	_	
113-25	21516-21524	striatum	_	
113-26	21525-21526	P	_	
113-27	21527-21528	=	_	
113-28	21529-21532	.63	_	
113-29	21532-21533	;	_	
113-30	21534-21542	although	_	
113-31	21543-21546	VTA	_	
113-32	21546-21547	/	_	
113-33	21547-21549	SN	_	
113-34	21550-21552	to	_	
113-35	21553-21561	striatum	_	
113-36	21562-21563	P	_	
113-37	21564-21565	=	_	
113-38	21566-21569	.47	_	
113-39	21569-21570	)	_	
113-40	21570-21571	.	_	

#Text=Effective Connectivity: Transition to Psychosis
#Text=Comparison of the CHR participants who subsequently developed psychosis and those who did not by PEB analysis also revealed a group difference: the CHR-T subgroup showed reduced connectivity from VTA/SN to striatum compared to the CHR-NT subgroup (P = .51; figure 3C).
114-1	21572-21581	Effective	_	
114-2	21582-21594	Connectivity	_	
114-3	21594-21595	:	_	
114-4	21596-21606	Transition	_	
114-5	21607-21609	to	_	
114-6	21610-21619	Psychosis	_	
114-7	21620-21630	Comparison	_	
114-8	21631-21633	of	_	
114-9	21634-21637	the	_	
114-10	21638-21641	CHR	_	
114-11	21642-21654	participants	_	
114-12	21655-21658	who	_	
114-13	21659-21671	subsequently	_	
114-14	21672-21681	developed	_	
114-15	21682-21691	psychosis	_	
114-16	21692-21695	and	_	
114-17	21696-21701	those	_	
114-18	21702-21705	who	_	
114-19	21706-21709	did	_	
114-20	21710-21713	not	_	
114-21	21714-21716	by	_	
114-22	21717-21720	PEB	_	
114-23	21721-21729	analysis	_	
114-24	21730-21734	also	_	
114-25	21735-21743	revealed	_	
114-26	21744-21745	a	_	
114-27	21746-21751	group	_	
114-28	21752-21762	difference	_	
114-29	21762-21763	:	_	
114-30	21764-21767	the	_	
114-31	21768-21773	CHR-T	_	
114-32	21774-21782	subgroup	_	
114-33	21783-21789	showed	_	
114-34	21790-21797	reduced	_	
114-35	21798-21810	connectivity	_	
114-36	21811-21815	from	_	
114-37	21816-21819	VTA	_	
114-38	21819-21820	/	_	
114-39	21820-21822	SN	_	
114-40	21823-21825	to	_	
114-41	21826-21834	striatum	_	
114-42	21835-21843	compared	_	
114-43	21844-21846	to	_	
114-44	21847-21850	the	_	
114-45	21851-21857	CHR-NT	_	
114-46	21858-21866	subgroup	_	
114-47	21867-21868	(	_	
114-48	21868-21869	P	_	
114-49	21870-21871	=	_	
114-50	21872-21875	.51	_	
114-51	21875-21876	;	_	
114-52	21877-21883	figure	_	
114-53	21884-21886	3C	_	
114-54	21886-21887	)	_	
114-55	21887-21888	.	_	

#Text=This finding remained unchanged after additionally adjusting the analysis for sex (P = .53).
115-1	21889-21893	This	_	
115-2	21894-21901	finding	_	
115-3	21902-21910	remained	_	
115-4	21911-21920	unchanged	_	
115-5	21921-21926	after	_	
115-6	21927-21939	additionally	_	
115-7	21940-21949	adjusting	_	
115-8	21950-21953	the	_	
115-9	21954-21962	analysis	_	
115-10	21963-21966	for	_	
115-11	21967-21970	sex	_	
115-12	21971-21972	(	_	
115-13	21972-21973	P	_	
115-14	21974-21975	=	_	
115-15	21976-21979	.53	_	
115-16	21979-21980	)	_	
115-17	21980-21981	.	_	

#Text=Repeating this analysis excluding the 6 individuals for which follow-up clinical information was not available revealed that the reduced connectivity in CHR-T individuals from VTA/SN to striatum remained significant (P = .71), and a further connectivity decrease was observed for the backward connection from the striatum to the VTA/SN (P = .75; supplementary eFigure 4).
116-1	21982-21991	Repeating	_	
116-2	21992-21996	this	_	
116-3	21997-22005	analysis	_	
116-4	22006-22015	excluding	_	
116-5	22016-22019	the	_	
116-6	22020-22021	6	_	
116-7	22022-22033	individuals	_	
116-8	22034-22037	for	_	
116-9	22038-22043	which	_	
116-10	22044-22053	follow-up	_	
116-11	22054-22062	clinical	_	
116-12	22063-22074	information	_	
116-13	22075-22078	was	_	
116-14	22079-22082	not	_	
116-15	22083-22092	available	_	
116-16	22093-22101	revealed	_	
116-17	22102-22106	that	_	
116-18	22107-22110	the	_	
116-19	22111-22118	reduced	_	
116-20	22119-22131	connectivity	_	
116-21	22132-22134	in	_	
116-22	22135-22140	CHR-T	_	
116-23	22141-22152	individuals	_	
116-24	22153-22157	from	_	
116-25	22158-22161	VTA	_	
116-26	22161-22162	/	_	
116-27	22162-22164	SN	_	
116-28	22165-22167	to	_	
116-29	22168-22176	striatum	_	
116-30	22177-22185	remained	_	
116-31	22186-22197	significant	_	
116-32	22198-22199	(	_	
116-33	22199-22200	P	_	
116-34	22201-22202	=	_	
116-35	22203-22206	.71	_	
116-36	22206-22207	)	_	
116-37	22207-22208	,	_	
116-38	22209-22212	and	_	
116-39	22213-22214	a	_	
116-40	22215-22222	further	_	
116-41	22223-22235	connectivity	_	
116-42	22236-22244	decrease	_	
116-43	22245-22248	was	_	
116-44	22249-22257	observed	_	
116-45	22258-22261	for	_	
116-46	22262-22265	the	_	
116-47	22266-22274	backward	_	
116-48	22275-22285	connection	_	
116-49	22286-22290	from	_	
116-50	22291-22294	the	_	
116-51	22295-22303	striatum	_	
116-52	22304-22306	to	_	
116-53	22307-22310	the	_	
116-54	22311-22314	VTA	_	
116-55	22314-22315	/	_	
116-56	22315-22317	SN	_	
116-57	22318-22319	(	_	
116-58	22319-22320	P	_	
116-59	22321-22322	=	_	
116-60	22323-22326	.75	_	
116-61	22326-22327	;	_	
116-62	22328-22341	supplementary	_	
116-63	22342-22349	eFigure	_	
116-64	22350-22351	4	_	
116-65	22351-22352	)	_	
116-66	22352-22353	.	_	

#Text=Discussion
#Text=Our first major finding was that participants at CHR for psychosis showed an altered anterior hippocampal response during pure stimulus novelty processing, suggesting that salience dysregulation is not only present in patients with psychosis, but is also evident before its onset.
117-1	22354-22364	Discussion	_	
117-2	22365-22368	Our	_	
117-3	22369-22374	first	_	
117-4	22375-22380	major	_	
117-5	22381-22388	finding	_	
117-6	22389-22392	was	_	
117-7	22393-22397	that	_	
117-8	22398-22410	participants	_	
117-9	22411-22413	at	_	
117-10	22414-22417	CHR	_	
117-11	22418-22421	for	_	
117-12	22422-22431	psychosis	_	
117-13	22432-22438	showed	_	
117-14	22439-22441	an	_	
117-15	22442-22449	altered	_	
117-16	22450-22458	anterior	_	
117-17	22459-22470	hippocampal	_	
117-18	22471-22479	response	_	
117-19	22480-22486	during	_	
117-20	22487-22491	pure	_	
117-21	22492-22500	stimulus	_	
117-22	22501-22508	novelty	_	
117-23	22509-22519	processing	_	
117-24	22519-22520	,	_	
117-25	22521-22531	suggesting	_	
117-26	22532-22536	that	_	
117-27	22537-22545	salience	_	
117-28	22546-22559	dysregulation	_	
117-29	22560-22562	is	_	
117-30	22563-22566	not	_	
117-31	22567-22571	only	_	
117-32	22572-22579	present	_	
117-33	22580-22582	in	_	
117-34	22583-22591	patients	_	
117-35	22592-22596	with	_	
117-36	22597-22606	psychosis	_	
117-37	22606-22607	,	_	
117-38	22608-22611	but	_	
117-39	22612-22614	is	_	
117-40	22615-22619	also	_	
117-41	22620-22627	evident	_	
117-42	22628-22634	before	_	
117-43	22635-22638	its	_	
117-44	22639-22644	onset	_	
117-45	22644-22645	.	_	

#Text=The result was not attributable to effects of age, treatment with antipsychotic or antidepressant medication, substance use, anxiety/depression symptoms, or differential behavioral engagement with the fMRI task.
118-1	22646-22649	The	_	
118-2	22650-22656	result	_	
118-3	22657-22660	was	_	
118-4	22661-22664	not	_	
118-5	22665-22677	attributable	_	
118-6	22678-22680	to	_	
118-7	22681-22688	effects	_	
118-8	22689-22691	of	_	
118-9	22692-22695	age	_	
118-10	22695-22696	,	_	
118-11	22697-22706	treatment	_	
118-12	22707-22711	with	_	
118-13	22712-22725	antipsychotic	_	
118-14	22726-22728	or	_	
118-15	22729-22743	antidepressant	_	
118-16	22744-22754	medication	_	
118-17	22754-22755	,	_	
118-18	22756-22765	substance	_	
118-19	22766-22769	use	_	
118-20	22769-22770	,	_	
118-21	22771-22778	anxiety	_	
118-22	22778-22779	/	_	
118-23	22779-22789	depression	_	
118-24	22790-22798	symptoms	_	
118-25	22798-22799	,	_	
118-26	22800-22802	or	_	
118-27	22803-22815	differential	_	
118-28	22816-22826	behavioral	_	
118-29	22827-22837	engagement	_	
118-30	22838-22842	with	_	
118-31	22843-22846	the	_	
118-32	22847-22851	fMRI	_	
118-33	22852-22856	task	_	
118-34	22856-22857	.	_	

#Text=Complementary whole-brain analysis showed no significant between-group differences (as shown in the supplementary material), suggesting that during “pure stimulus novelty” processing, regions outside our a priori hippocampal-striatal-midbrain mask would not be differentially engaged by CHR individuals.
119-1	22858-22871	Complementary	_	
119-2	22872-22883	whole-brain	_	
119-3	22884-22892	analysis	_	
119-4	22893-22899	showed	_	
119-5	22900-22902	no	_	
119-6	22903-22914	significant	_	
119-7	22915-22928	between-group	_	
119-8	22929-22940	differences	_	
119-9	22941-22942	(	_	
119-10	22942-22944	as	_	
119-11	22945-22950	shown	_	
119-12	22951-22953	in	_	
119-13	22954-22957	the	_	
119-14	22958-22971	supplementary	_	
119-15	22972-22980	material	_	
119-16	22980-22981	)	_	
119-17	22981-22982	,	_	
119-18	22983-22993	suggesting	_	
119-19	22994-22998	that	_	
119-20	22999-23005	during	_	
119-21	23006-23007	“	_	
119-22	23007-23011	pure	_	
119-23	23012-23020	stimulus	_	
119-24	23021-23028	novelty	_	
119-25	23028-23029	”	_	
119-26	23030-23040	processing	_	
119-27	23040-23041	,	_	
119-28	23042-23049	regions	_	
119-29	23050-23057	outside	_	
119-30	23058-23061	our	_	
119-31	23062-23063	a	_	
119-32	23064-23070	priori	_	
119-33	23071-23100	hippocampal-striatal-midbrain	_	
119-34	23101-23105	mask	_	
119-35	23106-23111	would	_	
119-36	23112-23115	not	_	
119-37	23116-23118	be	_	
119-38	23119-23133	differentially	_	
119-39	23134-23141	engaged	_	
119-40	23142-23144	by	_	
119-41	23145-23148	CHR	_	
119-42	23149-23160	individuals	_	
119-43	23160-23161	.	_	

#Text=The second major finding came from applying a circuit-based approach to examine functional coupling within a hippocampus–striatal–midbrain circuit during salience processing.
120-1	23162-23165	The	_	
120-2	23166-23172	second	_	
120-3	23173-23178	major	_	
120-4	23179-23186	finding	_	
120-5	23187-23191	came	_	
120-6	23192-23196	from	_	
120-7	23197-23205	applying	_	
120-8	23206-23207	a	_	
120-9	23208-23221	circuit-based	_	
120-10	23222-23230	approach	_	
120-11	23231-23233	to	_	
120-12	23234-23241	examine	_	
120-13	23242-23252	functional	_	
120-14	23253-23261	coupling	_	
120-15	23262-23268	within	_	
120-16	23269-23270	a	_	
120-17	23271-23300	hippocampus–striatal–midbrain	_	
120-18	23301-23308	circuit	_	
120-19	23309-23315	during	_	
120-20	23316-23324	salience	_	
120-21	23325-23335	processing	_	
120-22	23335-23336	.	_	

#Text=CHR subjects showed significantly reduced effective connectivity from the midbrain to the striatum compared to controls, but greater connectivity from the hippocampus to the striatum and from the midbrain to the hippocampus.
121-1	23337-23340	CHR	_	
121-2	23341-23349	subjects	_	
121-3	23350-23356	showed	_	
121-4	23357-23370	significantly	_	
121-5	23371-23378	reduced	_	
121-6	23379-23388	effective	_	
121-7	23389-23401	connectivity	_	
121-8	23402-23406	from	_	
121-9	23407-23410	the	_	
121-10	23411-23419	midbrain	_	
121-11	23420-23422	to	_	
121-12	23423-23426	the	_	
121-13	23427-23435	striatum	_	
121-14	23436-23444	compared	_	
121-15	23445-23447	to	_	
121-16	23448-23456	controls	_	
121-17	23456-23457	,	_	
121-18	23458-23461	but	_	
121-19	23462-23469	greater	_	
121-20	23470-23482	connectivity	_	
121-21	23483-23487	from	_	
121-22	23488-23491	the	_	
121-23	23492-23503	hippocampus	_	
121-24	23504-23506	to	_	
121-25	23507-23510	the	_	
121-26	23511-23519	striatum	_	
121-27	23520-23523	and	_	
121-28	23524-23528	from	_	
121-29	23529-23532	the	_	
121-30	23533-23541	midbrain	_	
121-31	23542-23544	to	_	
121-32	23545-23548	the	_	
121-33	23549-23560	hippocampus	_	
121-34	23560-23561	.	_	

#Text=The reduction in midbrain-striatal connectivity in the whole sample was also evident in the subgroup who later became psychotic compared to the subgroup who did not.
122-1	23562-23565	The	_	
122-2	23566-23575	reduction	_	
122-3	23576-23578	in	_	
122-4	23579-23596	midbrain-striatal	_	
122-5	23597-23609	connectivity	_	
122-6	23610-23612	in	_	
122-7	23613-23616	the	_	
122-8	23617-23622	whole	_	
122-9	23623-23629	sample	_	
122-10	23630-23633	was	_	
122-11	23634-23638	also	_	
122-12	23639-23646	evident	_	
122-13	23647-23649	in	_	
122-14	23650-23653	the	_	
122-15	23654-23662	subgroup	_	
122-16	23663-23666	who	_	
122-17	23667-23672	later	_	
122-18	23673-23679	became	_	
122-19	23680-23689	psychotic	_	
122-20	23690-23698	compared	_	
122-21	23699-23701	to	_	
122-22	23702-23705	the	_	
122-23	23706-23714	subgroup	_	
122-24	23715-23718	who	_	
122-25	23719-23722	did	_	
122-26	23723-23726	not	_	
122-27	23726-23727	.	_	

#Text=Overall, the results support previous reports that altered salience-related response in the hippocampus is associated with psychosis risk, and suggest that the subsequent development of psychosis may rather be based on circuit-based connectivity disruptions.
123-1	23728-23735	Overall	_	
123-2	23735-23736	,	_	
123-3	23737-23740	the	_	
123-4	23741-23748	results	_	
123-5	23749-23756	support	_	
123-6	23757-23765	previous	_	
123-7	23766-23773	reports	_	
123-8	23774-23778	that	_	
123-9	23779-23786	altered	_	
123-10	23787-23803	salience-related	_	
123-11	23804-23812	response	_	
123-12	23813-23815	in	_	
123-13	23816-23819	the	_	
123-14	23820-23831	hippocampus	_	
123-15	23832-23834	is	_	
123-16	23835-23845	associated	_	
123-17	23846-23850	with	_	
123-18	23851-23860	psychosis	_	
123-19	23861-23865	risk	_	
123-20	23865-23866	,	_	
123-21	23867-23870	and	_	
123-22	23871-23878	suggest	_	
123-23	23879-23883	that	_	
123-24	23884-23887	the	_	
123-25	23888-23898	subsequent	_	
123-26	23899-23910	development	_	
123-27	23911-23913	of	_	
123-28	23914-23923	psychosis	_	
123-29	23924-23927	may	_	
123-30	23928-23934	rather	_	
123-31	23935-23937	be	_	
123-32	23938-23943	based	_	
123-33	23944-23946	on	_	
123-34	23947-23960	circuit-based	_	
123-35	23961-23973	connectivity	_	
123-36	23974-23985	disruptions	_	
123-37	23985-23986	.	_	

#Text=According to a well-validated neurodevelopmental animal model, the methylazoxymethanol acetate (MAM) model, increased tonic activity of the ventral/anterior hippocampus leads the ventral striatum to disinhibit the midbrain via inhibition of the ventral pallidum, which increases the number of spontaneously active midbrain dopamine neurons.
124-1	23987-23996	According	_	
124-2	23997-23999	to	_	
124-3	24000-24001	a	_	
124-4	24002-24016	well-validated	_	
124-5	24017-24035	neurodevelopmental	_	
124-6	24036-24042	animal	_	
124-7	24043-24048	model	_	
124-8	24048-24049	,	_	
124-9	24050-24053	the	_	
124-10	24054-24073	methylazoxymethanol	_	
124-11	24074-24081	acetate	_	
124-12	24082-24083	(	_	
124-13	24083-24086	MAM	_	
124-14	24086-24087	)	_	
124-15	24088-24093	model	_	
124-16	24093-24094	,	_	
124-17	24095-24104	increased	_	
124-18	24105-24110	tonic	_	
124-19	24111-24119	activity	_	
124-20	24120-24122	of	_	
124-21	24123-24126	the	_	
124-22	24127-24134	ventral	_	
124-23	24134-24135	/	_	
124-24	24135-24143	anterior	_	
124-25	24144-24155	hippocampus	_	
124-26	24156-24161	leads	_	
124-27	24162-24165	the	_	
124-28	24166-24173	ventral	_	
124-29	24174-24182	striatum	_	
124-30	24183-24185	to	_	
124-31	24186-24196	disinhibit	_	
124-32	24197-24200	the	_	
124-33	24201-24209	midbrain	_	
124-34	24210-24213	via	_	
124-35	24214-24224	inhibition	_	
124-36	24225-24227	of	_	
124-37	24228-24231	the	_	
124-38	24232-24239	ventral	_	
124-39	24240-24248	pallidum	_	
124-40	24248-24249	,	_	
124-41	24250-24255	which	_	
124-42	24256-24265	increases	_	
124-43	24266-24269	the	_	
124-44	24270-24276	number	_	
124-45	24277-24279	of	_	
124-46	24280-24293	spontaneously	_	
124-47	24294-24300	active	_	
124-48	24301-24309	midbrain	_	
124-49	24310-24318	dopamine	_	
124-50	24319-24326	neurons	_	
124-51	24326-24327	.	_	

#Text=Human imaging evidence has been largely consistent with this model.
125-1	24328-24333	Human	_	
125-2	24334-24341	imaging	_	
125-3	24342-24350	evidence	_	
125-4	24351-24354	has	_	
125-5	24355-24359	been	_	
125-6	24360-24367	largely	_	
125-7	24368-24378	consistent	_	
125-8	24379-24383	with	_	
125-9	24384-24388	this	_	
125-10	24389-24394	model	_	
125-11	24394-24395	.	_	

#Text=Resting cerebral blood volume (CBV) or flow (CBF) is elevated in the anterior hippocampus of patients with schizophrenia and CHR individuals.
126-1	24396-24403	Resting	_	
126-2	24404-24412	cerebral	_	
126-3	24413-24418	blood	_	
126-4	24419-24425	volume	_	
126-5	24426-24427	(	_	
126-6	24427-24430	CBV	_	
126-7	24430-24431	)	_	
126-8	24432-24434	or	_	
126-9	24435-24439	flow	_	
126-10	24440-24441	(	_	
126-11	24441-24444	CBF	_	
126-12	24444-24445	)	_	
126-13	24446-24448	is	_	
126-14	24449-24457	elevated	_	
126-15	24458-24460	in	_	
126-16	24461-24464	the	_	
126-17	24465-24473	anterior	_	
126-18	24474-24485	hippocampus	_	
126-19	24486-24488	of	_	
126-20	24489-24497	patients	_	
126-21	24498-24502	with	_	
126-22	24503-24516	schizophrenia	_	
126-23	24517-24520	and	_	
126-24	24521-24524	CHR	_	
126-25	24525-24536	individuals	_	
126-26	24536-24537	.	_	

#Text=Higher levels of CBV/CBF are positively associated with psychotic symptoms in CHR subjects and with subclinical psychotic-like experiences in schizotypal individuals.
127-1	24538-24544	Higher	_	
127-2	24545-24551	levels	_	
127-3	24552-24554	of	_	
127-4	24555-24558	CBV	_	
127-5	24558-24559	/	_	
127-6	24559-24562	CBF	_	
127-7	24563-24566	are	_	
127-8	24567-24577	positively	_	
127-9	24578-24588	associated	_	
127-10	24589-24593	with	_	
127-11	24594-24603	psychotic	_	
127-12	24604-24612	symptoms	_	
127-13	24613-24615	in	_	
127-14	24616-24619	CHR	_	
127-15	24620-24628	subjects	_	
127-16	24629-24632	and	_	
127-17	24633-24637	with	_	
127-18	24638-24649	subclinical	_	
127-19	24650-24664	psychotic-like	_	
127-20	24665-24676	experiences	_	
127-21	24677-24679	in	_	
127-22	24680-24691	schizotypal	_	
127-23	24692-24703	individuals	_	
127-24	24703-24704	.	_	

#Text=Furthermore, CHR subjects show elevated striatal dopamine function, an association between striatal dopamine function and reduced hippocampal activation during a memory task, and altered hippocampal glutamate levels.
128-1	24705-24716	Furthermore	_	
128-2	24716-24717	,	_	
128-3	24718-24721	CHR	_	
128-4	24722-24730	subjects	_	
128-5	24731-24735	show	_	
128-6	24736-24744	elevated	_	
128-7	24745-24753	striatal	_	
128-8	24754-24762	dopamine	_	
128-9	24763-24771	function	_	
128-10	24771-24772	,	_	
128-11	24773-24775	an	_	
128-12	24776-24787	association	_	
128-13	24788-24795	between	_	
128-14	24796-24804	striatal	_	
128-15	24805-24813	dopamine	_	
128-16	24814-24822	function	_	
128-17	24823-24826	and	_	
128-18	24827-24834	reduced	_	
128-19	24835-24846	hippocampal	_	
128-20	24847-24857	activation	_	
128-21	24858-24864	during	_	
128-22	24865-24866	a	_	
128-23	24867-24873	memory	_	
128-24	24874-24878	task	_	
128-25	24878-24879	,	_	
128-26	24880-24883	and	_	
128-27	24884-24891	altered	_	
128-28	24892-24903	hippocampal	_	
128-29	24904-24913	glutamate	_	
128-30	24914-24920	levels	_	
128-31	24920-24921	.	_	

#Text=In turn, altered hippocampal glutamate levels have been related to abnormal hippocampal activation during a memory task in CHR.
129-1	24922-24924	In	_	
129-2	24925-24929	turn	_	
129-3	24929-24930	,	_	
129-4	24931-24938	altered	_	
129-5	24939-24950	hippocampal	_	
129-6	24951-24960	glutamate	_	
129-7	24961-24967	levels	_	
129-8	24968-24972	have	_	
129-9	24973-24977	been	_	
129-10	24978-24985	related	_	
129-11	24986-24988	to	_	
129-12	24989-24997	abnormal	_	
129-13	24998-25009	hippocampal	_	
129-14	25010-25020	activation	_	
129-15	25021-25027	during	_	
129-16	25028-25029	a	_	
129-17	25030-25036	memory	_	
129-18	25037-25041	task	_	
129-19	25042-25044	in	_	
129-20	25045-25048	CHR	_	
129-21	25048-25049	.	_	

#Text=Our findings extend this literature by showing that hippocampal dysregulation is also evident when CHR individuals process novelty salience.
130-1	25050-25053	Our	_	
130-2	25054-25062	findings	_	
130-3	25063-25069	extend	_	
130-4	25070-25074	this	_	
130-5	25075-25085	literature	_	
130-6	25086-25088	by	_	
130-7	25089-25096	showing	_	
130-8	25097-25101	that	_	
130-9	25102-25113	hippocampal	_	
130-10	25114-25127	dysregulation	_	
130-11	25128-25130	is	_	
130-12	25131-25135	also	_	
130-13	25136-25143	evident	_	
130-14	25144-25148	when	_	
130-15	25149-25152	CHR	_	
130-16	25153-25164	individuals	_	
130-17	25165-25172	process	_	
130-18	25173-25180	novelty	_	
130-19	25181-25189	salience	_	
130-20	25189-25190	.	_	

#Text=An important consideration in the interpretation of fMRI data is that increases and decreases in BOLD response depend on (1) the direction of the change in regional brain activity relative to the baseline for both the control and the task condition, (2) the way in which the control condition and the condition of interest are compared, and (3) comparing groups which may have different baseline states.
131-1	25191-25193	An	_	
131-2	25194-25203	important	_	
131-3	25204-25217	consideration	_	
131-4	25218-25220	in	_	
131-5	25221-25224	the	_	
131-6	25225-25239	interpretation	_	
131-7	25240-25242	of	_	
131-8	25243-25247	fMRI	_	
131-9	25248-25252	data	_	
131-10	25253-25255	is	_	
131-11	25256-25260	that	_	
131-12	25261-25270	increases	_	
131-13	25271-25274	and	_	
131-14	25275-25284	decreases	_	
131-15	25285-25287	in	_	
131-16	25288-25292	BOLD	_	
131-17	25293-25301	response	_	
131-18	25302-25308	depend	_	
131-19	25309-25311	on	_	
131-20	25312-25313	(	_	
131-21	25313-25314	1	_	
131-22	25314-25315	)	_	
131-23	25316-25319	the	_	
131-24	25320-25329	direction	_	
131-25	25330-25332	of	_	
131-26	25333-25336	the	_	
131-27	25337-25343	change	_	
131-28	25344-25346	in	_	
131-29	25347-25355	regional	_	
131-30	25356-25361	brain	_	
131-31	25362-25370	activity	_	
131-32	25371-25379	relative	_	
131-33	25380-25382	to	_	
131-34	25383-25386	the	_	
131-35	25387-25395	baseline	_	
131-36	25396-25399	for	_	
131-37	25400-25404	both	_	
131-38	25405-25408	the	_	
131-39	25409-25416	control	_	
131-40	25417-25420	and	_	
131-41	25421-25424	the	_	
131-42	25425-25429	task	_	
131-43	25430-25439	condition	_	
131-44	25439-25440	,	_	
131-45	25441-25442	(	_	
131-46	25442-25443	2	_	
131-47	25443-25444	)	_	
131-48	25445-25448	the	_	
131-49	25449-25452	way	_	
131-50	25453-25455	in	_	
131-51	25456-25461	which	_	
131-52	25462-25465	the	_	
131-53	25466-25473	control	_	
131-54	25474-25483	condition	_	
131-55	25484-25487	and	_	
131-56	25488-25491	the	_	
131-57	25492-25501	condition	_	
131-58	25502-25504	of	_	
131-59	25505-25513	interest	_	
131-60	25514-25517	are	_	
131-61	25518-25526	compared	_	
131-62	25526-25527	,	_	
131-63	25528-25531	and	_	
131-64	25532-25533	(	_	
131-65	25533-25534	3	_	
131-66	25534-25535	)	_	
131-67	25536-25545	comparing	_	
131-68	25546-25552	groups	_	
131-69	25553-25558	which	_	
131-70	25559-25562	may	_	
131-71	25563-25567	have	_	
131-72	25568-25577	different	_	
131-73	25578-25586	baseline	_	
131-74	25587-25593	states	_	
131-75	25593-25594	.	_	

#Text=Our novelty salience paradigm was adapted from that employed by Bunzeck and Duzel, showing that the VTA/SN preferentially responds to stimulus novelty over other forms of stimulus salience.
132-1	25595-25598	Our	_	
132-2	25599-25606	novelty	_	
132-3	25607-25615	salience	_	
132-4	25616-25624	paradigm	_	
132-5	25625-25628	was	_	
132-6	25629-25636	adapted	_	
132-7	25637-25641	from	_	
132-8	25642-25646	that	_	
132-9	25647-25655	employed	_	
132-10	25656-25658	by	_	
132-11	25659-25666	Bunzeck	_	
132-12	25667-25670	and	_	
132-13	25671-25676	Duzel	_	
132-14	25676-25677	,	_	
132-15	25678-25685	showing	_	
132-16	25686-25690	that	_	
132-17	25691-25694	the	_	
132-18	25695-25698	VTA	_	
132-19	25698-25699	/	_	
132-20	25699-25701	SN	_	
132-21	25702-25716	preferentially	_	
132-22	25717-25725	responds	_	
132-23	25726-25728	to	_	
132-24	25729-25737	stimulus	_	
132-25	25738-25745	novelty	_	
132-26	25746-25750	over	_	
132-27	25751-25756	other	_	
132-28	25757-25762	forms	_	
132-29	25763-25765	of	_	
132-30	25766-25774	stimulus	_	
132-31	25775-25783	salience	_	
132-32	25783-25784	.	_	

#Text=The contrast between novel and neutral oddballs allowed quantification of neural response to what the authors called “pure stimulus novelty,” as opposed to rareness/deviance per se.
133-1	25785-25788	The	_	
133-2	25789-25797	contrast	_	
133-3	25798-25805	between	_	
133-4	25806-25811	novel	_	
133-5	25812-25815	and	_	
133-6	25816-25823	neutral	_	
133-7	25824-25832	oddballs	_	
133-8	25833-25840	allowed	_	
133-9	25841-25855	quantification	_	
133-10	25856-25858	of	_	
133-11	25859-25865	neural	_	
133-12	25866-25874	response	_	
133-13	25875-25877	to	_	
133-14	25878-25882	what	_	
133-15	25883-25886	the	_	
133-16	25887-25894	authors	_	
133-17	25895-25901	called	_	
133-18	25902-25903	“	_	
133-19	25903-25907	pure	_	
133-20	25908-25916	stimulus	_	
133-21	25917-25924	novelty	_	
133-22	25924-25925	,	_	
133-23	25925-25926	”	_	
133-24	25927-25929	as	_	
133-25	25930-25937	opposed	_	
133-26	25938-25940	to	_	
133-27	25941-25949	rareness	_	
133-28	25949-25950	/	_	
133-29	25950-25958	deviance	_	
133-30	25959-25962	per	_	
133-31	25963-25965	se	_	
133-32	25965-25966	.	_	

#Text=Our results suggest that the reduced response to pure stimulus novelty in the right anterior hippocampus in CHR individuals may be driven by increased response to the control condition comprising neutral stimuli (albeit at an uncorrected level).
134-1	25967-25970	Our	_	
134-2	25971-25978	results	_	
134-3	25979-25986	suggest	_	
134-4	25987-25991	that	_	
134-5	25992-25995	the	_	
134-6	25996-26003	reduced	_	
134-7	26004-26012	response	_	
134-8	26013-26015	to	_	
134-9	26016-26020	pure	_	
134-10	26021-26029	stimulus	_	
134-11	26030-26037	novelty	_	
134-12	26038-26040	in	_	
134-13	26041-26044	the	_	
134-14	26045-26050	right	_	
134-15	26051-26059	anterior	_	
134-16	26060-26071	hippocampus	_	
134-17	26072-26074	in	_	
134-18	26075-26078	CHR	_	
134-19	26079-26090	individuals	_	
134-20	26091-26094	may	_	
134-21	26095-26097	be	_	
134-22	26098-26104	driven	_	
134-23	26105-26107	by	_	
134-24	26108-26117	increased	_	
134-25	26118-26126	response	_	
134-26	26127-26129	to	_	
134-27	26130-26133	the	_	
134-28	26134-26141	control	_	
134-29	26142-26151	condition	_	
134-30	26152-26162	comprising	_	
134-31	26163-26170	neutral	_	
134-32	26171-26178	stimuli	_	
134-33	26179-26180	(	_	
134-34	26180-26186	albeit	_	
134-35	26187-26189	at	_	
134-36	26190-26192	an	_	
134-37	26193-26204	uncorrected	_	
134-38	26205-26210	level	_	
134-39	26210-26211	)	_	
134-40	26211-26212	.	_	

#Text=In terms of effective connectivity within this circuit, relative to controls, CHR subjects showed greater modulation by pure stimulus novelty in the connection from hippocampus to striatum and from midbrain to hippocampus.
135-1	26213-26215	In	_	
135-2	26216-26221	terms	_	
135-3	26222-26224	of	_	
135-4	26225-26234	effective	_	
135-5	26235-26247	connectivity	_	
135-6	26248-26254	within	_	
135-7	26255-26259	this	_	
135-8	26260-26267	circuit	_	
135-9	26267-26268	,	_	
135-10	26269-26277	relative	_	
135-11	26278-26280	to	_	
135-12	26281-26289	controls	_	
135-13	26289-26290	,	_	
135-14	26291-26294	CHR	_	
135-15	26295-26303	subjects	_	
135-16	26304-26310	showed	_	
135-17	26311-26318	greater	_	
135-18	26319-26329	modulation	_	
135-19	26330-26332	by	_	
135-20	26333-26337	pure	_	
135-21	26338-26346	stimulus	_	
135-22	26347-26354	novelty	_	
135-23	26355-26357	in	_	
135-24	26358-26361	the	_	
135-25	26362-26372	connection	_	
135-26	26373-26377	from	_	
135-27	26378-26389	hippocampus	_	
135-28	26390-26392	to	_	
135-29	26393-26401	striatum	_	
135-30	26402-26405	and	_	
135-31	26406-26410	from	_	
135-32	26411-26419	midbrain	_	
135-33	26420-26422	to	_	
135-34	26423-26434	hippocampus	_	
135-35	26434-26435	.	_	

#Text=While this analysis also indicated reduced modulation of connectivity from midbrain to striatum in CHR individuals, this effect was no longer significant once sex was adjusted for in the analysis, suggesting a potential relationship between midbrain-striatal connectivity and sex in the CHR state which merits further research.
136-1	26436-26441	While	_	
136-2	26442-26446	this	_	
136-3	26447-26455	analysis	_	
136-4	26456-26460	also	_	
136-5	26461-26470	indicated	_	
136-6	26471-26478	reduced	_	
136-7	26479-26489	modulation	_	
136-8	26490-26492	of	_	
136-9	26493-26505	connectivity	_	
136-10	26506-26510	from	_	
136-11	26511-26519	midbrain	_	
136-12	26520-26522	to	_	
136-13	26523-26531	striatum	_	
136-14	26532-26534	in	_	
136-15	26535-26538	CHR	_	
136-16	26539-26550	individuals	_	
136-17	26550-26551	,	_	
136-18	26552-26556	this	_	
136-19	26557-26563	effect	_	
136-20	26564-26567	was	_	
136-21	26568-26570	no	_	
136-22	26571-26577	longer	_	
136-23	26578-26589	significant	_	
136-24	26590-26594	once	_	
136-25	26595-26598	sex	_	
136-26	26599-26602	was	_	
136-27	26603-26611	adjusted	_	
136-28	26612-26615	for	_	
136-29	26616-26618	in	_	
136-30	26619-26622	the	_	
136-31	26623-26631	analysis	_	
136-32	26631-26632	,	_	
136-33	26633-26643	suggesting	_	
136-34	26644-26645	a	_	
136-35	26646-26655	potential	_	
136-36	26656-26668	relationship	_	
136-37	26669-26676	between	_	
136-38	26677-26694	midbrain-striatal	_	
136-39	26695-26707	connectivity	_	
136-40	26708-26711	and	_	
136-41	26712-26715	sex	_	
136-42	26716-26718	in	_	
136-43	26719-26722	the	_	
136-44	26723-26726	CHR	_	
136-45	26727-26732	state	_	
136-46	26733-26738	which	_	
136-47	26739-26745	merits	_	
136-48	26746-26753	further	_	
136-49	26754-26762	research	_	
136-50	26762-26763	.	_	

#Text=Overall, these findings suggest that, in CHR subjects, afferent and efferent connectivity of the hippocampus were increased, consistent with disrupted interactions within a hippocampal-striatal-midbrain circuit being associated with increased risk for psychosis.
137-1	26764-26771	Overall	_	
137-2	26771-26772	,	_	
137-3	26773-26778	these	_	
137-4	26779-26787	findings	_	
137-5	26788-26795	suggest	_	
137-6	26796-26800	that	_	
137-7	26800-26801	,	_	
137-8	26802-26804	in	_	
137-9	26805-26808	CHR	_	
137-10	26809-26817	subjects	_	
137-11	26817-26818	,	_	
137-12	26819-26827	afferent	_	
137-13	26828-26831	and	_	
137-14	26832-26840	efferent	_	
137-15	26841-26853	connectivity	_	
137-16	26854-26856	of	_	
137-17	26857-26860	the	_	
137-18	26861-26872	hippocampus	_	
137-19	26873-26877	were	_	
137-20	26878-26887	increased	_	
137-21	26887-26888	,	_	
137-22	26889-26899	consistent	_	
137-23	26900-26904	with	_	
137-24	26905-26914	disrupted	_	
137-25	26915-26927	interactions	_	
137-26	26928-26934	within	_	
137-27	26935-26936	a	_	
137-28	26937-26966	hippocampal-striatal-midbrain	_	
137-29	26967-26974	circuit	_	
137-30	26975-26980	being	_	
137-31	26981-26991	associated	_	
137-32	26992-26996	with	_	
137-33	26997-27006	increased	_	
137-34	27007-27011	risk	_	
137-35	27012-27015	for	_	
137-36	27016-27025	psychosis	_	
137-37	27025-27026	.	_	

#Text=This pattern of dysconnectivity would be in line with the maximal tonic activation of dopamine neuron firing hypothesized to occur in psychosis, thought to obscure salience-driven increases in population activity of mesostriatal dopamine neurons, leading to all stimuli being inappropriately registered as salient.
138-1	27027-27031	This	_	
138-2	27032-27039	pattern	_	
138-3	27040-27042	of	_	
138-4	27043-27058	dysconnectivity	_	
138-5	27059-27064	would	_	
138-6	27065-27067	be	_	
138-7	27068-27070	in	_	
138-8	27071-27075	line	_	
138-9	27076-27080	with	_	
138-10	27081-27084	the	_	
138-11	27085-27092	maximal	_	
138-12	27093-27098	tonic	_	
138-13	27099-27109	activation	_	
138-14	27110-27112	of	_	
138-15	27113-27121	dopamine	_	
138-16	27122-27128	neuron	_	
138-17	27129-27135	firing	_	
138-18	27136-27148	hypothesized	_	
138-19	27149-27151	to	_	
138-20	27152-27157	occur	_	
138-21	27158-27160	in	_	
138-22	27161-27170	psychosis	_	
138-23	27170-27171	,	_	
138-24	27172-27179	thought	_	
138-25	27180-27182	to	_	
138-26	27183-27190	obscure	_	
138-27	27191-27206	salience-driven	_	
138-28	27207-27216	increases	_	
138-29	27217-27219	in	_	
138-30	27220-27230	population	_	
138-31	27231-27239	activity	_	
138-32	27240-27242	of	_	
138-33	27243-27255	mesostriatal	_	
138-34	27256-27264	dopamine	_	
138-35	27265-27272	neurons	_	
138-36	27272-27273	,	_	
138-37	27274-27281	leading	_	
138-38	27282-27284	to	_	
138-39	27285-27288	all	_	
138-40	27289-27296	stimuli	_	
138-41	27297-27302	being	_	
138-42	27303-27318	inappropriately	_	
138-43	27319-27329	registered	_	
138-44	27330-27332	as	_	
138-45	27333-27340	salient	_	
138-46	27340-27341	.	_	

#Text=This could account for the increased response to non-novel stimuli, and the attenuation of the hippocampal response to salient stimuli, observed in the CHR group.
139-1	27342-27346	This	_	
139-2	27347-27352	could	_	
139-3	27353-27360	account	_	
139-4	27361-27364	for	_	
139-5	27365-27368	the	_	
139-6	27369-27378	increased	_	
139-7	27379-27387	response	_	
139-8	27388-27390	to	_	
139-9	27391-27400	non-novel	_	
139-10	27401-27408	stimuli	_	
139-11	27408-27409	,	_	
139-12	27410-27413	and	_	
139-13	27414-27417	the	_	
139-14	27418-27429	attenuation	_	
139-15	27430-27432	of	_	
139-16	27433-27436	the	_	
139-17	27437-27448	hippocampal	_	
139-18	27449-27457	response	_	
139-19	27458-27460	to	_	
139-20	27461-27468	salient	_	
139-21	27469-27476	stimuli	_	
139-22	27476-27477	,	_	
139-23	27478-27486	observed	_	
139-24	27487-27489	in	_	
139-25	27490-27493	the	_	
139-26	27494-27497	CHR	_	
139-27	27498-27503	group	_	
139-28	27503-27504	.	_	

#Text=Although the later onset of psychosis in CHR subjects was not associated with significant differences in hippocampal activation, this subgroup showed reduced modulation by pure stimulus novelty of the effective connectivity from midbrain to striatum compared to CHR subjects who did not become psychotic.
140-1	27505-27513	Although	_	
140-2	27514-27517	the	_	
140-3	27518-27523	later	_	
140-4	27524-27529	onset	_	
140-5	27530-27532	of	_	
140-6	27533-27542	psychosis	_	
140-7	27543-27545	in	_	
140-8	27546-27549	CHR	_	
140-9	27550-27558	subjects	_	
140-10	27559-27562	was	_	
140-11	27563-27566	not	_	
140-12	27567-27577	associated	_	
140-13	27578-27582	with	_	
140-14	27583-27594	significant	_	
140-15	27595-27606	differences	_	
140-16	27607-27609	in	_	
140-17	27610-27621	hippocampal	_	
140-18	27622-27632	activation	_	
140-19	27632-27633	,	_	
140-20	27634-27638	this	_	
140-21	27639-27647	subgroup	_	
140-22	27648-27654	showed	_	
140-23	27655-27662	reduced	_	
140-24	27663-27673	modulation	_	
140-25	27674-27676	by	_	
140-26	27677-27681	pure	_	
140-27	27682-27690	stimulus	_	
140-28	27691-27698	novelty	_	
140-29	27699-27701	of	_	
140-30	27702-27705	the	_	
140-31	27706-27715	effective	_	
140-32	27716-27728	connectivity	_	
140-33	27729-27733	from	_	
140-34	27734-27742	midbrain	_	
140-35	27743-27745	to	_	
140-36	27746-27754	striatum	_	
140-37	27755-27763	compared	_	
140-38	27764-27766	to	_	
140-39	27767-27770	CHR	_	
140-40	27771-27779	subjects	_	
140-41	27780-27783	who	_	
140-42	27784-27787	did	_	
140-43	27788-27791	not	_	
140-44	27792-27798	become	_	
140-45	27799-27808	psychotic	_	
140-46	27808-27809	.	_	

#Text=As a similar alteration in midbrain-striatal connectivity was also evident in the total CHR sample relative to controls (above), this suggests that among the changes in connectivity seen in the CHR sample, alterations in communication from midbrain to striatum may be particularly relevant to the subsequent onset of psychosis.
141-1	27810-27812	As	_	
141-2	27813-27814	a	_	
141-3	27815-27822	similar	_	
141-4	27823-27833	alteration	_	
141-5	27834-27836	in	_	
141-6	27837-27854	midbrain-striatal	_	
141-7	27855-27867	connectivity	_	
141-8	27868-27871	was	_	
141-9	27872-27876	also	_	
141-10	27877-27884	evident	_	
141-11	27885-27887	in	_	
141-12	27888-27891	the	_	
141-13	27892-27897	total	_	
141-14	27898-27901	CHR	_	
141-15	27902-27908	sample	_	
141-16	27909-27917	relative	_	
141-17	27918-27920	to	_	
141-18	27921-27929	controls	_	
141-19	27930-27931	(	_	
141-20	27931-27936	above	_	
141-21	27936-27937	)	_	
141-22	27937-27938	,	_	
141-23	27939-27943	this	_	
141-24	27944-27952	suggests	_	
141-25	27953-27957	that	_	
141-26	27958-27963	among	_	
141-27	27964-27967	the	_	
141-28	27968-27975	changes	_	
141-29	27976-27978	in	_	
141-30	27979-27991	connectivity	_	
141-31	27992-27996	seen	_	
141-32	27997-27999	in	_	
141-33	28000-28003	the	_	
141-34	28004-28007	CHR	_	
141-35	28008-28014	sample	_	
141-36	28014-28015	,	_	
141-37	28016-28027	alterations	_	
141-38	28028-28030	in	_	
141-39	28031-28044	communication	_	
141-40	28045-28049	from	_	
141-41	28050-28058	midbrain	_	
141-42	28059-28061	to	_	
141-43	28062-28070	striatum	_	
141-44	28071-28074	may	_	
141-45	28075-28077	be	_	
141-46	28078-28090	particularly	_	
141-47	28091-28099	relevant	_	
141-48	28100-28102	to	_	
141-49	28103-28106	the	_	
141-50	28107-28117	subsequent	_	
141-51	28118-28123	onset	_	
141-52	28124-28126	of	_	
141-53	28127-28136	psychosis	_	
141-54	28136-28137	.	_	

#Text=This would be consistent with PET studies in CHR subjects showing elevated midbrain and striatal dopamine function linked to later transition to psychosis.
142-1	28138-28142	This	_	
142-2	28143-28148	would	_	
142-3	28149-28151	be	_	
142-4	28152-28162	consistent	_	
142-5	28163-28167	with	_	
142-6	28168-28171	PET	_	
142-7	28172-28179	studies	_	
142-8	28180-28182	in	_	
142-9	28183-28186	CHR	_	
142-10	28187-28195	subjects	_	
142-11	28196-28203	showing	_	
142-12	28204-28212	elevated	_	
142-13	28213-28221	midbrain	_	
142-14	28222-28225	and	_	
142-15	28226-28234	striatal	_	
142-16	28235-28243	dopamine	_	
142-17	28244-28252	function	_	
142-18	28253-28259	linked	_	
142-19	28260-28262	to	_	
142-20	28263-28268	later	_	
142-21	28269-28279	transition	_	
142-22	28280-28282	to	_	
142-23	28283-28292	psychosis	_	
142-24	28292-28293	.	_	

#Text=An alternative explanation relates to a “ceiling effect” for hippocampal activity and subcortical connectivity in dopamine-related regions; the lower hippocampal response to novel vs non-novel stimuli could reflect a reduced signal-to-noise ratio in the comparison between these 2 conditions in CHR individuals, supported by the (uncorrected) hyper-responsivity to the neutral comparator condition.
143-1	28294-28296	An	_	
143-2	28297-28308	alternative	_	
143-3	28309-28320	explanation	_	
143-4	28321-28328	relates	_	
143-5	28329-28331	to	_	
143-6	28332-28333	a	_	
143-7	28334-28335	“	_	
143-8	28335-28342	ceiling	_	
143-9	28343-28349	effect	_	
143-10	28349-28350	”	_	
143-11	28351-28354	for	_	
143-12	28355-28366	hippocampal	_	
143-13	28367-28375	activity	_	
143-14	28376-28379	and	_	
143-15	28380-28391	subcortical	_	
143-16	28392-28404	connectivity	_	
143-17	28405-28407	in	_	
143-18	28408-28424	dopamine-related	_	
143-19	28425-28432	regions	_	
143-20	28432-28433	;	_	
143-21	28434-28437	the	_	
143-22	28438-28443	lower	_	
143-23	28444-28455	hippocampal	_	
143-24	28456-28464	response	_	
143-25	28465-28467	to	_	
143-26	28468-28473	novel	_	
143-27	28474-28476	vs	_	
143-28	28477-28486	non-novel	_	
143-29	28487-28494	stimuli	_	
143-30	28495-28500	could	_	
143-31	28501-28508	reflect	_	
143-32	28509-28510	a	_	
143-33	28511-28518	reduced	_	
143-34	28519-28534	signal-to-noise	_	
143-35	28535-28540	ratio	_	
143-36	28541-28543	in	_	
143-37	28544-28547	the	_	
143-38	28548-28558	comparison	_	
143-39	28559-28566	between	_	
143-40	28567-28572	these	_	
143-41	28573-28574	2	_	
143-42	28575-28585	conditions	_	
143-43	28586-28588	in	_	
143-44	28589-28592	CHR	_	
143-45	28593-28604	individuals	_	
143-46	28604-28605	,	_	
143-47	28606-28615	supported	_	
143-48	28616-28618	by	_	
143-49	28619-28622	the	_	
143-50	28623-28624	(	_	
143-51	28624-28635	uncorrected	_	
143-52	28635-28636	)	_	
143-53	28637-28655	hyper-responsivity	_	
143-54	28656-28658	to	_	
143-55	28659-28662	the	_	
143-56	28663-28670	neutral	_	
143-57	28671-28681	comparator	_	
143-58	28682-28691	condition	_	
143-59	28691-28692	.	_	

#Text=This notion is consistent with previous findings on emotional salience in CHR groups that lower responses to emotional stimuli are driven by increased responses to the neutral, nonemotional condition, and by reports of increased resting hippocampal perfusion in CHR.
144-1	28693-28697	This	_	
144-2	28698-28704	notion	_	
144-3	28705-28707	is	_	
144-4	28708-28718	consistent	_	
144-5	28719-28723	with	_	
144-6	28724-28732	previous	_	
144-7	28733-28741	findings	_	
144-8	28742-28744	on	_	
144-9	28745-28754	emotional	_	
144-10	28755-28763	salience	_	
144-11	28764-28766	in	_	
144-12	28767-28770	CHR	_	
144-13	28771-28777	groups	_	
144-14	28778-28782	that	_	
144-15	28783-28788	lower	_	
144-16	28789-28798	responses	_	
144-17	28799-28801	to	_	
144-18	28802-28811	emotional	_	
144-19	28812-28819	stimuli	_	
144-20	28820-28823	are	_	
144-21	28824-28830	driven	_	
144-22	28831-28833	by	_	
144-23	28834-28843	increased	_	
144-24	28844-28853	responses	_	
144-25	28854-28856	to	_	
144-26	28857-28860	the	_	
144-27	28861-28868	neutral	_	
144-28	28868-28869	,	_	
144-29	28870-28882	nonemotional	_	
144-30	28883-28892	condition	_	
144-31	28892-28893	,	_	
144-32	28894-28897	and	_	
144-33	28898-28900	by	_	
144-34	28901-28908	reports	_	
144-35	28909-28911	of	_	
144-36	28912-28921	increased	_	
144-37	28922-28929	resting	_	
144-38	28930-28941	hippocampal	_	
144-39	28942-28951	perfusion	_	
144-40	28952-28954	in	_	
144-41	28955-28958	CHR	_	
144-42	28958-28959	.	_	

#Text=Taken together, these results suggest that increased baseline activity/tonic dopamine signaling within this circuitry may render CHR/CHR-T individuals less able to “effectively” distinguish between novel (salient) and non-novel (non-salient) stimuli.
145-1	28960-28965	Taken	_	
145-2	28966-28974	together	_	
145-3	28974-28975	,	_	
145-4	28976-28981	these	_	
145-5	28982-28989	results	_	
145-6	28990-28997	suggest	_	
145-7	28998-29002	that	_	
145-8	29003-29012	increased	_	
145-9	29013-29021	baseline	_	
145-10	29022-29030	activity	_	
145-11	29030-29031	/	_	
145-12	29031-29036	tonic	_	
145-13	29037-29045	dopamine	_	
145-14	29046-29055	signaling	_	
145-15	29056-29062	within	_	
145-16	29063-29067	this	_	
145-17	29068-29077	circuitry	_	
145-18	29078-29081	may	_	
145-19	29082-29088	render	_	
145-20	29089-29092	CHR	_	
145-21	29092-29093	/	_	
145-22	29093-29098	CHR-T	_	
145-23	29099-29110	individuals	_	
145-24	29111-29115	less	_	
145-25	29116-29120	able	_	
145-26	29121-29123	to	_	
145-27	29124-29125	“	_	
145-28	29125-29136	effectively	_	
145-29	29136-29137	”	_	
145-30	29138-29149	distinguish	_	
145-31	29150-29157	between	_	
145-32	29158-29163	novel	_	
145-33	29164-29165	(	_	
145-34	29165-29172	salient	_	
145-35	29172-29173	)	_	
145-36	29174-29177	and	_	
145-37	29178-29187	non-novel	_	
145-38	29188-29189	(	_	
145-39	29189-29200	non-salient	_	
145-40	29200-29201	)	_	
145-41	29202-29209	stimuli	_	
145-42	29209-29210	.	_	

#Text=Despite studying a relatively large sample of CHR subjects, the number in the CHR-T subgroup was small; the findings in this subgroup should, therefore, be interpreted with caution, and warrant replication in larger samples.
146-1	29211-29218	Despite	_	
146-2	29219-29227	studying	_	
146-3	29228-29229	a	_	
146-4	29230-29240	relatively	_	
146-5	29241-29246	large	_	
146-6	29247-29253	sample	_	
146-7	29254-29256	of	_	
146-8	29257-29260	CHR	_	
146-9	29261-29269	subjects	_	
146-10	29269-29270	,	_	
146-11	29271-29274	the	_	
146-12	29275-29281	number	_	
146-13	29282-29284	in	_	
146-14	29285-29288	the	_	
146-15	29289-29294	CHR-T	_	
146-16	29295-29303	subgroup	_	
146-17	29304-29307	was	_	
146-18	29308-29313	small	_	
146-19	29313-29314	;	_	
146-20	29315-29318	the	_	
146-21	29319-29327	findings	_	
146-22	29328-29330	in	_	
146-23	29331-29335	this	_	
146-24	29336-29344	subgroup	_	
146-25	29345-29351	should	_	
146-26	29351-29352	,	_	
146-27	29353-29362	therefore	_	
146-28	29362-29363	,	_	
146-29	29364-29366	be	_	
146-30	29367-29378	interpreted	_	
146-31	29379-29383	with	_	
146-32	29384-29391	caution	_	
146-33	29391-29392	,	_	
146-34	29393-29396	and	_	
146-35	29397-29404	warrant	_	
146-36	29405-29416	replication	_	
146-37	29417-29419	in	_	
146-38	29420-29426	larger	_	
146-39	29427-29434	samples	_	
146-40	29434-29435	.	_	

#Text=Previous imaging studies of salience processing in CHR individuals relative to HCs have found significant differences in activation of the hippocampal-striatal-midbrain circuit in the context of reward/motivational salience, but not novelty or emotional salience.
147-1	29436-29444	Previous	_	
147-2	29445-29452	imaging	_	
147-3	29453-29460	studies	_	
147-4	29461-29463	of	_	
147-5	29464-29472	salience	_	
147-6	29473-29483	processing	_	
147-7	29484-29486	in	_	
147-8	29487-29490	CHR	_	
147-9	29491-29502	individuals	_	
147-10	29503-29511	relative	_	
147-11	29512-29514	to	_	
147-12	29515-29518	HCs	_	
147-13	29519-29523	have	_	
147-14	29524-29529	found	_	
147-15	29530-29541	significant	_	
147-16	29542-29553	differences	_	
147-17	29554-29556	in	_	
147-18	29557-29567	activation	_	
147-19	29568-29570	of	_	
147-20	29571-29574	the	_	
147-21	29575-29604	hippocampal-striatal-midbrain	_	
147-22	29605-29612	circuit	_	
147-23	29613-29615	in	_	
147-24	29616-29619	the	_	
147-25	29620-29627	context	_	
147-26	29628-29630	of	_	
147-27	29631-29637	reward	_	
147-28	29637-29638	/	_	
147-29	29638-29650	motivational	_	
147-30	29651-29659	salience	_	
147-31	29659-29660	,	_	
147-32	29661-29664	but	_	
147-33	29665-29668	not	_	
147-34	29669-29676	novelty	_	
147-35	29677-29679	or	_	
147-36	29680-29689	emotional	_	
147-37	29690-29698	salience	_	
147-38	29698-29699	.	_	

#Text=A possible explanation for this discrepancy might relate to modest sample sizes in previous studies, as we included a relatively large CHR sample (n = 76).
148-1	29700-29701	A	_	
148-2	29702-29710	possible	_	
148-3	29711-29722	explanation	_	
148-4	29723-29726	for	_	
148-5	29727-29731	this	_	
148-6	29732-29743	discrepancy	_	
148-7	29744-29749	might	_	
148-8	29750-29756	relate	_	
148-9	29757-29759	to	_	
148-10	29760-29766	modest	_	
148-11	29767-29773	sample	_	
148-12	29774-29779	sizes	_	
148-13	29780-29782	in	_	
148-14	29783-29791	previous	_	
148-15	29792-29799	studies	_	
148-16	29799-29800	,	_	
148-17	29801-29803	as	_	
148-18	29804-29806	we	_	
148-19	29807-29815	included	_	
148-20	29816-29817	a	_	
148-21	29818-29828	relatively	_	
148-22	29829-29834	large	_	
148-23	29835-29838	CHR	_	
148-24	29839-29845	sample	_	
148-25	29846-29847	(	_	
148-26	29847-29848	n	_	
148-27	29849-29850	=	_	
148-28	29851-29853	76	_	
148-29	29853-29854	)	_	
148-30	29854-29855	.	_	

#Text=Additional sources for discrepancies might relate to the use of different salience task paradigms, tapping on different dimensions of salience processing.
149-1	29856-29866	Additional	_	
149-2	29867-29874	sources	_	
149-3	29875-29878	for	_	
149-4	29879-29892	discrepancies	_	
149-5	29893-29898	might	_	
149-6	29899-29905	relate	_	
149-7	29906-29908	to	_	
149-8	29909-29912	the	_	
149-9	29913-29916	use	_	
149-10	29917-29919	of	_	
149-11	29920-29929	different	_	
149-12	29930-29938	salience	_	
149-13	29939-29943	task	_	
149-14	29944-29953	paradigms	_	
149-15	29953-29954	,	_	
149-16	29955-29962	tapping	_	
149-17	29963-29965	on	_	
149-18	29966-29975	different	_	
149-19	29976-29986	dimensions	_	
149-20	29987-29989	of	_	
149-21	29990-29998	salience	_	
149-22	29999-30009	processing	_	
149-23	30009-30010	.	_	

#Text=More specifically, Roiser et al used the Salience Attribution Task (SAT), a monetary reward task measuring adaptive and aberrant motivational salience.
150-1	30011-30015	More	_	
150-2	30016-30028	specifically	_	
150-3	30028-30029	,	_	
150-4	30030-30036	Roiser	_	
150-5	30037-30039	et	_	
150-6	30040-30042	al	_	
150-7	30043-30047	used	_	
150-8	30048-30051	the	_	
150-9	30052-30060	Salience	_	
150-10	30061-30072	Attribution	_	
150-11	30073-30077	Task	_	
150-12	30078-30079	(	_	
150-13	30079-30082	SAT	_	
150-14	30082-30083	)	_	
150-15	30083-30084	,	_	
150-16	30085-30086	a	_	
150-17	30087-30095	monetary	_	
150-18	30096-30102	reward	_	
150-19	30103-30107	task	_	
150-20	30108-30117	measuring	_	
150-21	30118-30126	adaptive	_	
150-22	30127-30130	and	_	
150-23	30131-30139	aberrant	_	
150-24	30140-30152	motivational	_	
150-25	30153-30161	salience	_	
150-26	30161-30162	.	_	

#Text=In contrast, Winton-Brown et al used the Salience Integration Task (SIT), a monetary incentive delay task in which conditions were manipulated to examine reward (monetary), novelty (with half of the trials as pre-familiarized and the other half as novel), and aversion (with half of the pictures as emotionally aversive).
151-1	30163-30165	In	_	
151-2	30166-30174	contrast	_	
151-3	30174-30175	,	_	
151-4	30176-30188	Winton-Brown	_	
151-5	30189-30191	et	_	
151-6	30192-30194	al	_	
151-7	30195-30199	used	_	
151-8	30200-30203	the	_	
151-9	30204-30212	Salience	_	
151-10	30213-30224	Integration	_	
151-11	30225-30229	Task	_	
151-12	30230-30231	(	_	
151-13	30231-30234	SIT	_	
151-14	30234-30235	)	_	
151-15	30235-30236	,	_	
151-16	30237-30238	a	_	
151-17	30239-30247	monetary	_	
151-18	30248-30257	incentive	_	
151-19	30258-30263	delay	_	
151-20	30264-30268	task	_	
151-21	30269-30271	in	_	
151-22	30272-30277	which	_	
151-23	30278-30288	conditions	_	
151-24	30289-30293	were	_	
151-25	30294-30305	manipulated	_	
151-26	30306-30308	to	_	
151-27	30309-30316	examine	_	
151-28	30317-30323	reward	_	
151-29	30324-30325	(	_	
151-30	30325-30333	monetary	_	
151-31	30333-30334	)	_	
151-32	30334-30335	,	_	
151-33	30336-30343	novelty	_	
151-34	30344-30345	(	_	
151-35	30345-30349	with	_	
151-36	30350-30354	half	_	
151-37	30355-30357	of	_	
151-38	30358-30361	the	_	
151-39	30362-30368	trials	_	
151-40	30369-30371	as	_	
151-41	30372-30388	pre-familiarized	_	
151-42	30389-30392	and	_	
151-43	30393-30396	the	_	
151-44	30397-30402	other	_	
151-45	30403-30407	half	_	
151-46	30408-30410	as	_	
151-47	30411-30416	novel	_	
151-48	30416-30417	)	_	
151-49	30417-30418	,	_	
151-50	30419-30422	and	_	
151-51	30423-30431	aversion	_	
151-52	30432-30433	(	_	
151-53	30433-30437	with	_	
151-54	30438-30442	half	_	
151-55	30443-30445	of	_	
151-56	30446-30449	the	_	
151-57	30450-30458	pictures	_	
151-58	30459-30461	as	_	
151-59	30462-30473	emotionally	_	
151-60	30474-30482	aversive	_	
151-61	30482-30483	)	_	
151-62	30483-30484	.	_	

#Text=Given that salience is a multifaceted construct, and that novelty salience had not been studied in relation to transition to psychosis, we used a task paradigm known to robustly isolate the specific processing of novelty.
152-1	30485-30490	Given	_	
152-2	30491-30495	that	_	
152-3	30496-30504	salience	_	
152-4	30505-30507	is	_	
152-5	30508-30509	a	_	
152-6	30510-30522	multifaceted	_	
152-7	30523-30532	construct	_	
152-8	30532-30533	,	_	
152-9	30534-30537	and	_	
152-10	30538-30542	that	_	
152-11	30543-30550	novelty	_	
152-12	30551-30559	salience	_	
152-13	30560-30563	had	_	
152-14	30564-30567	not	_	
152-15	30568-30572	been	_	
152-16	30573-30580	studied	_	
152-17	30581-30583	in	_	
152-18	30584-30592	relation	_	
152-19	30593-30595	to	_	
152-20	30596-30606	transition	_	
152-21	30607-30609	to	_	
152-22	30610-30619	psychosis	_	
152-23	30619-30620	,	_	
152-24	30621-30623	we	_	
152-25	30624-30628	used	_	
152-26	30629-30630	a	_	
152-27	30631-30635	task	_	
152-28	30636-30644	paradigm	_	
152-29	30645-30650	known	_	
152-30	30651-30653	to	_	
152-31	30654-30662	robustly	_	
152-32	30663-30670	isolate	_	
152-33	30671-30674	the	_	
152-34	30675-30683	specific	_	
152-35	30684-30694	processing	_	
152-36	30695-30697	of	_	
152-37	30698-30705	novelty	_	
152-38	30705-30706	.	_	

#Text=In terms of findings, Roiser et al focused on the dorsolateral prefrontal cortex, hippocampus, and midbrain, and found that the magnitude of aberrant motivational salience attribution was positively correlated with ventral striatal responses to non-salient cue features.
153-1	30707-30709	In	_	
153-2	30710-30715	terms	_	
153-3	30716-30718	of	_	
153-4	30719-30727	findings	_	
153-5	30727-30728	,	_	
153-6	30729-30735	Roiser	_	
153-7	30736-30738	et	_	
153-8	30739-30741	al	_	
153-9	30742-30749	focused	_	
153-10	30750-30752	on	_	
153-11	30753-30756	the	_	
153-12	30757-30769	dorsolateral	_	
153-13	30770-30780	prefrontal	_	
153-14	30781-30787	cortex	_	
153-15	30787-30788	,	_	
153-16	30789-30800	hippocampus	_	
153-17	30800-30801	,	_	
153-18	30802-30805	and	_	
153-19	30806-30814	midbrain	_	
153-20	30814-30815	,	_	
153-21	30816-30819	and	_	
153-22	30820-30825	found	_	
153-23	30826-30830	that	_	
153-24	30831-30834	the	_	
153-25	30835-30844	magnitude	_	
153-26	30845-30847	of	_	
153-27	30848-30856	aberrant	_	
153-28	30857-30869	motivational	_	
153-29	30870-30878	salience	_	
153-30	30879-30890	attribution	_	
153-31	30891-30894	was	_	
153-32	30895-30905	positively	_	
153-33	30906-30916	correlated	_	
153-34	30917-30921	with	_	
153-35	30922-30929	ventral	_	
153-36	30930-30938	striatal	_	
153-37	30939-30948	responses	_	
153-38	30949-30951	to	_	
153-39	30952-30963	non-salient	_	
153-40	30964-30967	cue	_	
153-41	30968-30976	features	_	
153-42	30976-30977	.	_	

#Text=Winton-Brown et al focused on the hippocampus, striatum, and midbrain, and found significant group differences with CHR subjects showing greater activation than HC to reward-predicting stimuli in the ventral pallidum and in the midbrain/hippocampus, while they did not observe any significant effects for novelty or emotional salience.
154-1	30978-30990	Winton-Brown	_	
154-2	30991-30993	et	_	
154-3	30994-30996	al	_	
154-4	30997-31004	focused	_	
154-5	31005-31007	on	_	
154-6	31008-31011	the	_	
154-7	31012-31023	hippocampus	_	
154-8	31023-31024	,	_	
154-9	31025-31033	striatum	_	
154-10	31033-31034	,	_	
154-11	31035-31038	and	_	
154-12	31039-31047	midbrain	_	
154-13	31047-31048	,	_	
154-14	31049-31052	and	_	
154-15	31053-31058	found	_	
154-16	31059-31070	significant	_	
154-17	31071-31076	group	_	
154-18	31077-31088	differences	_	
154-19	31089-31093	with	_	
154-20	31094-31097	CHR	_	
154-21	31098-31106	subjects	_	
154-22	31107-31114	showing	_	
154-23	31115-31122	greater	_	
154-24	31123-31133	activation	_	
154-25	31134-31138	than	_	
154-26	31139-31141	HC	_	
154-27	31142-31144	to	_	
154-28	31145-31162	reward-predicting	_	
154-29	31163-31170	stimuli	_	
154-30	31171-31173	in	_	
154-31	31174-31177	the	_	
154-32	31178-31185	ventral	_	
154-33	31186-31194	pallidum	_	
154-34	31195-31198	and	_	
154-35	31199-31201	in	_	
154-36	31202-31205	the	_	
154-37	31206-31214	midbrain	_	
154-38	31214-31215	/	_	
154-39	31215-31226	hippocampus	_	
154-40	31226-31227	,	_	
154-41	31228-31233	while	_	
154-42	31234-31238	they	_	
154-43	31239-31242	did	_	
154-44	31243-31246	not	_	
154-45	31247-31254	observe	_	
154-46	31255-31258	any	_	
154-47	31259-31270	significant	_	
154-48	31271-31278	effects	_	
154-49	31279-31282	for	_	
154-50	31283-31290	novelty	_	
154-51	31291-31293	or	_	
154-52	31294-31303	emotional	_	
154-53	31304-31312	salience	_	
154-54	31312-31313	.	_	

#Text=In the present study, using a specific “pure stimulus novelty” salience task, we observed a significant difference in hippocampal responsivity between HC and CHR individuals.
155-1	31314-31316	In	_	
155-2	31317-31320	the	_	
155-3	31321-31328	present	_	
155-4	31329-31334	study	_	
155-5	31334-31335	,	_	
155-6	31336-31341	using	_	
155-7	31342-31343	a	_	
155-8	31344-31352	specific	_	
155-9	31353-31354	“	_	
155-10	31354-31358	pure	_	
155-11	31359-31367	stimulus	_	
155-12	31368-31375	novelty	_	
155-13	31375-31376	”	_	
155-14	31377-31385	salience	_	
155-15	31386-31390	task	_	
155-16	31390-31391	,	_	
155-17	31392-31394	we	_	
155-18	31395-31403	observed	_	
155-19	31404-31405	a	_	
155-20	31406-31417	significant	_	
155-21	31418-31428	difference	_	
155-22	31429-31431	in	_	
155-23	31432-31443	hippocampal	_	
155-24	31444-31456	responsivity	_	
155-25	31457-31464	between	_	
155-26	31465-31467	HC	_	
155-27	31468-31471	and	_	
155-28	31472-31475	CHR	_	
155-29	31476-31487	individuals	_	
155-30	31487-31488	.	_	

#Text=Finally, Roiser et al had shown an abnormal association between hippocampal response to motivational salience and dopamine synthesis capacity in a smaller sample of CHR individuals.
156-1	31489-31496	Finally	_	
156-2	31496-31497	,	_	
156-3	31498-31504	Roiser	_	
156-4	31505-31507	et	_	
156-5	31508-31510	al	_	
156-6	31511-31514	had	_	
156-7	31515-31520	shown	_	
156-8	31521-31523	an	_	
156-9	31524-31532	abnormal	_	
156-10	31533-31544	association	_	
156-11	31545-31552	between	_	
156-12	31553-31564	hippocampal	_	
156-13	31565-31573	response	_	
156-14	31574-31576	to	_	
156-15	31577-31589	motivational	_	
156-16	31590-31598	salience	_	
156-17	31599-31602	and	_	
156-18	31603-31611	dopamine	_	
156-19	31612-31621	synthesis	_	
156-20	31622-31630	capacity	_	
156-21	31631-31633	in	_	
156-22	31634-31635	a	_	
156-23	31636-31643	smaller	_	
156-24	31644-31650	sample	_	
156-25	31651-31653	of	_	
156-26	31654-31657	CHR	_	
156-27	31658-31669	individuals	_	
156-28	31669-31670	.	_	

#Text=Given that the hippocampus is central to the processing of novelty salience, it would be interesting to determine whether the hippocampal alteration we detected during novelty processing is also abnormally associated with dopamine synthesis capacity in CHR individuals.
157-1	31671-31676	Given	_	
157-2	31677-31681	that	_	
157-3	31682-31685	the	_	
157-4	31686-31697	hippocampus	_	
157-5	31698-31700	is	_	
157-6	31701-31708	central	_	
157-7	31709-31711	to	_	
157-8	31712-31715	the	_	
157-9	31716-31726	processing	_	
157-10	31727-31729	of	_	
157-11	31730-31737	novelty	_	
157-12	31738-31746	salience	_	
157-13	31746-31747	,	_	
157-14	31748-31750	it	_	
157-15	31751-31756	would	_	
157-16	31757-31759	be	_	
157-17	31760-31771	interesting	_	
157-18	31772-31774	to	_	
157-19	31775-31784	determine	_	
157-20	31785-31792	whether	_	
157-21	31793-31796	the	_	
157-22	31797-31808	hippocampal	_	
157-23	31809-31819	alteration	_	
157-24	31820-31822	we	_	
157-25	31823-31831	detected	_	
157-26	31832-31838	during	_	
157-27	31839-31846	novelty	_	
157-28	31847-31857	processing	_	
157-29	31858-31860	is	_	
157-30	31861-31865	also	_	
157-31	31866-31876	abnormally	_	
157-32	31877-31887	associated	_	
157-33	31888-31892	with	_	
157-34	31893-31901	dopamine	_	
157-35	31902-31911	synthesis	_	
157-36	31912-31920	capacity	_	
157-37	31921-31923	in	_	
157-38	31924-31927	CHR	_	
157-39	31928-31939	individuals	_	
157-40	31939-31940	.	_	

#Text=In summary, the data from the present study indicate both perturbed hippocampal activation and hippocampal-striatal-midbrain effective connectivity in the context of novelty salience in people at CHR for psychosis, and that the later onset of psychosis is associated with alterations in midbrain-striatal connectivity.
158-1	31941-31943	In	_	
158-2	31944-31951	summary	_	
158-3	31951-31952	,	_	
158-4	31953-31956	the	_	
158-5	31957-31961	data	_	
158-6	31962-31966	from	_	
158-7	31967-31970	the	_	
158-8	31971-31978	present	_	
158-9	31979-31984	study	_	
158-10	31985-31993	indicate	_	
158-11	31994-31998	both	_	
158-12	31999-32008	perturbed	_	
158-13	32009-32020	hippocampal	_	
158-14	32021-32031	activation	_	
158-15	32032-32035	and	_	
158-16	32036-32065	hippocampal-striatal-midbrain	_	
158-17	32066-32075	effective	_	
158-18	32076-32088	connectivity	_	
158-19	32089-32091	in	_	
158-20	32092-32095	the	_	
158-21	32096-32103	context	_	
158-22	32104-32106	of	_	
158-23	32107-32114	novelty	_	
158-24	32115-32123	salience	_	
158-25	32124-32126	in	_	
158-26	32127-32133	people	_	
158-27	32134-32136	at	_	
158-28	32137-32140	CHR	_	
158-29	32141-32144	for	_	
158-30	32145-32154	psychosis	_	
158-31	32154-32155	,	_	
158-32	32156-32159	and	_	
158-33	32160-32164	that	_	
158-34	32165-32168	the	_	
158-35	32169-32174	later	_	
158-36	32175-32180	onset	_	
158-37	32181-32183	of	_	
158-38	32184-32193	psychosis	_	
158-39	32194-32196	is	_	
158-40	32197-32207	associated	_	
158-41	32208-32212	with	_	
158-42	32213-32224	alterations	_	
158-43	32225-32227	in	_	
158-44	32228-32245	midbrain-striatal	_	
158-45	32246-32258	connectivity	_	
158-46	32258-32259	.	_	

#Text=These findings are consistent with data from preclinical models of psychosis implicating alterations in a hippocampal–striatal-midbrain circuit in the development of psychosis.
159-1	32260-32265	These	_	
159-2	32266-32274	findings	_	
159-3	32275-32278	are	_	
159-4	32279-32289	consistent	_	
159-5	32290-32294	with	_	
159-6	32295-32299	data	_	
159-7	32300-32304	from	_	
159-8	32305-32316	preclinical	_	
159-9	32317-32323	models	_	
159-10	32324-32326	of	_	
159-11	32327-32336	psychosis	_	
159-12	32337-32348	implicating	_	
159-13	32349-32360	alterations	_	
159-14	32361-32363	in	_	
159-15	32364-32365	a	_	
159-16	32366-32395	hippocampal–striatal-midbrain	_	
159-17	32396-32403	circuit	_	
159-18	32404-32406	in	_	
159-19	32407-32410	the	_	
159-20	32411-32422	development	_	
159-21	32423-32425	of	_	
159-22	32426-32435	psychosis	_	
159-23	32435-32436	.	_	

#Text=Supplementary Material
#Text=Supplementary material is available at Schizophrenia Bulletin online.
160-1	32437-32450	Supplementary	_	
160-2	32451-32459	Material	_	
160-3	32460-32473	Supplementary	_	
160-4	32474-32482	material	_	
160-5	32483-32485	is	_	
160-6	32486-32495	available	_	
160-7	32496-32498	at	_	
160-8	32499-32512	Schizophrenia	_	
160-9	32513-32521	Bulletin	_	
160-10	32522-32528	online	_	
160-11	32528-32529	.	_	

#Text=Matilda Azis: 0000-0001-8164-0357
#Text=Conflicts of Interest Statement
#Text=A.A.G. receives consulting fees from Johnson & Johnson, Lundbeck, Pfizer, GSK, Merck, Takeda, Dainippon Sumitomo, Otsuka, Lilly, Roche, Asubio, and Abbott; and receives research funding from Lundbeck, Lilly, Autifony, Alkermes and Johnson & Johnson.
161-1	32530-32537	Matilda	_	
161-2	32538-32542	Azis	_	
161-3	32542-32543	:	_	
161-4	32544-32548	0000	_	
161-5	32548-32549	-	_	
161-6	32549-32553	0001	_	
161-7	32553-32554	-	_	
161-8	32554-32558	8164	_	
161-9	32558-32559	-	_	
161-10	32559-32563	0357	_	
161-11	32564-32573	Conflicts	_	
161-12	32574-32576	of	_	
161-13	32577-32585	Interest	_	
161-14	32586-32595	Statement	_	
161-15	32596-32601	A.A.G	_	
161-16	32601-32602	.	_	
161-17	32603-32611	receives	_	
161-18	32612-32622	consulting	_	
161-19	32623-32627	fees	_	
161-20	32628-32632	from	_	
161-21	32633-32640	Johnson	_	
161-22	32641-32642	&	_	
161-23	32643-32650	Johnson	_	
161-24	32650-32651	,	_	
161-25	32652-32660	Lundbeck	_	
161-26	32660-32661	,	_	
161-27	32662-32668	Pfizer	_	
161-28	32668-32669	,	_	
161-29	32670-32673	GSK	_	
161-30	32673-32674	,	_	
161-31	32675-32680	Merck	_	
161-32	32680-32681	,	_	
161-33	32682-32688	Takeda	_	
161-34	32688-32689	,	_	
161-35	32690-32699	Dainippon	_	
161-36	32700-32708	Sumitomo	_	
161-37	32708-32709	,	_	
161-38	32710-32716	Otsuka	_	
161-39	32716-32717	,	_	
161-40	32718-32723	Lilly	_	
161-41	32723-32724	,	_	
161-42	32725-32730	Roche	_	
161-43	32730-32731	,	_	
161-44	32732-32738	Asubio	_	
161-45	32738-32739	,	_	
161-46	32740-32743	and	_	
161-47	32744-32750	Abbott	_	
161-48	32750-32751	;	_	
161-49	32752-32755	and	_	
161-50	32756-32764	receives	_	
161-51	32765-32773	research	_	
161-52	32774-32781	funding	_	
161-53	32782-32786	from	_	
161-54	32787-32795	Lundbeck	_	
161-55	32795-32796	,	_	
161-56	32797-32802	Lilly	_	
161-57	32802-32803	,	_	
161-58	32804-32812	Autifony	_	
161-59	32812-32813	,	_	
161-60	32814-32822	Alkermes	_	
161-61	32823-32826	and	_	
161-62	32827-32834	Johnson	_	
161-63	32835-32836	&	_	
161-64	32837-32844	Johnson	_	
161-65	32844-32845	.	_	

#Text=O.D.H. has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche.
162-1	32846-32851	O.D.H	_	
162-2	32851-32852	.	_	
162-3	32853-32856	has	_	
162-4	32857-32865	received	_	
162-5	32866-32888	investigator-initiated	_	
162-6	32889-32897	research	_	
162-7	32898-32905	funding	_	
162-8	32906-32910	from	_	
162-9	32911-32914	and	_	
162-10	32914-32915	/	_	
162-11	32915-32917	or	_	
162-12	32918-32930	participated	_	
162-13	32931-32933	in	_	
162-14	32934-32942	advisory	_	
162-15	32942-32943	/	_	
162-16	32943-32950	speaker	_	
162-17	32951-32959	meetings	_	
162-18	32960-32969	organized	_	
162-19	32970-32972	by	_	
162-20	32973-32985	Astra-Zeneca	_	
162-21	32985-32986	,	_	
162-22	32987-32995	Autifony	_	
162-23	32995-32996	,	_	
162-24	32997-33000	BMS	_	
162-25	33000-33001	,	_	
162-26	33002-33005	Eli	_	
162-27	33006-33011	Lilly	_	
162-28	33011-33012	,	_	
162-29	33013-33021	Heptares	_	
162-30	33021-33022	,	_	
162-31	33023-33030	Jansenn	_	
162-32	33030-33031	,	_	
162-33	33032-33040	Lundbeck	_	
162-34	33040-33041	,	_	
162-35	33042-33053	Lyden-Delta	_	
162-36	33053-33054	,	_	
162-37	33055-33061	Otsuka	_	
162-38	33061-33062	,	_	
162-39	33063-33070	Servier	_	
162-40	33070-33071	,	_	
162-41	33072-33080	Sunovion	_	
162-42	33080-33081	,	_	
162-43	33082-33086	Rand	_	
162-44	33087-33090	and	_	
162-45	33091-33096	Roche	_	
162-46	33096-33097	.	_	

#Text=Neither O.D.H. or his family have been employed by or have holdings/a financial stake in any biomedical company.
163-1	33098-33105	Neither	_	
163-2	33106-33111	O.D.H	_	
163-3	33111-33112	.	_	
163-4	33113-33115	or	_	
163-5	33116-33119	his	_	
163-6	33120-33126	family	_	
163-7	33127-33131	have	_	
163-8	33132-33136	been	_	
163-9	33137-33145	employed	_	
163-10	33146-33148	by	_	
163-11	33149-33151	or	_	
163-12	33152-33156	have	_	
163-13	33157-33165	holdings	_	
163-14	33165-33166	/	_	
163-15	33166-33167	a	_	
163-16	33168-33177	financial	_	
163-17	33178-33183	stake	_	
163-18	33184-33186	in	_	
163-19	33187-33190	any	_	
163-20	33191-33201	biomedical	_	
163-21	33202-33209	company	_	
163-22	33209-33210	.	_	

#Text=The other authors declare no competing financial interests.
164-1	33211-33214	The	_	
164-2	33215-33220	other	_	
164-3	33221-33228	authors	_	
164-4	33229-33236	declare	_	
164-5	33237-33239	no	_	
164-6	33240-33249	competing	_	
164-7	33250-33259	financial	_	
164-8	33260-33269	interests	_	
164-9	33269-33270	.	_	

#Text=Dopaminergic dysfunction in alcoholism and schizophrenia–psychopathological and behavioral correlates
#Text=Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia
#Text=Animal models of schizophrenia
#Text=Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
#Text=Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
#Text=Dysfunction of ventral striatal reward prediction in schizophrenia
#Text=Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions
#Text=Altered activation and connectivity in a hippocampal-basal ganglia-midbrain circuit during salience processing in subjects at ultra high risk for psychosis
#Text=Aberrant effective connectivity in schizophrenia patients during appetitive conditioning
#Text=Do patients with schizophrenia exhibit aberrant salience?
165-1	33271-33283	Dopaminergic	_	
165-2	33284-33295	dysfunction	_	
165-3	33296-33298	in	_	
165-4	33299-33309	alcoholism	_	
165-5	33310-33313	and	_	
165-6	33314-33346	schizophrenia–psychopathological	_	
165-7	33347-33350	and	_	
165-8	33351-33361	behavioral	_	
165-9	33362-33372	correlates	_	
165-10	33373-33382	Psychosis	_	
165-11	33383-33385	as	_	
165-12	33386-33387	a	_	
165-13	33388-33393	state	_	
165-14	33394-33396	of	_	
165-15	33397-33405	aberrant	_	
165-16	33406-33414	salience	_	
165-17	33414-33415	:	_	
165-18	33416-33417	a	_	
165-19	33418-33427	framework	_	
165-20	33428-33435	linking	_	
165-21	33436-33443	biology	_	
165-22	33443-33444	,	_	
165-23	33445-33458	phenomenology	_	
165-24	33458-33459	,	_	
165-25	33460-33463	and	_	
165-26	33464-33476	pharmacology	_	
165-27	33477-33479	in	_	
165-28	33480-33493	schizophrenia	_	
165-29	33494-33500	Animal	_	
165-30	33501-33507	models	_	
165-31	33508-33510	of	_	
165-32	33511-33524	schizophrenia	_	
165-33	33525-33536	Hippocampal	_	
165-34	33537-33550	dysregulation	_	
165-35	33551-33553	of	_	
165-36	33554-33562	dopamine	_	
165-37	33563-33569	system	_	
165-38	33570-33578	function	_	
165-39	33579-33582	and	_	
165-40	33583-33586	the	_	
165-41	33587-33602	pathophysiology	_	
165-42	33603-33605	of	_	
165-43	33606-33619	schizophrenia	_	
165-44	33620-33633	Circuit-based	_	
165-45	33634-33643	framework	_	
165-46	33644-33647	for	_	
165-47	33648-33661	understanding	_	
165-48	33662-33678	neurotransmitter	_	
165-49	33679-33682	and	_	
165-50	33683-33687	risk	_	
165-51	33688-33692	gene	_	
165-52	33693-33705	interactions	_	
165-53	33706-33708	in	_	
165-54	33709-33722	schizophrenia	_	
165-55	33723-33734	Dysfunction	_	
165-56	33735-33737	of	_	
165-57	33738-33745	ventral	_	
165-58	33746-33754	striatal	_	
165-59	33755-33761	reward	_	
165-60	33762-33772	prediction	_	
165-61	33773-33775	in	_	
165-62	33776-33789	schizophrenia	_	
165-63	33790-33796	Reward	_	
165-64	33797-33805	feedback	_	
165-65	33806-33817	alterations	_	
165-66	33818-33820	in	_	
165-67	33821-33832	unmedicated	_	
165-68	33833-33846	schizophrenia	_	
165-69	33847-33855	patients	_	
165-70	33855-33856	:	_	
165-71	33857-33866	relevance	_	
165-72	33867-33870	for	_	
165-73	33871-33880	delusions	_	
165-74	33881-33888	Altered	_	
165-75	33889-33899	activation	_	
165-76	33900-33903	and	_	
165-77	33904-33916	connectivity	_	
165-78	33917-33919	in	_	
165-79	33920-33921	a	_	
165-80	33922-33939	hippocampal-basal	_	
165-81	33940-33956	ganglia-midbrain	_	
165-82	33957-33964	circuit	_	
165-83	33965-33971	during	_	
165-84	33972-33980	salience	_	
165-85	33981-33991	processing	_	
165-86	33992-33994	in	_	
165-87	33995-34003	subjects	_	
165-88	34004-34006	at	_	
165-89	34007-34012	ultra	_	
165-90	34013-34017	high	_	
165-91	34018-34022	risk	_	
165-92	34023-34026	for	_	
165-93	34027-34036	psychosis	_	
165-94	34037-34045	Aberrant	_	
165-95	34046-34055	effective	_	
165-96	34056-34068	connectivity	_	
165-97	34069-34071	in	_	
165-98	34072-34085	schizophrenia	_	
165-99	34086-34094	patients	_	
165-100	34095-34101	during	_	
165-101	34102-34112	appetitive	_	
165-102	34113-34125	conditioning	_	
165-103	34126-34128	Do	_	
165-104	34129-34137	patients	_	
165-105	34138-34142	with	_	
165-106	34143-34156	schizophrenia	_	
165-107	34157-34164	exhibit	_	
165-108	34165-34173	aberrant	_	
165-109	34174-34182	salience	_	
165-110	34182-34183	?	_	

#Text=Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis
#Text=Dopaminergic basis of salience dysregulation in psychosis
#Text=The short-latency dopamine signal: a role in discovering novel actions?
166-1	34184-34190	Neural	_	
166-2	34191-34194	and	_	
166-3	34195-34205	behavioral	_	
166-4	34206-34216	correlates	_	
166-5	34217-34219	of	_	
166-6	34220-34228	aberrant	_	
166-7	34229-34237	salience	_	
166-8	34238-34240	in	_	
166-9	34241-34252	individuals	_	
166-10	34253-34255	at	_	
166-11	34256-34260	risk	_	
166-12	34261-34264	for	_	
166-13	34265-34274	psychosis	_	
166-14	34275-34287	Dopaminergic	_	
166-15	34288-34293	basis	_	
166-16	34294-34296	of	_	
166-17	34297-34305	salience	_	
166-18	34306-34319	dysregulation	_	
166-19	34320-34322	in	_	
166-20	34323-34332	psychosis	_	
166-21	34333-34336	The	_	
166-22	34337-34350	short-latency	_	
166-23	34351-34359	dopamine	_	
166-24	34360-34366	signal	_	
166-25	34366-34367	:	_	
166-26	34368-34369	a	_	
166-27	34370-34374	role	_	
166-28	34375-34377	in	_	
166-29	34378-34389	discovering	_	
166-30	34390-34395	novel	_	
166-31	34396-34403	actions	_	
166-32	34403-34404	?	_	

#Text=Dopamine signals for reward value and risk: basic and recent data
#Text=Absolute coding of stimulus novelty in the human substantia nigra/VTA
#Text=Dynamic causal modelling
#Text=Outreach and support in South London (OASIS), 2001–2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis
#Text=Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States
#Text=
#Text=The assessment of anxiety states by rating
#Text=
#Text=Measurement of handedness via self-report: the relationship between brief and extended inventories
#Text=Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates
#Text=Cluster failure revisited: impact of first level design and physiological noise on cluster false positive rates
#Text=Adaptive and aberrant reward prediction signals in the human brain
#Text=Resting hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in people at high risk for psychosis
#Text=Increased resting Hippocampal and Basal Ganglia perfusion in people at ultra high risk for psychosis: replication in a second cohort
#Text=Ten simple rules for dynamic causal modeling
#Text=Bayesian model reduction and empirical Bayes for group (DCM) studies
#Text=Bayes factors
#Text=On p-values and Bayes factors
#Text=Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification
#Text=Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders
#Text=Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver
#Text=Searching for a baseline: functional imaging and the resting human brain
#Text=Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia
#Text=Translating the MAM model of psychosis to humans
#Text=Increased hippocampal CA1 cerebral blood volume in schizophrenia
#Text=Increased hippocampal blood volume and normal blood flow in schizophrenia
#Text=Increased resting perfusion of the hippocampus in high positive schizotypy: a pseudocontinuous arterial spin labeling study
#Text=Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort
#Text=Elevated striatal dopamine function linked to prodromal signs of schizophrenia
#Text=Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis
#Text=Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume
#Text=Association of Hippocampal Glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis
#Text=Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis
#Text=Resting neural activity distinguishes subgroups of schizophrenia patients
#Text=Neural correlates of aberrant emotional salience predict psychotic symptoms and global functioning in high-risk and first-episode psychosis
#Text=Sustained activation of the hippocampus in response to fearful faces in schizophrenia
#Text=Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia
#Text=Overactivation of fear systems to neutral faces in schizophrenia
#Text=Increased neural response related to neutral faces in individuals at risk for psychosis
#Text=Anticipation of novelty recruits reward system and hippocampus while promoting recollection
#Text=(A) Task paradigm.
167-1	34405-34413	Dopamine	_	
167-2	34414-34421	signals	_	
167-3	34422-34425	for	_	
167-4	34426-34432	reward	_	
167-5	34433-34438	value	_	
167-6	34439-34442	and	_	
167-7	34443-34447	risk	_	
167-8	34447-34448	:	_	
167-9	34449-34454	basic	_	
167-10	34455-34458	and	_	
167-11	34459-34465	recent	_	
167-12	34466-34470	data	_	
167-13	34471-34479	Absolute	_	
167-14	34480-34486	coding	_	
167-15	34487-34489	of	_	
167-16	34490-34498	stimulus	_	
167-17	34499-34506	novelty	_	
167-18	34507-34509	in	_	
167-19	34510-34513	the	_	
167-20	34514-34519	human	_	
167-21	34520-34530	substantia	_	
167-22	34531-34536	nigra	_	
167-23	34536-34537	/	_	
167-24	34537-34540	VTA	_	
167-25	34541-34548	Dynamic	_	
167-26	34549-34555	causal	_	
167-27	34556-34565	modelling	_	
167-28	34566-34574	Outreach	_	
167-29	34575-34578	and	_	
167-30	34579-34586	support	_	
167-31	34587-34589	in	_	
167-32	34590-34595	South	_	
167-33	34596-34602	London	_	
167-34	34603-34604	(	_	
167-35	34604-34609	OASIS	_	
167-36	34609-34610	)	_	
167-37	34610-34611	,	_	
167-38	34612-34616	2001	_	
167-39	34616-34617	–	_	
167-40	34617-34621	2011	_	
167-41	34621-34622	:	_	
167-42	34623-34626	ten	_	
167-43	34627-34632	years	_	
167-44	34633-34635	of	_	
167-45	34636-34641	early	_	
167-46	34642-34651	diagnosis	_	
167-47	34652-34655	and	_	
167-48	34656-34665	treatment	_	
167-49	34666-34669	for	_	
167-50	34670-34675	young	_	
167-51	34676-34687	individuals	_	
167-52	34688-34690	at	_	
167-53	34691-34695	high	_	
167-54	34696-34704	clinical	_	
167-55	34705-34709	risk	_	
167-56	34710-34713	for	_	
167-57	34714-34723	psychosis	_	
167-58	34724-34731	Mapping	_	
167-59	34732-34735	the	_	
167-60	34736-34741	onset	_	
167-61	34742-34744	of	_	
167-62	34745-34754	psychosis	_	
167-63	34754-34755	:	_	
167-64	34756-34759	the	_	
167-65	34760-34773	Comprehensive	_	
167-66	34774-34784	Assessment	_	
167-67	34785-34787	of	_	
167-68	34788-34795	At-Risk	_	
167-69	34796-34802	Mental	_	
167-70	34803-34809	States	_	
167-71	34811-34814	The	_	
167-72	34815-34825	assessment	_	
167-73	34826-34828	of	_	
167-74	34829-34836	anxiety	_	
167-75	34837-34843	states	_	
167-76	34844-34846	by	_	
167-77	34847-34853	rating	_	
167-78	34855-34866	Measurement	_	
167-79	34867-34869	of	_	
167-80	34870-34880	handedness	_	
167-81	34881-34884	via	_	
167-82	34885-34896	self-report	_	
167-83	34896-34897	:	_	
167-84	34898-34901	the	_	
167-85	34902-34914	relationship	_	
167-86	34915-34922	between	_	
167-87	34923-34928	brief	_	
167-88	34929-34932	and	_	
167-89	34933-34941	extended	_	
167-90	34942-34953	inventories	_	
167-91	34954-34961	Cluster	_	
167-92	34962-34969	failure	_	
167-93	34969-34970	:	_	
167-94	34971-34974	why	_	
167-95	34975-34979	fMRI	_	
167-96	34980-34990	inferences	_	
167-97	34991-34994	for	_	
167-98	34995-35002	spatial	_	
167-99	35003-35009	extent	_	
167-100	35010-35014	have	_	
167-101	35015-35023	inflated	_	
167-102	35024-35038	false-positive	_	
167-103	35039-35044	rates	_	
167-104	35045-35052	Cluster	_	
167-105	35053-35060	failure	_	
167-106	35061-35070	revisited	_	
167-107	35070-35071	:	_	
167-108	35072-35078	impact	_	
167-109	35079-35081	of	_	
167-110	35082-35087	first	_	
167-111	35088-35093	level	_	
167-112	35094-35100	design	_	
167-113	35101-35104	and	_	
167-114	35105-35118	physiological	_	
167-115	35119-35124	noise	_	
167-116	35125-35127	on	_	
167-117	35128-35135	cluster	_	
167-118	35136-35141	false	_	
167-119	35142-35150	positive	_	
167-120	35151-35156	rates	_	
167-121	35157-35165	Adaptive	_	
167-122	35166-35169	and	_	
167-123	35170-35178	aberrant	_	
167-124	35179-35185	reward	_	
167-125	35186-35196	prediction	_	
167-126	35197-35204	signals	_	
167-127	35205-35207	in	_	
167-128	35208-35211	the	_	
167-129	35212-35217	human	_	
167-130	35218-35223	brain	_	
167-131	35224-35231	Resting	_	
167-132	35232-35246	hyperperfusion	_	
167-133	35247-35249	of	_	
167-134	35250-35253	the	_	
167-135	35254-35265	Hippocampus	_	
167-136	35265-35266	,	_	
167-137	35267-35275	Midbrain	_	
167-138	35275-35276	,	_	
167-139	35277-35280	and	_	
167-140	35281-35286	Basal	_	
167-141	35287-35294	Ganglia	_	
167-142	35295-35297	in	_	
167-143	35298-35304	people	_	
167-144	35305-35307	at	_	
167-145	35308-35312	high	_	
167-146	35313-35317	risk	_	
167-147	35318-35321	for	_	
167-148	35322-35331	psychosis	_	
167-149	35332-35341	Increased	_	
167-150	35342-35349	resting	_	
167-151	35350-35361	Hippocampal	_	
167-152	35362-35365	and	_	
167-153	35366-35371	Basal	_	
167-154	35372-35379	Ganglia	_	
167-155	35380-35389	perfusion	_	
167-156	35390-35392	in	_	
167-157	35393-35399	people	_	
167-158	35400-35402	at	_	
167-159	35403-35408	ultra	_	
167-160	35409-35413	high	_	
167-161	35414-35418	risk	_	
167-162	35419-35422	for	_	
167-163	35423-35432	psychosis	_	
167-164	35432-35433	:	_	
167-165	35434-35445	replication	_	
167-166	35446-35448	in	_	
167-167	35449-35450	a	_	
167-168	35451-35457	second	_	
167-169	35458-35464	cohort	_	
167-170	35465-35468	Ten	_	
167-171	35469-35475	simple	_	
167-172	35476-35481	rules	_	
167-173	35482-35485	for	_	
167-174	35486-35493	dynamic	_	
167-175	35494-35500	causal	_	
167-176	35501-35509	modeling	_	
167-177	35510-35518	Bayesian	_	
167-178	35519-35524	model	_	
167-179	35525-35534	reduction	_	
167-180	35535-35538	and	_	
167-181	35539-35548	empirical	_	
167-182	35549-35554	Bayes	_	
167-183	35555-35558	for	_	
167-184	35559-35564	group	_	
167-185	35565-35566	(	_	
167-186	35566-35569	DCM	_	
167-187	35569-35570	)	_	
167-188	35571-35578	studies	_	
167-189	35579-35584	Bayes	_	
167-190	35585-35592	factors	_	
167-191	35593-35595	On	_	
167-192	35596-35604	p-values	_	
167-193	35605-35608	and	_	
167-194	35609-35614	Bayes	_	
167-195	35615-35622	factors	_	
167-196	35623-35636	Heterogeneity	_	
167-197	35637-35639	of	_	
167-198	35640-35649	psychosis	_	
167-199	35650-35654	risk	_	
167-200	35655-35661	within	_	
167-201	35662-35673	individuals	_	
167-202	35674-35676	at	_	
167-203	35677-35685	clinical	_	
167-204	35686-35690	high	_	
167-205	35691-35695	risk	_	
167-206	35695-35696	:	_	
167-207	35697-35698	a	_	
167-208	35699-35714	meta-analytical	_	
167-209	35715-35729	stratification	_	
167-210	35730-35742	Differential	_	
167-211	35743-35752	targeting	_	
167-212	35753-35755	of	_	
167-213	35756-35759	the	_	
167-214	35760-35763	CA1	_	
167-215	35764-35772	subfield	_	
167-216	35773-35775	of	_	
167-217	35776-35779	the	_	
167-218	35780-35791	hippocampal	_	
167-219	35792-35801	formation	_	
167-220	35802-35804	by	_	
167-221	35805-35818	schizophrenia	_	
167-222	35819-35822	and	_	
167-223	35823-35830	related	_	
167-224	35831-35840	psychotic	_	
167-225	35841-35850	disorders	_	
167-226	35851-35858	Imaging	_	
167-227	35859-35867	patients	_	
167-228	35868-35872	with	_	
167-229	35873-35882	psychosis	_	
167-230	35883-35886	and	_	
167-231	35887-35888	a	_	
167-232	35889-35894	mouse	_	
167-233	35895-35900	model	_	
167-234	35901-35912	establishes	_	
167-235	35913-35914	a	_	
167-236	35915-35924	spreading	_	
167-237	35925-35932	pattern	_	
167-238	35933-35935	of	_	
167-239	35936-35947	hippocampal	_	
167-240	35948-35959	dysfunction	_	
167-241	35960-35963	and	_	
167-242	35964-35974	implicates	_	
167-243	35975-35984	glutamate	_	
167-244	35985-35987	as	_	
167-245	35988-35989	a	_	
167-246	35990-35996	driver	_	
167-247	35997-36006	Searching	_	
167-248	36007-36010	for	_	
167-249	36011-36012	a	_	
167-250	36013-36021	baseline	_	
167-251	36021-36022	:	_	
167-252	36023-36033	functional	_	
167-253	36034-36041	imaging	_	
167-254	36042-36045	and	_	
167-255	36046-36049	the	_	
167-256	36050-36057	resting	_	
167-257	36058-36063	human	_	
167-258	36064-36069	brain	_	
167-259	36070-36078	Dopamine	_	
167-260	36079-36085	system	_	
167-261	36086-36099	dysregulation	_	
167-262	36100-36102	by	_	
167-263	36103-36106	the	_	
167-264	36107-36118	hippocampus	_	
167-265	36118-36119	:	_	
167-266	36120-36132	implications	_	
167-267	36133-36136	for	_	
167-268	36137-36140	the	_	
167-269	36141-36156	pathophysiology	_	
167-270	36157-36160	and	_	
167-271	36161-36170	treatment	_	
167-272	36171-36173	of	_	
167-273	36174-36187	schizophrenia	_	
167-274	36188-36199	Translating	_	
167-275	36200-36203	the	_	
167-276	36204-36207	MAM	_	
167-277	36208-36213	model	_	
167-278	36214-36216	of	_	
167-279	36217-36226	psychosis	_	
167-280	36227-36229	to	_	
167-281	36230-36236	humans	_	
167-282	36237-36246	Increased	_	
167-283	36247-36258	hippocampal	_	
167-284	36259-36262	CA1	_	
167-285	36263-36271	cerebral	_	
167-286	36272-36277	blood	_	
167-287	36278-36284	volume	_	
167-288	36285-36287	in	_	
167-289	36288-36301	schizophrenia	_	
167-290	36302-36311	Increased	_	
167-291	36312-36323	hippocampal	_	
167-292	36324-36329	blood	_	
167-293	36330-36336	volume	_	
167-294	36337-36340	and	_	
167-295	36341-36347	normal	_	
167-296	36348-36353	blood	_	
167-297	36354-36358	flow	_	
167-298	36359-36361	in	_	
167-299	36362-36375	schizophrenia	_	
167-300	36376-36385	Increased	_	
167-301	36386-36393	resting	_	
167-302	36394-36403	perfusion	_	
167-303	36404-36406	of	_	
167-304	36407-36410	the	_	
167-305	36411-36422	hippocampus	_	
167-306	36423-36425	in	_	
167-307	36426-36430	high	_	
167-308	36431-36439	positive	_	
167-309	36440-36450	schizotypy	_	
167-310	36450-36451	:	_	
167-311	36452-36453	a	_	
167-312	36454-36470	pseudocontinuous	_	
167-313	36471-36479	arterial	_	
167-314	36480-36484	spin	_	
167-315	36485-36493	labeling	_	
167-316	36494-36499	study	_	
167-317	36500-36511	Presynaptic	_	
167-318	36512-36520	striatal	_	
167-319	36521-36529	dopamine	_	
167-320	36530-36541	dysfunction	_	
167-321	36542-36544	in	_	
167-322	36545-36551	people	_	
167-323	36552-36554	at	_	
167-324	36555-36565	ultra-high	_	
167-325	36566-36570	risk	_	
167-326	36571-36574	for	_	
167-327	36575-36584	psychosis	_	
167-328	36584-36585	:	_	
167-329	36586-36594	findings	_	
167-330	36595-36597	in	_	
167-331	36598-36599	a	_	
167-332	36600-36606	second	_	
167-333	36607-36613	cohort	_	
167-334	36614-36622	Elevated	_	
167-335	36623-36631	striatal	_	
167-336	36632-36640	dopamine	_	
167-337	36641-36649	function	_	
167-338	36650-36656	linked	_	
167-339	36657-36659	to	_	
167-340	36660-36669	prodromal	_	
167-341	36670-36675	signs	_	
167-342	36676-36678	of	_	
167-343	36679-36692	schizophrenia	_	
167-344	36693-36701	Abnormal	_	
167-345	36702-36714	relationship	_	
167-346	36715-36722	between	_	
167-347	36723-36729	medial	_	
167-348	36730-36738	temporal	_	
167-349	36739-36743	lobe	_	
167-350	36744-36747	and	_	
167-351	36748-36759	subcortical	_	
167-352	36760-36768	dopamine	_	
167-353	36769-36777	function	_	
167-354	36778-36780	in	_	
167-355	36781-36787	people	_	
167-356	36788-36792	with	_	
167-357	36793-36795	an	_	
167-358	36796-36801	ultra	_	
167-359	36802-36806	high	_	
167-360	36807-36811	risk	_	
167-361	36812-36815	for	_	
167-362	36816-36825	psychosis	_	
167-363	36826-36835	Glutamate	_	
167-364	36836-36847	dysfunction	_	
167-365	36848-36850	in	_	
167-366	36851-36857	people	_	
167-367	36858-36862	with	_	
167-368	36863-36872	prodromal	_	
167-369	36873-36881	symptoms	_	
167-370	36882-36884	of	_	
167-371	36885-36894	psychosis	_	
167-372	36894-36895	:	_	
167-373	36896-36908	relationship	_	
167-374	36909-36911	to	_	
167-375	36912-36916	gray	_	
167-376	36917-36923	matter	_	
167-377	36924-36930	volume	_	
167-378	36931-36942	Association	_	
167-379	36943-36945	of	_	
167-380	36946-36957	Hippocampal	_	
167-381	36958-36967	Glutamate	_	
167-382	36968-36974	levels	_	
167-383	36975-36979	with	_	
167-384	36980-36987	adverse	_	
167-385	36988-36996	outcomes	_	
167-386	36997-36999	in	_	
167-387	37000-37011	individuals	_	
167-388	37012-37014	at	_	
167-389	37015-37023	clinical	_	
167-390	37024-37028	high	_	
167-391	37029-37033	risk	_	
167-392	37034-37037	for	_	
167-393	37038-37047	psychosis	_	
167-394	37048-37055	Altered	_	
167-395	37056-37062	medial	_	
167-396	37063-37071	temporal	_	
167-397	37072-37082	activation	_	
167-398	37083-37090	related	_	
167-399	37091-37093	to	_	
167-400	37094-37099	local	_	
167-401	37100-37109	glutamate	_	
167-402	37110-37116	levels	_	
167-403	37117-37119	in	_	
167-404	37120-37128	subjects	_	
167-405	37129-37133	with	_	
167-406	37134-37143	prodromal	_	
167-407	37144-37149	signs	_	
167-408	37150-37152	of	_	
167-409	37153-37162	psychosis	_	
167-410	37163-37170	Resting	_	
167-411	37171-37177	neural	_	
167-412	37178-37186	activity	_	
167-413	37187-37200	distinguishes	_	
167-414	37201-37210	subgroups	_	
167-415	37211-37213	of	_	
167-416	37214-37227	schizophrenia	_	
167-417	37228-37236	patients	_	
167-418	37237-37243	Neural	_	
167-419	37244-37254	correlates	_	
167-420	37255-37257	of	_	
167-421	37258-37266	aberrant	_	
167-422	37267-37276	emotional	_	
167-423	37277-37285	salience	_	
167-424	37286-37293	predict	_	
167-425	37294-37303	psychotic	_	
167-426	37304-37312	symptoms	_	
167-427	37313-37316	and	_	
167-428	37317-37323	global	_	
167-429	37324-37335	functioning	_	
167-430	37336-37338	in	_	
167-431	37339-37348	high-risk	_	
167-432	37349-37352	and	_	
167-433	37353-37366	first-episode	_	
167-434	37367-37376	psychosis	_	
167-435	37377-37386	Sustained	_	
167-436	37387-37397	activation	_	
167-437	37398-37400	of	_	
167-438	37401-37404	the	_	
167-439	37405-37416	hippocampus	_	
167-440	37417-37419	in	_	
167-441	37420-37428	response	_	
167-442	37429-37431	to	_	
167-443	37432-37439	fearful	_	
167-444	37440-37445	faces	_	
167-445	37446-37448	in	_	
167-446	37449-37462	schizophrenia	_	
167-447	37463-37472	Increased	_	
167-448	37473-37479	medial	_	
167-449	37480-37488	temporal	_	
167-450	37489-37493	lobe	_	
167-451	37494-37504	activation	_	
167-452	37505-37511	during	_	
167-453	37512-37515	the	_	
167-454	37516-37523	passive	_	
167-455	37524-37531	viewing	_	
167-456	37532-37534	of	_	
167-457	37535-37544	emotional	_	
167-458	37545-37548	and	_	
167-459	37549-37556	neutral	_	
167-460	37557-37563	facial	_	
167-461	37564-37575	expressions	_	
167-462	37576-37578	in	_	
167-463	37579-37592	schizophrenia	_	
167-464	37593-37607	Overactivation	_	
167-465	37608-37610	of	_	
167-466	37611-37615	fear	_	
167-467	37616-37623	systems	_	
167-468	37624-37626	to	_	
167-469	37627-37634	neutral	_	
167-470	37635-37640	faces	_	
167-471	37641-37643	in	_	
167-472	37644-37657	schizophrenia	_	
167-473	37658-37667	Increased	_	
167-474	37668-37674	neural	_	
167-475	37675-37683	response	_	
167-476	37684-37691	related	_	
167-477	37692-37694	to	_	
167-478	37695-37702	neutral	_	
167-479	37703-37708	faces	_	
167-480	37709-37711	in	_	
167-481	37712-37723	individuals	_	
167-482	37724-37726	at	_	
167-483	37727-37731	risk	_	
167-484	37732-37735	for	_	
167-485	37736-37745	psychosis	_	
167-486	37746-37758	Anticipation	_	
167-487	37759-37761	of	_	
167-488	37762-37769	novelty	_	
167-489	37770-37778	recruits	_	
167-490	37779-37785	reward	_	
167-491	37786-37792	system	_	
167-492	37793-37796	and	_	
167-493	37797-37808	hippocampus	_	
167-494	37809-37814	while	_	
167-495	37815-37824	promoting	_	
167-496	37825-37837	recollection	_	
167-497	37838-37839	(	_	
167-498	37839-37840	A	_	
167-499	37840-37841	)	_	
167-500	37842-37846	Task	_	
167-501	37847-37855	paradigm	_	
167-502	37855-37856	.	_	

#Text=(B) Region-of-interest mask used for small volume correction on the fMRI analysis, including the hippocampus, striatum, and midbrain.
168-1	37857-37858	(	_	
168-2	37858-37859	B	_	
168-3	37859-37860	)	_	
168-4	37861-37879	Region-of-interest	_	
168-5	37880-37884	mask	_	
168-6	37885-37889	used	_	
168-7	37890-37893	for	_	
168-8	37894-37899	small	_	
168-9	37900-37906	volume	_	
168-10	37907-37917	correction	_	
168-11	37918-37920	on	_	
168-12	37921-37924	the	_	
168-13	37925-37929	fMRI	_	
168-14	37930-37938	analysis	_	
168-15	37938-37939	,	_	
168-16	37940-37949	including	_	
168-17	37950-37953	the	_	
168-18	37954-37965	hippocampus	_	
168-19	37965-37966	,	_	
168-20	37967-37975	striatum	_	
168-21	37975-37976	,	_	
168-22	37977-37980	and	_	
168-23	37981-37989	midbrain	_	
168-24	37989-37990	.	_	

#Text=L = left hemisphere; R = right hemisphere.
169-1	37991-37992	L	_	
169-2	37993-37994	=	_	
169-3	37995-37999	left	_	
169-4	38000-38010	hemisphere	_	
169-5	38010-38011	;	_	
169-6	38012-38013	R	_	
169-7	38014-38015	=	_	
169-8	38016-38021	right	_	
169-9	38022-38032	hemisphere	_	
169-10	38032-38033	.	_	

#Text=(A) Novel > Neutral oddball trials across groups and (B) Between-group clinical high-risk (CHR) vs healthy control (HC) results in right hippocampus for the contrasts of novel > neutral oddballs with activation superimposed on a standard T1 template.
170-1	38034-38035	(	_	
170-2	38035-38036	A	_	
170-3	38036-38037	)	_	
170-4	38038-38043	Novel	_	
170-5	38044-38045	>	_	
170-6	38046-38053	Neutral	_	
170-7	38054-38061	oddball	_	
170-8	38062-38068	trials	_	
170-9	38069-38075	across	_	
170-10	38076-38082	groups	_	
170-11	38083-38086	and	_	
170-12	38087-38088	(	_	
170-13	38088-38089	B	_	
170-14	38089-38090	)	_	
170-15	38091-38104	Between-group	_	
170-16	38105-38113	clinical	_	
170-17	38114-38123	high-risk	_	
170-18	38124-38125	(	_	
170-19	38125-38128	CHR	_	
170-20	38128-38129	)	_	
170-21	38130-38132	vs	_	
170-22	38133-38140	healthy	_	
170-23	38141-38148	control	_	
170-24	38149-38150	(	_	
170-25	38150-38152	HC	_	
170-26	38152-38153	)	_	
170-27	38154-38161	results	_	
170-28	38162-38164	in	_	
170-29	38165-38170	right	_	
170-30	38171-38182	hippocampus	_	
170-31	38183-38186	for	_	
170-32	38187-38190	the	_	
170-33	38191-38200	contrasts	_	
170-34	38201-38203	of	_	
170-35	38204-38209	novel	_	
170-36	38210-38211	>	_	
170-37	38212-38219	neutral	_	
170-38	38220-38228	oddballs	_	
170-39	38229-38233	with	_	
170-40	38234-38244	activation	_	
170-41	38245-38257	superimposed	_	
170-42	38258-38260	on	_	
170-43	38261-38262	a	_	
170-44	38263-38271	standard	_	
170-45	38272-38274	T1	_	
170-46	38275-38283	template	_	
170-47	38283-38284	.	_	

#Text=(C) Boxplots show mean hippocampal activation in each group for novel > neutral (pure stimulus novelty) and neutral > standard (stimulus rareness/deviance).
171-1	38285-38286	(	_	
171-2	38286-38287	C	_	
171-3	38287-38288	)	_	
171-4	38289-38297	Boxplots	_	
171-5	38298-38302	show	_	
171-6	38303-38307	mean	_	
171-7	38308-38319	hippocampal	_	
171-8	38320-38330	activation	_	
171-9	38331-38333	in	_	
171-10	38334-38338	each	_	
171-11	38339-38344	group	_	
171-12	38345-38348	for	_	
171-13	38349-38354	novel	_	
171-14	38355-38356	>	_	
171-15	38357-38364	neutral	_	
171-16	38365-38366	(	_	
171-17	38366-38370	pure	_	
171-18	38371-38379	stimulus	_	
171-19	38380-38387	novelty	_	
171-20	38387-38388	)	_	
171-21	38389-38392	and	_	
171-22	38393-38400	neutral	_	
171-23	38401-38402	>	_	
171-24	38403-38411	standard	_	
171-25	38412-38413	(	_	
171-26	38413-38421	stimulus	_	
171-27	38422-38430	rareness	_	
171-28	38430-38431	/	_	
171-29	38431-38439	deviance	_	
171-30	38439-38440	)	_	
171-31	38440-38441	.	_	

#Text=L = left hemisphere; R = right hemisphere.
172-1	38442-38443	L	_	
172-2	38444-38445	=	_	
172-3	38446-38450	left	_	
172-4	38451-38461	hemisphere	_	
172-5	38461-38462	;	_	
172-6	38463-38464	R	_	
172-7	38465-38466	=	_	
172-8	38467-38472	right	_	
172-9	38473-38483	hemisphere	_	
172-10	38483-38484	.	_	

#Text=(A) DCM model.
173-1	38485-38486	(	_	
173-2	38486-38487	A	_	
173-3	38487-38488	)	_	
173-4	38489-38492	DCM	_	
173-5	38493-38498	model	_	
173-6	38498-38499	.	_	

#Text=(B) Group effects on PEB models between HC and CHR.
174-1	38500-38501	(	_	
174-2	38501-38502	B	_	
174-3	38502-38503	)	_	
174-4	38504-38509	Group	_	
174-5	38510-38517	effects	_	
174-6	38518-38520	on	_	
174-7	38521-38524	PEB	_	
174-8	38525-38531	models	_	
174-9	38532-38539	between	_	
174-10	38540-38542	HC	_	
174-11	38543-38546	and	_	
174-12	38547-38550	CHR	_	
174-13	38550-38551	.	_	

#Text=(C) Group effects on PEB models between CHR-NT and CHR-T.
175-1	38552-38553	(	_	
175-2	38553-38554	C	_	
175-3	38554-38555	)	_	
175-4	38556-38561	Group	_	
175-5	38562-38569	effects	_	
175-6	38570-38572	on	_	
175-7	38573-38576	PEB	_	
175-8	38577-38583	models	_	
175-9	38584-38591	between	_	
175-10	38592-38598	CHR-NT	_	
175-11	38599-38602	and	_	
175-12	38603-38608	CHR-T	_	
175-13	38608-38609	.	_	

#Text=Gray bars show posterior probabilities for model evidence.
176-1	38610-38614	Gray	_	
176-2	38615-38619	bars	_	
176-3	38620-38624	show	_	
176-4	38625-38634	posterior	_	
176-5	38635-38648	probabilities	_	
176-6	38649-38652	for	_	
176-7	38653-38658	model	_	
176-8	38659-38667	evidence	_	
176-9	38667-38668	.	_	

#Text=Bars represent the Bayesian 95% confidence interval.
177-1	38669-38673	Bars	_	
177-2	38674-38683	represent	_	
177-3	38684-38687	the	_	
177-4	38688-38696	Bayesian	_	
177-5	38697-38700	95%	_	
177-6	38701-38711	confidence	_	
177-7	38712-38720	interval	_	
177-8	38720-38721	.	_	

#Text=Demographic and Questionnaire Data
#Text=Measure\tHC (n = 31)\tCHR (n = 76)\tg or V\tP\tCHR-NT (n = 63)\tCHR-T (n = 13)\tg or V\tP\t \tAge (y)\t  25.0 (4.1)\t22.46 (3.6)\t0.677\t  .003\t  22.7 (3.8)\t  21.9 (2.6)\t0.220\t.488\t \tGender (male/female)\t  15/16\t  42/34\t0.063\t  .518\t  36/27\t     6/7\t0.083\t.468\t \tNART IQ\t104.9 (13.7)\t103.5 (14.6)\t0.097\t  .669\t103.6 (15.6)\t103.1 (8.2)\t0.034\t.878\t \tYears of education\t  15.8 (3.5)\t  14.6 (2.2)\t0.455\t  .071\t  14.6 (2.2)\t  14.5 (2.5)\t0.044\t.907\t \tCAARMS\t \t    Positive score\t        -\t  10.1 (4.1)\t-\t\t    9.7 (3.9)\t  11.8 (4.7)\t0.520\t.102\t \t    Negative score\t        -\t    5.1 (4.1)\t-\t\t    5.1 (4.1)\t    4.8 (4.3)\t0.073\t.785\t \t    Total score\t        -\t  42.3 (22.4)\t-\t\t  42.1 (21.9)\t  43.2 (25.5)\t0.050\t.873\t \tGAF score\t  92.9 (5.0)\t  58.0 (9.5)\t4.124\t<.001\t  58.5 (9.7)\t  55.3 (8.5)\t0.336\t.272\t \tHAM-A score\t    3.4 (4.2)\t  18.4 (11.2)\t1.542\t<.001\t  17.5 (10.4)\t  22.8 (14.2)\t0.477\t.173\t \tHAM-D score\t    1.7 (3.5)\t  17.6 (11.1)\t1.662\t<.001\t  17.0 (11.1)\t  20.3 (11.2)\t0.297\t.396\t \tTobacco (cigarettes/d)\t    1.9 (3.4)\t    6.3 (9.0)\t0.563\t  .001\t    7.2 (9.6)\t    2.1 (3.6)\t0.573\t.074\t \tAlcohol (units/d)\t    1.7 (2.2)\t    1.6 (3.4)\t0.032\t  .964\t    1.8 (3.6)\t    0.9 (0.7)\t0.272\t.426\t \tCannabis (median [range])a\t0 [0–3]\t0 [0–4]\t0.146\t  .703\t0 [0–4]\t0 [0–4]\t0.147\t.811\t \tAntipsychotic medication (n)\t        -\t       9 (12%)\t-\t  -\t       8 (13%)\t       1 (8%)\t0.058\t.611\t \tAntidepressant medication (n)\t       1 (3.2%)\t     28 (37%)\t0.343\t<.001\t     25 (40%)\t       3 (23%)\t0.130\t.258\t \tRight-handed (n)\t     26 (90%)\t     64 (85%)\t0.187\t  .162\t     52 (83%)\t     12 (92%)\t0.090\t.434\t \t
#Text=Note: CAARMS, Comprehensive Assessment for the At-Risk Mental State; CHR, clinical high-risk; CHR-NT, clinical high-risk non-transition; CHR-T, clinical high-risk transition; GAF, Global Assessment of Functioning scale; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; HC, healthy controls; NART, National Adult Reading Test. g or V, Hedges’ g or Cramer’s V.
178-1	38722-38733	Demographic	_	
178-2	38734-38737	and	_	
178-3	38738-38751	Questionnaire	_	
178-4	38752-38756	Data	_	
178-5	38757-38764	Measure	_	
178-6	38765-38767	HC	_	
178-7	38768-38769	(	_	
178-8	38769-38770	n	_	
178-9	38771-38772	=	_	
178-10	38773-38775	31	_	
178-11	38775-38776	)	_	
178-12	38777-38780	CHR	_	
178-13	38781-38782	(	_	
178-14	38782-38783	n	_	
178-15	38784-38785	=	_	
178-16	38786-38788	76	_	
178-17	38788-38789	)	_	
178-18	38790-38791	g	_	
178-19	38792-38794	or	_	
178-20	38795-38796	V	_	
178-21	38797-38798	P	_	
178-22	38799-38805	CHR-NT	_	
178-23	38806-38807	(	_	
178-24	38807-38808	n	_	
178-25	38809-38810	=	_	
178-26	38811-38813	63	_	
178-27	38813-38814	)	_	
178-28	38815-38820	CHR-T	_	
178-29	38821-38822	(	_	
178-30	38822-38823	n	_	
178-31	38824-38825	=	_	
178-32	38826-38828	13	_	
178-33	38828-38829	)	_	
178-34	38830-38831	g	_	
178-35	38832-38834	or	_	
178-36	38835-38836	V	_	
178-37	38837-38838	P	_	
178-38	38841-38844	Age	_	
178-39	38845-38846	(	_	
178-40	38846-38847	y	_	
178-41	38847-38848	)	_	
178-42	38849-38851	  	_	
178-43	38851-38855	25.0	_	
178-44	38856-38857	(	_	
178-45	38857-38860	4.1	_	
178-46	38860-38861	)	_	
178-47	38862-38867	22.46	_	
178-48	38868-38869	(	_	
178-49	38869-38872	3.6	_	
178-50	38872-38873	)	_	
178-51	38874-38879	0.677	_	
178-52	38880-38882	  	_	
178-53	38882-38886	.003	_	
178-54	38887-38889	  	_	
178-55	38889-38893	22.7	_	
178-56	38894-38895	(	_	
178-57	38895-38898	3.8	_	
178-58	38898-38899	)	_	
178-59	38900-38902	  	_	
178-60	38902-38906	21.9	_	
178-61	38907-38908	(	_	
178-62	38908-38911	2.6	_	
178-63	38911-38912	)	_	
178-64	38913-38918	0.220	_	
178-65	38919-38923	.488	_	
178-66	38926-38932	Gender	_	
178-67	38933-38934	(	_	
178-68	38934-38938	male	_	
178-69	38938-38939	/	_	
178-70	38939-38945	female	_	
178-71	38945-38946	)	_	
178-72	38947-38949	  	_	
178-73	38949-38951	15	_	
178-74	38951-38952	/	_	
178-75	38952-38954	16	_	
178-76	38955-38957	  	_	
178-77	38957-38959	42	_	
178-78	38959-38960	/	_	
178-79	38960-38962	34	_	
178-80	38963-38968	0.063	_	
178-81	38969-38971	  	_	
178-82	38971-38975	.518	_	
178-83	38976-38978	  	_	
178-84	38978-38980	36	_	
178-85	38980-38981	/	_	
178-86	38981-38983	27	_	
178-87	38984-38989	     	_	
178-88	38989-38990	6	_	
178-89	38990-38991	/	_	
178-90	38991-38992	7	_	
178-91	38993-38998	0.083	_	
178-92	38999-39003	.468	_	
178-93	39006-39010	NART	_	
178-94	39011-39013	IQ	_	
178-95	39014-39019	104.9	_	
178-96	39020-39021	(	_	
178-97	39021-39025	13.7	_	
178-98	39025-39026	)	_	
178-99	39027-39032	103.5	_	
178-100	39033-39034	(	_	
178-101	39034-39038	14.6	_	
178-102	39038-39039	)	_	
178-103	39040-39045	0.097	_	
178-104	39046-39048	  	_	
178-105	39048-39052	.669	_	
178-106	39053-39058	103.6	_	
178-107	39059-39060	(	_	
178-108	39060-39064	15.6	_	
178-109	39064-39065	)	_	
178-110	39066-39071	103.1	_	
178-111	39072-39073	(	_	
178-112	39073-39076	8.2	_	
178-113	39076-39077	)	_	
178-114	39078-39083	0.034	_	
178-115	39084-39088	.878	_	
178-116	39091-39096	Years	_	
178-117	39097-39099	of	_	
178-118	39100-39109	education	_	
178-119	39110-39112	  	_	
178-120	39112-39116	15.8	_	
178-121	39117-39118	(	_	
178-122	39118-39121	3.5	_	
178-123	39121-39122	)	_	
178-124	39123-39125	  	_	
178-125	39125-39129	14.6	_	
178-126	39130-39131	(	_	
178-127	39131-39134	2.2	_	
178-128	39134-39135	)	_	
178-129	39136-39141	0.455	_	
178-130	39142-39144	  	_	
178-131	39144-39148	.071	_	
178-132	39149-39151	  	_	
178-133	39151-39155	14.6	_	
178-134	39156-39157	(	_	
178-135	39157-39160	2.2	_	
178-136	39160-39161	)	_	
178-137	39162-39164	  	_	
178-138	39164-39168	14.5	_	
178-139	39169-39170	(	_	
178-140	39170-39173	2.5	_	
178-141	39173-39174	)	_	
178-142	39175-39180	0.044	_	
178-143	39181-39185	.907	_	
178-144	39188-39194	CAARMS	_	
178-145	39197-39201	    	_	
178-146	39201-39209	Positive	_	
178-147	39210-39215	score	_	
178-148	39216-39224	        	_	
178-149	39224-39225	-	_	
178-150	39226-39228	  	_	
178-151	39228-39232	10.1	_	
178-152	39233-39234	(	_	
178-153	39234-39237	4.1	_	
178-154	39237-39238	)	_	
178-155	39239-39240	-	_	
178-156	39242-39246	    	_	
178-157	39246-39249	9.7	_	
178-158	39250-39251	(	_	
178-159	39251-39254	3.9	_	
178-160	39254-39255	)	_	
178-161	39256-39258	  	_	
178-162	39258-39262	11.8	_	
178-163	39263-39264	(	_	
178-164	39264-39267	4.7	_	
178-165	39267-39268	)	_	
178-166	39269-39274	0.520	_	
178-167	39275-39279	.102	_	
178-168	39282-39286	    	_	
178-169	39286-39294	Negative	_	
178-170	39295-39300	score	_	
178-171	39301-39309	        	_	
178-172	39309-39310	-	_	
178-173	39311-39315	    	_	
178-174	39315-39318	5.1	_	
178-175	39319-39320	(	_	
178-176	39320-39323	4.1	_	
178-177	39323-39324	)	_	
178-178	39325-39326	-	_	
178-179	39328-39332	    	_	
178-180	39332-39335	5.1	_	
178-181	39336-39337	(	_	
178-182	39337-39340	4.1	_	
178-183	39340-39341	)	_	
178-184	39342-39346	    	_	
178-185	39346-39349	4.8	_	
178-186	39350-39351	(	_	
178-187	39351-39354	4.3	_	
178-188	39354-39355	)	_	
178-189	39356-39361	0.073	_	
178-190	39362-39366	.785	_	
178-191	39369-39373	    	_	
178-192	39373-39378	Total	_	
178-193	39379-39384	score	_	
178-194	39385-39393	        	_	
178-195	39393-39394	-	_	
178-196	39395-39397	  	_	
178-197	39397-39401	42.3	_	
178-198	39402-39403	(	_	
178-199	39403-39407	22.4	_	
178-200	39407-39408	)	_	
178-201	39409-39410	-	_	
178-202	39412-39414	  	_	
178-203	39414-39418	42.1	_	
178-204	39419-39420	(	_	
178-205	39420-39424	21.9	_	
178-206	39424-39425	)	_	
178-207	39426-39428	  	_	
178-208	39428-39432	43.2	_	
178-209	39433-39434	(	_	
178-210	39434-39438	25.5	_	
178-211	39438-39439	)	_	
178-212	39440-39445	0.050	_	
178-213	39446-39450	.873	_	
178-214	39453-39456	GAF	_	
178-215	39457-39462	score	_	
178-216	39463-39465	  	_	
178-217	39465-39469	92.9	_	
178-218	39470-39471	(	_	
178-219	39471-39474	5.0	_	
178-220	39474-39475	)	_	
178-221	39476-39478	  	_	
178-222	39478-39482	58.0	_	
178-223	39483-39484	(	_	
178-224	39484-39487	9.5	_	
178-225	39487-39488	)	_	
178-226	39489-39494	4.124	_	
178-227	39495-39496	<	_	
178-228	39496-39500	.001	_	
178-229	39501-39503	  	_	
178-230	39503-39507	58.5	_	
178-231	39508-39509	(	_	
178-232	39509-39512	9.7	_	
178-233	39512-39513	)	_	
178-234	39514-39516	  	_	
178-235	39516-39520	55.3	_	
178-236	39521-39522	(	_	
178-237	39522-39525	8.5	_	
178-238	39525-39526	)	_	
178-239	39527-39532	0.336	_	
178-240	39533-39537	.272	_	
178-241	39540-39545	HAM-A	_	
178-242	39546-39551	score	_	
178-243	39552-39556	    	_	
178-244	39556-39559	3.4	_	
178-245	39560-39561	(	_	
178-246	39561-39564	4.2	_	
178-247	39564-39565	)	_	
178-248	39566-39568	  	_	
178-249	39568-39572	18.4	_	
178-250	39573-39574	(	_	
178-251	39574-39578	11.2	_	
178-252	39578-39579	)	_	
178-253	39580-39585	1.542	_	
178-254	39586-39587	<	_	
178-255	39587-39591	.001	_	
178-256	39592-39594	  	_	
178-257	39594-39598	17.5	_	
178-258	39599-39600	(	_	
178-259	39600-39604	10.4	_	
178-260	39604-39605	)	_	
178-261	39606-39608	  	_	
178-262	39608-39612	22.8	_	
178-263	39613-39614	(	_	
178-264	39614-39618	14.2	_	
178-265	39618-39619	)	_	
178-266	39620-39625	0.477	_	
178-267	39626-39630	.173	_	
178-268	39633-39638	HAM-D	_	
178-269	39639-39644	score	_	
178-270	39645-39649	    	_	
178-271	39649-39652	1.7	_	
178-272	39653-39654	(	_	
178-273	39654-39657	3.5	_	
178-274	39657-39658	)	_	
178-275	39659-39661	  	_	
178-276	39661-39665	17.6	_	
178-277	39666-39667	(	_	
178-278	39667-39671	11.1	_	
178-279	39671-39672	)	_	
178-280	39673-39678	1.662	_	
178-281	39679-39680	<	_	
178-282	39680-39684	.001	_	
178-283	39685-39687	  	_	
178-284	39687-39691	17.0	_	
178-285	39692-39693	(	_	
178-286	39693-39697	11.1	_	
178-287	39697-39698	)	_	
178-288	39699-39701	  	_	
178-289	39701-39705	20.3	_	
178-290	39706-39707	(	_	
178-291	39707-39711	11.2	_	
178-292	39711-39712	)	_	
178-293	39713-39718	0.297	_	
178-294	39719-39723	.396	_	
178-295	39726-39733	Tobacco	_	
178-296	39734-39735	(	_	
178-297	39735-39745	cigarettes	_	
178-298	39745-39746	/	_	
178-299	39746-39747	d	_	
178-300	39747-39748	)	_	
178-301	39749-39753	    	_	
178-302	39753-39756	1.9	_	
178-303	39757-39758	(	_	
178-304	39758-39761	3.4	_	
178-305	39761-39762	)	_	
178-306	39763-39767	    	_	
178-307	39767-39770	6.3	_	
178-308	39771-39772	(	_	
178-309	39772-39775	9.0	_	
178-310	39775-39776	)	_	
178-311	39777-39782	0.563	_	
178-312	39783-39785	  	_	
178-313	39785-39789	.001	_	
178-314	39790-39794	    	_	
178-315	39794-39797	7.2	_	
178-316	39798-39799	(	_	
178-317	39799-39802	9.6	_	
178-318	39802-39803	)	_	
178-319	39804-39808	    	_	
178-320	39808-39811	2.1	_	
178-321	39812-39813	(	_	
178-322	39813-39816	3.6	_	
178-323	39816-39817	)	_	
178-324	39818-39823	0.573	_	
178-325	39824-39828	.074	_	
178-326	39831-39838	Alcohol	_	
178-327	39839-39840	(	_	
178-328	39840-39845	units	_	
178-329	39845-39846	/	_	
178-330	39846-39847	d	_	
178-331	39847-39848	)	_	
178-332	39849-39853	    	_	
178-333	39853-39856	1.7	_	
178-334	39857-39858	(	_	
178-335	39858-39861	2.2	_	
178-336	39861-39862	)	_	
178-337	39863-39867	    	_	
178-338	39867-39870	1.6	_	
178-339	39871-39872	(	_	
178-340	39872-39875	3.4	_	
178-341	39875-39876	)	_	
178-342	39877-39882	0.032	_	
178-343	39883-39885	  	_	
178-344	39885-39889	.964	_	
178-345	39890-39894	    	_	
178-346	39894-39897	1.8	_	
178-347	39898-39899	(	_	
178-348	39899-39902	3.6	_	
178-349	39902-39903	)	_	
178-350	39904-39908	    	_	
178-351	39908-39911	0.9	_	
178-352	39912-39913	(	_	
178-353	39913-39916	0.7	_	
178-354	39916-39917	)	_	
178-355	39918-39923	0.272	_	
178-356	39924-39928	.426	_	
178-357	39931-39939	Cannabis	_	
178-358	39940-39941	(	_	
178-359	39941-39947	median	_	
178-360	39948-39949	[	_	
178-361	39949-39954	range	_	
178-362	39954-39955	]	_	
178-363	39955-39956	)	_	
178-364	39956-39957	a	_	
178-365	39958-39959	0	_	
178-366	39960-39961	[	_	
178-367	39961-39962	0	_	
178-368	39962-39963	–	_	
178-369	39963-39964	3	_	
178-370	39964-39965	]	_	
178-371	39966-39967	0	_	
178-372	39968-39969	[	_	
178-373	39969-39970	0	_	
178-374	39970-39971	–	_	
178-375	39971-39972	4	_	
178-376	39972-39973	]	_	
178-377	39974-39979	0.146	_	
178-378	39980-39982	  	_	
178-379	39982-39986	.703	_	
178-380	39987-39988	0	_	
178-381	39989-39990	[	_	
178-382	39990-39991	0	_	
178-383	39991-39992	–	_	
178-384	39992-39993	4	_	
178-385	39993-39994	]	_	
178-386	39995-39996	0	_	
178-387	39997-39998	[	_	
178-388	39998-39999	0	_	
178-389	39999-40000	–	_	
178-390	40000-40001	4	_	
178-391	40001-40002	]	_	
178-392	40003-40008	0.147	_	
178-393	40009-40013	.811	_	
178-394	40016-40029	Antipsychotic	_	
178-395	40030-40040	medication	_	
178-396	40041-40042	(	_	
178-397	40042-40043	n	_	
178-398	40043-40044	)	_	
178-399	40045-40053	        	_	
178-400	40053-40054	-	_	
178-401	40055-40062	       	_	
178-402	40062-40063	9	_	
178-403	40064-40065	(	_	
178-404	40065-40068	12%	_	
178-405	40068-40069	)	_	
178-406	40070-40071	-	_	
178-407	40072-40074	  	_	
178-408	40074-40075	-	_	
178-409	40076-40083	       	_	
178-410	40083-40084	8	_	
178-411	40085-40086	(	_	
178-412	40086-40089	13%	_	
178-413	40089-40090	)	_	
178-414	40091-40098	       	_	
178-415	40098-40099	1	_	
178-416	40100-40101	(	_	
178-417	40101-40103	8%	_	
178-418	40103-40104	)	_	
178-419	40105-40110	0.058	_	
178-420	40111-40115	.611	_	
178-421	40118-40132	Antidepressant	_	
178-422	40133-40143	medication	_	
178-423	40144-40145	(	_	
178-424	40145-40146	n	_	
178-425	40146-40147	)	_	
178-426	40148-40155	       	_	
178-427	40155-40156	1	_	
178-428	40157-40158	(	_	
178-429	40158-40162	3.2%	_	
178-430	40162-40163	)	_	
178-431	40164-40169	     	_	
178-432	40169-40171	28	_	
178-433	40172-40173	(	_	
178-434	40173-40176	37%	_	
178-435	40176-40177	)	_	
178-436	40178-40183	0.343	_	
178-437	40184-40185	<	_	
178-438	40185-40189	.001	_	
178-439	40190-40195	     	_	
178-440	40195-40197	25	_	
178-441	40198-40199	(	_	
178-442	40199-40202	40%	_	
178-443	40202-40203	)	_	
178-444	40204-40211	       	_	
178-445	40211-40212	3	_	
178-446	40213-40214	(	_	
178-447	40214-40217	23%	_	
178-448	40217-40218	)	_	
178-449	40219-40224	0.130	_	
178-450	40225-40229	.258	_	
178-451	40232-40244	Right-handed	_	
178-452	40245-40246	(	_	
178-453	40246-40247	n	_	
178-454	40247-40248	)	_	
178-455	40249-40254	     	_	
178-456	40254-40256	26	_	
178-457	40257-40258	(	_	
178-458	40258-40261	90%	_	
178-459	40261-40262	)	_	
178-460	40263-40268	     	_	
178-461	40268-40270	64	_	
178-462	40271-40272	(	_	
178-463	40272-40275	85%	_	
178-464	40275-40276	)	_	
178-465	40277-40282	0.187	_	
178-466	40283-40285	  	_	
178-467	40285-40289	.162	_	
178-468	40290-40295	     	_	
178-469	40295-40297	52	_	
178-470	40298-40299	(	_	
178-471	40299-40302	83%	_	
178-472	40302-40303	)	_	
178-473	40304-40309	     	_	
178-474	40309-40311	12	_	
178-475	40312-40313	(	_	
178-476	40313-40316	92%	_	
178-477	40316-40317	)	_	
178-478	40318-40323	0.090	_	
178-479	40324-40328	.434	_	
178-480	40332-40336	Note	_	
178-481	40336-40337	:	_	
178-482	40338-40344	CAARMS	_	
178-483	40344-40345	,	_	
178-484	40346-40359	Comprehensive	_	
178-485	40360-40370	Assessment	_	
178-486	40371-40374	for	_	
178-487	40375-40378	the	_	
178-488	40379-40386	At-Risk	_	
178-489	40387-40393	Mental	_	
178-490	40394-40399	State	_	
178-491	40399-40400	;	_	
178-492	40401-40404	CHR	_	
178-493	40404-40405	,	_	
178-494	40406-40414	clinical	_	
178-495	40415-40424	high-risk	_	
178-496	40424-40425	;	_	
178-497	40426-40432	CHR-NT	_	
178-498	40432-40433	,	_	
178-499	40434-40442	clinical	_	
178-500	40443-40452	high-risk	_	
178-501	40453-40467	non-transition	_	
178-502	40467-40468	;	_	
178-503	40469-40474	CHR-T	_	
178-504	40474-40475	,	_	
178-505	40476-40484	clinical	_	
178-506	40485-40494	high-risk	_	
178-507	40495-40505	transition	_	
178-508	40505-40506	;	_	
178-509	40507-40510	GAF	_	
178-510	40510-40511	,	_	
178-511	40512-40518	Global	_	
178-512	40519-40529	Assessment	_	
178-513	40530-40532	of	_	
178-514	40533-40544	Functioning	_	
178-515	40545-40550	scale	_	
178-516	40550-40551	;	_	
178-517	40552-40557	HAM-A	_	
178-518	40557-40558	,	_	
178-519	40559-40567	Hamilton	_	
178-520	40568-40575	Anxiety	_	
178-521	40576-40582	Rating	_	
178-522	40583-40588	Scale	_	
178-523	40588-40589	;	_	
178-524	40590-40595	HAM-D	_	
178-525	40595-40596	,	_	
178-526	40597-40605	Hamilton	_	
178-527	40606-40616	Depression	_	
178-528	40617-40623	Rating	_	
178-529	40624-40629	Scale	_	
178-530	40629-40630	;	_	
178-531	40631-40633	HC	_	
178-532	40633-40634	,	_	
178-533	40635-40642	healthy	_	
178-534	40643-40651	controls	_	
178-535	40651-40652	;	_	
178-536	40653-40657	NART	_	
178-537	40657-40658	,	_	
178-538	40659-40667	National	_	
178-539	40668-40673	Adult	_	
178-540	40674-40681	Reading	_	
178-541	40682-40686	Test	_	
178-542	40686-40687	.	_	
178-543	40688-40689	g	_	
178-544	40690-40692	or	_	
178-545	40693-40694	V	_	
178-546	40694-40695	,	_	
178-547	40696-40702	Hedges	_	
178-548	40702-40703	’	_	
178-549	40704-40705	g	_	
178-550	40706-40708	or	_	
178-551	40709-40715	Cramer	_	
178-552	40715-40716	’	_	
178-553	40716-40717	s	_	
178-554	40718-40719	V	_	
178-555	40719-40720	.	_	

#Text=Statistically significant results (after correction as described in the Statistics section) are shown in bold text.
#Text=0 = never, 1 = experimental use, 2 = occasional use, 3 = moderate use, 4 = severe use.
179-1	40721-40734	Statistically	_	
179-2	40735-40746	significant	_	
179-3	40747-40754	results	_	
179-4	40755-40756	(	_	
179-5	40756-40761	after	_	
179-6	40762-40772	correction	_	
179-7	40773-40775	as	_	
179-8	40776-40785	described	_	
179-9	40786-40788	in	_	
179-10	40789-40792	the	_	
179-11	40793-40803	Statistics	_	
179-12	40804-40811	section	_	
179-13	40811-40812	)	_	
179-14	40813-40816	are	_	
179-15	40817-40822	shown	_	
179-16	40823-40825	in	_	
179-17	40826-40830	bold	_	
179-18	40831-40835	text	_	
179-19	40835-40836	.	_	
179-20	40837-40838	0	_	
179-21	40839-40840	=	_	
179-22	40841-40846	never	_	
179-23	40846-40847	,	_	
179-24	40848-40849	1	_	
179-25	40850-40851	=	_	
179-26	40852-40864	experimental	_	
179-27	40865-40868	use	_	
179-28	40868-40869	,	_	
179-29	40870-40871	2	_	
179-30	40872-40873	=	_	
179-31	40874-40884	occasional	_	
179-32	40885-40888	use	_	
179-33	40888-40889	,	_	
179-34	40890-40891	3	_	
179-35	40892-40893	=	_	
179-36	40894-40902	moderate	_	
179-37	40903-40906	use	_	
179-38	40906-40907	,	_	
179-39	40908-40909	4	_	
179-40	40910-40911	=	_	
179-41	40912-40918	severe	_	
179-42	40919-40922	use	_	
179-43	40922-40923	.	_	

#Text=Random Effects Analysis for Novel Oddballs vs Neutral Oddballs Across and Within Groups in the Hippocampal-Striatal-Midbrain Region-of-Interest
#Text=\tMNI Coordinates\t\t\t\t\t \tBrain area\tx\ty\tz\tk\tT\tZ\tVoxel-Wise PFWE\t \tAcross all participants (n = 107)\t \t    R anterior hippocampus\t  32\t−12\t−14\t568\t5.52\t5.16\t<0.001\t \t    L hippocampus\t−26\t−30\t  −6\t560\t4.77\t4.53\t  0.001\t \t    R midbrain\t  12\t−24\t−16\t50\t4.37\t4.18\t<0.001\t \t    R ventral putamen\t  28\t  20\t  −2\t963\t5.91\t5.47\t<0.001\t \t    R dorsal pallidum\t  18\t    4\t    6\t\t4.25\t4.07\t  0.008\t \t    R ventral caudate\t  14\t    8\t    6\t\t4.15\t3.98\t  0.012\t \t    L ventral putamen\t−26\t  14\t  −4\t540\t4.28\t4.10\t  0.008\t \tHC (n = 31)\t \t    R anterior hippocampus\t  32\t−14\t−14\t542\t4.89\t4.62\t<0.001\t \t    L hippocampus\t−22\t−34\t  −6\t552\t3.96\t3.82\t  0.011\t \t    R midbrain\t  14\t−18\t−14\t5\t3.22\t3.13\t  0.014\t \t    R ventral putamen\t  32\t    4\t  −8\t42\t3.77\t3.64\t  0.019\t \tCHR (n = 76)\t \t    R hippocampus\t  22\t−32\t  −2\t18\t3.63\t3.51\t  0.031\t \t    R midbrain\t  12\t−24\t−16\t24\t4.00\t3.85\t  0.002\t \t    R ventral putamen\t  28\t  20\t  −2\t247\t5.57\t5.20\t<0.001\t \t    L ventral putamen\t−26\t  14\t  −6\t19\t3.68\t3.56\t  0.024\t \tCHR-NT (n = 63)\t \t    R midbrain\t  12\t−24\t−16\t17\t3.59\t3.48\t  0.005\t \t    R ventral putamen\t  28\t  20\t  −2\t124\t5.43\t5.08\t<0.001\t \tCHR-T (n = 13)\t \tNo suprathreshold voxels\t \t
#Text=Note: L, left; R, right.
180-1	40924-40930	Random	_	
180-2	40931-40938	Effects	_	
180-3	40939-40947	Analysis	_	
180-4	40948-40951	for	_	
180-5	40952-40957	Novel	_	
180-6	40958-40966	Oddballs	_	
180-7	40967-40969	vs	_	
180-8	40970-40977	Neutral	_	
180-9	40978-40986	Oddballs	_	
180-10	40987-40993	Across	_	
180-11	40994-40997	and	_	
180-12	40998-41004	Within	_	
180-13	41005-41011	Groups	_	
180-14	41012-41014	in	_	
180-15	41015-41018	the	_	
180-16	41019-41048	Hippocampal-Striatal-Midbrain	_	
180-17	41049-41067	Region-of-Interest	_	
180-18	41069-41072	MNI	_	
180-19	41073-41084	Coordinates	_	
180-20	41091-41096	Brain	_	
180-21	41097-41101	area	_	
180-22	41102-41103	x	_	
180-23	41104-41105	y	_	
180-24	41106-41107	z	_	
180-25	41108-41109	k	_	
180-26	41110-41111	T	_	
180-27	41112-41113	Z	_	
180-28	41114-41124	Voxel-Wise	_	
180-29	41125-41129	PFWE	_	
180-30	41132-41138	Across	_	
180-31	41139-41142	all	_	
180-32	41143-41155	participants	_	
180-33	41156-41157	(	_	
180-34	41157-41158	n	_	
180-35	41159-41160	=	_	
180-36	41161-41164	107	_	
180-37	41164-41165	)	_	
180-38	41168-41172	    	_	
180-39	41172-41173	R	_	
180-40	41174-41182	anterior	_	
180-41	41183-41194	hippocampus	_	
180-42	41195-41197	  	_	
180-43	41197-41199	32	_	
180-44	41200-41201	−	_	
180-45	41201-41203	12	_	
180-46	41204-41205	−	_	
180-47	41205-41207	14	_	
180-48	41208-41211	568	_	
180-49	41212-41216	5.52	_	
180-50	41217-41221	5.16	_	
180-51	41222-41223	<	_	
180-52	41223-41228	0.001	_	
180-53	41231-41235	    	_	
180-54	41235-41236	L	_	
180-55	41237-41248	hippocampus	_	
180-56	41249-41250	−	_	
180-57	41250-41252	26	_	
180-58	41253-41254	−	_	
180-59	41254-41256	30	_	
180-60	41257-41259	  	_	
180-61	41259-41260	−	_	
180-62	41260-41261	6	_	
180-63	41262-41265	560	_	
180-64	41266-41270	4.77	_	
180-65	41271-41275	4.53	_	
180-66	41276-41278	  	_	
180-67	41278-41283	0.001	_	
180-68	41286-41290	    	_	
180-69	41290-41291	R	_	
180-70	41292-41300	midbrain	_	
180-71	41301-41303	  	_	
180-72	41303-41305	12	_	
180-73	41306-41307	−	_	
180-74	41307-41309	24	_	
180-75	41310-41311	−	_	
180-76	41311-41313	16	_	
180-77	41314-41316	50	_	
180-78	41317-41321	4.37	_	
180-79	41322-41326	4.18	_	
180-80	41327-41328	<	_	
180-81	41328-41333	0.001	_	
180-82	41336-41340	    	_	
180-83	41340-41341	R	_	
180-84	41342-41349	ventral	_	
180-85	41350-41357	putamen	_	
180-86	41358-41360	  	_	
180-87	41360-41362	28	_	
180-88	41363-41365	  	_	
180-89	41365-41367	20	_	
180-90	41368-41370	  	_	
180-91	41370-41371	−	_	
180-92	41371-41372	2	_	
180-93	41373-41376	963	_	
180-94	41377-41381	5.91	_	
180-95	41382-41386	5.47	_	
180-96	41387-41388	<	_	
180-97	41388-41393	0.001	_	
180-98	41396-41400	    	_	
180-99	41400-41401	R	_	
180-100	41402-41408	dorsal	_	
180-101	41409-41417	pallidum	_	
180-102	41418-41420	  	_	
180-103	41420-41422	18	_	
180-104	41423-41427	    	_	
180-105	41427-41428	4	_	
180-106	41429-41433	    	_	
180-107	41433-41434	6	_	
180-108	41436-41440	4.25	_	
180-109	41441-41445	4.07	_	
180-110	41446-41448	  	_	
180-111	41448-41453	0.008	_	
180-112	41456-41460	    	_	
180-113	41460-41461	R	_	
180-114	41462-41469	ventral	_	
180-115	41470-41477	caudate	_	
180-116	41478-41480	  	_	
180-117	41480-41482	14	_	
180-118	41483-41487	    	_	
180-119	41487-41488	8	_	
180-120	41489-41493	    	_	
180-121	41493-41494	6	_	
180-122	41496-41500	4.15	_	
180-123	41501-41505	3.98	_	
180-124	41506-41508	  	_	
180-125	41508-41513	0.012	_	
180-126	41516-41520	    	_	
180-127	41520-41521	L	_	
180-128	41522-41529	ventral	_	
180-129	41530-41537	putamen	_	
180-130	41538-41539	−	_	
180-131	41539-41541	26	_	
180-132	41542-41544	  	_	
180-133	41544-41546	14	_	
180-134	41547-41549	  	_	
180-135	41549-41550	−	_	
180-136	41550-41551	4	_	
180-137	41552-41555	540	_	
180-138	41556-41560	4.28	_	
180-139	41561-41565	4.10	_	
180-140	41566-41568	  	_	
180-141	41568-41573	0.008	_	
180-142	41576-41578	HC	_	
180-143	41579-41580	(	_	
180-144	41580-41581	n	_	
180-145	41582-41583	=	_	
180-146	41584-41586	31	_	
180-147	41586-41587	)	_	
180-148	41590-41594	    	_	
180-149	41594-41595	R	_	
180-150	41596-41604	anterior	_	
180-151	41605-41616	hippocampus	_	
180-152	41617-41619	  	_	
180-153	41619-41621	32	_	
180-154	41622-41623	−	_	
180-155	41623-41625	14	_	
180-156	41626-41627	−	_	
180-157	41627-41629	14	_	
180-158	41630-41633	542	_	
180-159	41634-41638	4.89	_	
180-160	41639-41643	4.62	_	
180-161	41644-41645	<	_	
180-162	41645-41650	0.001	_	
180-163	41653-41657	    	_	
180-164	41657-41658	L	_	
180-165	41659-41670	hippocampus	_	
180-166	41671-41672	−	_	
180-167	41672-41674	22	_	
180-168	41675-41676	−	_	
180-169	41676-41678	34	_	
180-170	41679-41681	  	_	
180-171	41681-41682	−	_	
180-172	41682-41683	6	_	
180-173	41684-41687	552	_	
180-174	41688-41692	3.96	_	
180-175	41693-41697	3.82	_	
180-176	41698-41700	  	_	
180-177	41700-41705	0.011	_	
180-178	41708-41712	    	_	
180-179	41712-41713	R	_	
180-180	41714-41722	midbrain	_	
180-181	41723-41725	  	_	
180-182	41725-41727	14	_	
180-183	41728-41729	−	_	
180-184	41729-41731	18	_	
180-185	41732-41733	−	_	
180-186	41733-41735	14	_	
180-187	41736-41737	5	_	
180-188	41738-41742	3.22	_	
180-189	41743-41747	3.13	_	
180-190	41748-41750	  	_	
180-191	41750-41755	0.014	_	
180-192	41758-41762	    	_	
180-193	41762-41763	R	_	
180-194	41764-41771	ventral	_	
180-195	41772-41779	putamen	_	
180-196	41780-41782	  	_	
180-197	41782-41784	32	_	
180-198	41785-41789	    	_	
180-199	41789-41790	4	_	
180-200	41791-41793	  	_	
180-201	41793-41794	−	_	
180-202	41794-41795	8	_	
180-203	41796-41798	42	_	
180-204	41799-41803	3.77	_	
180-205	41804-41808	3.64	_	
180-206	41809-41811	  	_	
180-207	41811-41816	0.019	_	
180-208	41819-41822	CHR	_	
180-209	41823-41824	(	_	
180-210	41824-41825	n	_	
180-211	41826-41827	=	_	
180-212	41828-41830	76	_	
180-213	41830-41831	)	_	
180-214	41834-41838	    	_	
180-215	41838-41839	R	_	
180-216	41840-41851	hippocampus	_	
180-217	41852-41854	  	_	
180-218	41854-41856	22	_	
180-219	41857-41858	−	_	
180-220	41858-41860	32	_	
180-221	41861-41863	  	_	
180-222	41863-41864	−	_	
180-223	41864-41865	2	_	
180-224	41866-41868	18	_	
180-225	41869-41873	3.63	_	
180-226	41874-41878	3.51	_	
180-227	41879-41881	  	_	
180-228	41881-41886	0.031	_	
180-229	41889-41893	    	_	
180-230	41893-41894	R	_	
180-231	41895-41903	midbrain	_	
180-232	41904-41906	  	_	
180-233	41906-41908	12	_	
180-234	41909-41910	−	_	
180-235	41910-41912	24	_	
180-236	41913-41914	−	_	
180-237	41914-41916	16	_	
180-238	41917-41919	24	_	
180-239	41920-41924	4.00	_	
180-240	41925-41929	3.85	_	
180-241	41930-41932	  	_	
180-242	41932-41937	0.002	_	
180-243	41940-41944	    	_	
180-244	41944-41945	R	_	
180-245	41946-41953	ventral	_	
180-246	41954-41961	putamen	_	
180-247	41962-41964	  	_	
180-248	41964-41966	28	_	
180-249	41967-41969	  	_	
180-250	41969-41971	20	_	
180-251	41972-41974	  	_	
180-252	41974-41975	−	_	
180-253	41975-41976	2	_	
180-254	41977-41980	247	_	
180-255	41981-41985	5.57	_	
180-256	41986-41990	5.20	_	
180-257	41991-41992	<	_	
180-258	41992-41997	0.001	_	
180-259	42000-42004	    	_	
180-260	42004-42005	L	_	
180-261	42006-42013	ventral	_	
180-262	42014-42021	putamen	_	
180-263	42022-42023	−	_	
180-264	42023-42025	26	_	
180-265	42026-42028	  	_	
180-266	42028-42030	14	_	
180-267	42031-42033	  	_	
180-268	42033-42034	−	_	
180-269	42034-42035	6	_	
180-270	42036-42038	19	_	
180-271	42039-42043	3.68	_	
180-272	42044-42048	3.56	_	
180-273	42049-42051	  	_	
180-274	42051-42056	0.024	_	
180-275	42059-42065	CHR-NT	_	
180-276	42066-42067	(	_	
180-277	42067-42068	n	_	
180-278	42069-42070	=	_	
180-279	42071-42073	63	_	
180-280	42073-42074	)	_	
180-281	42077-42081	    	_	
180-282	42081-42082	R	_	
180-283	42083-42091	midbrain	_	
180-284	42092-42094	  	_	
180-285	42094-42096	12	_	
180-286	42097-42098	−	_	
180-287	42098-42100	24	_	
180-288	42101-42102	−	_	
180-289	42102-42104	16	_	
180-290	42105-42107	17	_	
180-291	42108-42112	3.59	_	
180-292	42113-42117	3.48	_	
180-293	42118-42120	  	_	
180-294	42120-42125	0.005	_	
180-295	42128-42132	    	_	
180-296	42132-42133	R	_	
180-297	42134-42141	ventral	_	
180-298	42142-42149	putamen	_	
180-299	42150-42152	  	_	
180-300	42152-42154	28	_	
180-301	42155-42157	  	_	
180-302	42157-42159	20	_	
180-303	42160-42162	  	_	
180-304	42162-42163	−	_	
180-305	42163-42164	2	_	
180-306	42165-42168	124	_	
180-307	42169-42173	5.43	_	
180-308	42174-42178	5.08	_	
180-309	42179-42180	<	_	
180-310	42180-42185	0.001	_	
180-311	42188-42193	CHR-T	_	
180-312	42194-42195	(	_	
180-313	42195-42196	n	_	
180-314	42197-42198	=	_	
180-315	42199-42201	13	_	
180-316	42201-42202	)	_	
180-317	42205-42207	No	_	
180-318	42208-42222	suprathreshold	_	
180-319	42223-42229	voxels	_	
180-320	42233-42237	Note	_	
180-321	42237-42238	:	_	
180-322	42239-42240	L	_	
180-323	42240-42241	,	_	
180-324	42242-42246	left	_	
180-325	42246-42247	;	_	
180-326	42248-42249	R	_	
180-327	42249-42250	,	_	
180-328	42251-42256	right	_	
180-329	42256-42257	.	_	

#Text=CHR, clinical high-risk; CHR-NT, clinical high-risk non-transition; CHR-T, clinical high-risk transition; HC, healthy controls.
181-1	42258-42261	CHR	_	
181-2	42261-42262	,	_	
181-3	42263-42271	clinical	_	
181-4	42272-42281	high-risk	_	
181-5	42281-42282	;	_	
181-6	42283-42289	CHR-NT	_	
181-7	42289-42290	,	_	
181-8	42291-42299	clinical	_	
181-9	42300-42309	high-risk	_	
181-10	42310-42324	non-transition	_	
181-11	42324-42325	;	_	
181-12	42326-42331	CHR-T	_	
181-13	42331-42332	,	_	
181-14	42333-42341	clinical	_	
181-15	42342-42351	high-risk	_	
181-16	42352-42362	transition	_	
181-17	42362-42363	;	_	
181-18	42364-42366	HC	_	
181-19	42366-42367	,	_	
181-20	42368-42375	healthy	_	
181-21	42376-42384	controls	_	
181-22	42384-42385	.	_	
